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Background: Bowel cancer screening reduces cancer-specific mortality. There is a socioeconomic gradient
in the uptake of the English NHS Bowel Cancer Screening Programme (BCSP), which may lead to
inequalities in cancer outcomes.
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Objective: To reduce socioeconomic inequalities in uptake of the NHS BCSP’s guaiac faecal occult blood
test (gFOBt) without compromising uptake in any socioeconomic group.
Design: Workstream 1 explored psychosocial determinants of non-uptake of gFOBt in focus groups
and interviews. Workstream 2 developed and tested four theoretically based interventions: (1) ‘gist’
information, (2) a ‘narrative’ leaflet, (3) ‘general practice endorsement’ (GPE) and (4) an ‘enhanced
reminder’ (ER). Workstream 3 comprised four national cluster randomised controlled trials (RCTs) of the
cost-effectiveness of each intervention.
Methods: Interventions were co-designed with user panels, user tested using interviews and focus groups,
and piloted with postal questionnaires. RCTs compared ‘usual care’ (existing NHS BCSP invitations) with
usual care plus each intervention. The four trials tested: (1) ‘gist’ leaflet (n = 163,525), (2) ‘narrative’ leaflet
(n = 150,417), (3) GPE on the invitation letter (n = 265,434) and (4) ER (n = 168,480). Randomisation
was based on day of mailing of the screening invitation. The Index of Multiple Deprivation (IMD) score
associated with each individual’s home address was used as the marker of socioeconomic circumstances
(SECs). Change in the socioeconomic gradient in uptake (interaction between treatment group and IMD
quintile) was the primary outcome. Screening uptake was defined as the return of a gFOBt kit within
18 weeks of the invitation that led to a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation
required) or ‘abnormal’ (i.e. requiring referral for further testing). Difference in overall uptake was the
secondary outcome.
Results: The gist and narrative trials showed no effect on the SECs gradient or overall uptake (57.6% and
56.7%, respectively, compared with 57.3% and 58.5%, respectively, for usual care; all p-values > 0.05).
GPE showed no effect on the gradient (p = 0.5) but increased overall uptake [58.2% vs. 57.5% in usual
care, odds ratio (OR) = 1.07, 95% confidence interval (CI) 1.04 to 1.10; p < 0.0001]. ER showed a
significant interaction with SECs (p = 0.005), with a stronger effect in the most deprived IMD quintile
(14.1% vs. 13.3% in usual care, OR = 1.11, 95% CI 1.04 to 1.20; p = 0.003) than the least deprived
(34.7% vs. 34.9% in usual care OR = 1.00, 95% CI 0.94 to 1.06; p = 0.98), and higher overall uptake
(25.8% vs. 25.1% in usual care, OR = 1.07, 95% CI 1.03 to 1.11; p = 0.001). All interventions were
inexpensive to provide.
Limitations: In line with NHS policy, the gist and narrative leaflets supplemented rather than replaced
existing NHS BCSP information. This may have undermined their effect.
Conclusions: Enhanced reminder reduced the gradient and modestly increased overall uptake, whereas
GPE increased overall uptake but did not reduce the gradient. Therefore, given their effectiveness and very
low cost, the findings suggest that implementation of both by the NHS BCSP would be beneficial. The gist
and narrative results highlight the challenge of achieving equitable delivery of the screening offer when all
communication is written; the format is universal and informed decision-making mandates extensive
medical information.
Future work: Socioculturally tailored research to promote communication about screening with family
and friends should be developed and evaluated.
Trial registration: Current Controlled Trials ISRCTN74121020.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme Grants
for Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 5, No. 8. See the NIHR Journals Library website for further project information.
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Plain English summary
Bowel cancer is the second most common cause of cancer death in the UK. People who are diagnosedearly have a better chance of survival. The NHS Bowel Cancer Screening Programme was set up in
2006 to help detect early-stage bowel cancer. The programme invites men and women aged 60–74 years
to complete a screening test kit every 2 years.
Only about half of the people offered this screening choose to complete and return the test kit and we
know that people in socially disadvantaged groups are less likely to do so. We designed four studies to try
to improve uptake of screening among all social groups. Two of these studies tested the effectiveness of
information leaflets: one tested an easy to understand version of the screening information leaflet included
in the invitation pack sent out by the screening programme and the second provided personal stories
describing the screening experience. The third study included an endorsement from the person’s general
practice on the invitation to participate in screening and the final study made improvements to the
reminder letter that the screening programme sends out.
We found that adding leaflets to the usual invitation material did not improve uptake of screening; however,
both the general practice endorsement and the improved reminder letter increased screening uptake and at
very low cost. Only the improved reminder letter increased uptake among more deprived groups.
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Scientific summary
Background
Bowel cancer is the third most common cancer in the UK and the second most common cause of cancer
death. This significant public health burden can be diminished by screening using the guaiac faecal occult
blood test (gFOBt), which reduces bowel cancer mortality by 16% among people offered screening.
The NHS Bowel Cancer Screening Programme (BCSP) commenced biennial screening in 2006 and now
offers gFOBt to 60- to 74-year-olds in England.
Overall, screening uptake [defined as the return of a gFOBt kit within 18 weeks of the invitation that led to
a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or ‘abnormal’ (i.e. requiring
referral for further testing, usually colonoscopy)] is about 56%, but uptake varies from 61% in the least
deprived to 35% in the most deprived areas of the country. Uptake within South Asian communities
further varies: 31.9% in the Muslim community, 34.6% in the Sikh community and 43.7% in the Hindu
community when compared with ‘non-Asians’. Previous research to tackle socioeconomic inequalities in
uptake has focused on specific underserved groups rather than reducing the gradient in uptake across the
entire population.
Therefore, we explored reasons for non-uptake and subsequent uptake of bowel cancer screening in men
and women from different socioeconomic backgrounds in England (London and Yorkshire) and in South
Asian communities in London (workstream 1). We developed and tested four theoretically derived, novel
interventions that aimed to increase uptake among individuals with lower socioeconomic circumstances
(SECs) without compromising uptake in any socioeconomic group (workstream 2). We then tested the
effectiveness and cost-effectiveness of our interventions in four randomised controlled trials (RCTs), which
incorporated the interventions within the NHS BCSP (workstream 3).
Objectives
Overall objective: to reduce socioeconomic inequalities in bowel cancer screening uptake without
compromising uptake in any socioeconomic group.
Objectives of each workstream
Workstream 1: to explore psychosocial and cultural determinants of low uptake of gFOBt in the general
population and in South Asian communities.
Workstream 2: to develop and test four theoretically based interventions designed specifically to reduce
the socioeconomic gradient in bowel cancer screening uptake.
Workstream 3: to use a RCT design to evaluate the effectiveness and cost-effectiveness of each individual
intervention within the NHS BCSP.
Workstream 1
Methods
We conducted 18 focus groups with individuals eligible for screening and from a range of socioeconomic
backgrounds in London and South Yorkshire. Sixteen groups were recruited via a postal invitation sent from the
NHS BCSP. One group was recruited via a community setting and another via a market research recruitment
agency.
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In addition, we carried out interviews with individuals who acted as key informants for a variety of South
Asian communities in London. South Asian communities were chosen because they represent the largest
ethnic minority group in England (approximately 7% of the population) and low uptake of colorectal
cancer (CRC) screening in the UK has continued to be identified within all South Asian religolinguistic
groups even when age, deprivation and gender are adjusted for. Key informants were purposively sampled
to ensure representation from the three dominant faith backgrounds (Islam, Hinduism and Sikhism).
Interviews were recorded, transcribed and analysed using thematic analysis.
Results
Focus groups
In all, 128 men and women from diverse occupational backgrounds took part in a focus group. The
majority of participants recalled receiving invitation(s) and gFOBt kit(s) from the NHS BCSP. One hundred
participants reported gFOBt non-uptake on at least one occasion, of whom 31 went on to complete the
gFOBt kit when invited to take part in a subsequent screening round. Nine participants had not completed
the gFOBt kit owing to having had investigations outside the NHS BCSP, such as colonoscopy, endoscopy
or gFOBt kit completion in primary or private care.
We identified the following themes summarising why people did not to take part in the NHS BCSP:
(1) risks to hygiene and personal risk posed by dealing with faeces; (2) detachment from familiar
health-care settings; (3) implications of knowing the screening results; (4) judgements of good health
and low levels of screening; and (5) delaying uptake leading to non-uptake.
Among individuals who had not taken part in screening in one episode but had subsequently participated,
the key ‘tipping point’ that changed their decision was discussions about bowel cancer and screening with
their peers.
Key informant interviews
Interviews were conducted with 16 London-based ‘key informants’ representing three South Asian faith
communities in order to explore reasons for the variability of low uptake between faith communities and
to identify reasons for low uptake of bowel cancer screening in South Asian communities as well as
strategies by which uptake might be improved. Twelve key informants held roles in faith, community or
charity organisations and four were general practitioners (GPs). Across South Asian faith groups key
informants identified limitations posed by the written word, low awareness of CRC and screening,
difficulties with handling faeces and gFOBt completion as reasons for low bowel cancer screening uptake.
In addition, written materials were deemed particularly inappropriate for the Sylheti-speaking Bangladeshi
Muslim community and a social stigma surrounding cancer was described in Sikh communities, which may
hinder engagement with screening. Non-written information delivered within faith or community settings
was preferred across all faith groups.
Efforts to increase accessibility to bowel cancer screening in South Asian communities should use local
ethnic media and face-to-face approaches within community and faith settings to increase awareness of
bowel cancer and screening, to address challenges posed by written materials and to challenge the social
stigma surrounding cancer.
Workstream 2
We developed and tested four theoretically grounded, simple, low-cost interventions that could easily be
implemented within the NHS BCSP.
SCIENTIFIC SUMMARY
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Intervention 1: a ‘gist’ leaflet
We undertook qualitative research to establish how the existing NHS BCSP materials were received. We
then designed a leaflet summarising the key screening information in language suited to respondents with
low health literacy and tested the leaflet for readability and comprehensibility via a number of small
qualitative studies. Next, we conducted a multicentre RCT with individuals approaching the screening-
eligible age (n = 4452) to examine the impact of the leaflet on intentions to complete screening. We found
that inclusion of the gist-based leaflet alongside the standard screening information materials increased
knowledge of bowel cancer and bowel cancer screening, but did not increase intention to participate in
screening. However, we found that the RCT respondents in both the intervention and control groups had
very high intention levels.
Intervention 2: a ‘narrative’ leaflet
We conducted 20 narrative style interviews with individuals who had some experience of taking part in
bowel cancer screening. A narrative leaflet based on the ‘stories’ told was developed. The leaflet was
particularly consistent with workstream 1 findings concerning resistance to handling faecal matter, the
implications of knowing gFOBt results and the power of talk.
We designed the leaflet in consultation with a leading social marketing group and refined the leaflet
design before user testing it via a number of focus groups and interviews, which resulted in further minor
refinements. We then conducted a multicentre RCT with screening-naive individuals (n = 4125) to examine
the impact of the leaflet on screening intentions. The addition of the narrative leaflet to standard
information material had a positive effect on intention to take part in the NHS BCSP and on beliefs about
bowel cancer screening, which were previously found to be predictive of intention.
Intervention 3: general practice endorsement
Following insights from the workstream 1 focus groups about the perceived lack of involvement of known
and trusted NHS information sources, and in consultation with our Primary Care Advisory Group (five GPs,
a practice manager, a NHS BCSP hub director and two clinical academics), we developed text that would
appear on the NHS BCSP invitation materials and designed materials to invite GPs to agree to have their
practice endorse the NHS BCSP. We then invited all GPs across England to endorse the NHS BCSP. In total,
after sending up to three reminder letters, 80% of GPs agreed to endorse the programme.
Intervention 4: enhanced reminder
First, we asked NHS BCSP staff to note details of telephone calls to the NHS BCSP helpline directly relating
to the usual reminder letter to assess what issues were raised by potential participants at this stage. We
then developed an enhanced reminder (ER) letter to address specific concerns that inhibit test completion,
particularly among subjects with lower SECs, including lack of awareness of bowel cancer and of perceived
benefits of bowel cancer screening. We then user tested the ER letter in four focus groups (n = 26).
Workstream 3
Methods
National, cluster-randomised trials compared ‘usual care’ with each of four intervention strategies designed
to target known barriers to uptake among people with lower SECs. Each strategy supplemented existing
NHS BCSP information/invitation materials with (1) ‘gist’ information (n = 163,525), a leaflet summarising
key information in language suited to respondents with low health literacy; (2) ‘narrative’ information
(n = 150,417), a leaflet describing the experiences of people who had participated in screening; (3) a general
practice endorsement (GPE) added to the screening invitation letter (n = 265,434); and (4) enhancing the
reminder letter by reiterating the screening offer (ER, n = 168,480) sent to initial non-responders. SECs
were measured using the Index of Multiple Deprivation (IMD) score associated with each individual’s home
address. Change in the socioeconomic gradient in uptake (interaction between treatment group and IMD
quintile) was the primary outcome.
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Randomisation was based on day of invitation. Trials 1 and 2 (gist and narrative) were run over 10
consecutive days between 5 and 16 November 2012 and 4 and 15 March 2013, respectively. Trials 3 and
4 (GPE and ER) were run over 20 consecutive days between 3 and 28 June 2013 and 8 July and 2 August
2013, respectively. Two weeks before the start of each intervention a randomisation number sequence
was generated. For trials 1 and 2, randomisation schedules were sent to REAL Digital International
(Croydon, UK) for the Southern, London and Eastern Hubs, and the ‘in house’ invitation system for the
North East and Midlands and North West Hubs. For trials 3 and 4, randomisation was undertaken directly
through the Bowel Cancer Screening System. Schedules were not provided to the hubs and were instead
sent to the Health and Social Care Information Centre (HSCIC), formerly Connecting for Health. Hubs were
‘blind’ to the randomisation schedule and confirmed whether or not the intervention was included on the
S1 letter every day, which the trial office then checked against the randomisation schedule. For each set of
numbers, days were randomly allocated to the intervention materials plus standard materials or standard
materials alone.
Although subsequent blinding was not possible, there was no direct contact with subjects (avoiding
biasing participation) and subjects were unaware of the comparator intervention, unless a member of their
household received an invitation during the study period that contained different information materials or
if they had been invited on a previous occasion and recalled the exact content of the previous invitation.
Findings
Baseline characteristics were well balanced for each trial and representative of the population served by
the NHS BCSP. Overall uptake (across the two arms) was 57.4%, 57.7% and 57.9% for trials 1, 2 and 3,
respectively, and 25.4% in the ER trial (trial 4), which only targeted individuals who had not responded to
the first invitation. In all four trial populations, uptake was strongly negatively associated with deprivation,
with the difference between the least and most deprived quintiles in each control arm ranging between
20% and 24%.
The effects of the interventions within IMD quintiles are expressed as adjusted odds ratios (ORs). For the
gist trial, the difference in uptake between the intervention and control arms was +0.2% in the least
deprived group and +1.0% in the most deprived group. The effect did not differ by IMD quintile (least to
most deprived quintiles: unadjusted ORs 1.01, 0.99, 1.01, 1.00, 1.04, interaction p = 0.6; adjusted ORs
1.06, 1.02, 1.00, 1.01, 1.04, interaction p = 0.7). There was no significant increase in overall uptake
[unadjusted OR 1.02, 95% confidence interval (CI) 0.92 to 1.13; p = 0.8; adjusted OR 1.03, 95% CI 0.99
to 1.06; p = 0.1]. The median number of days to return the test kit was 23 in the intervention and 22 in
the control arm.
Similarly, for the narrative trial, there was no significant differential effect of the intervention on uptake
between the least and most deprived groups (–2.2% and –3.6%, respectively). The effect did not differ by
IMD quintile (least to most deprived quintiles: unadjusted ORs 0.91, 0.97, 0.95, 0.91, 0.86, interaction
p = 0.4; adjusted ORs 0.98, 1.00, 1.05, 1.00, 0.92, interaction p = 0.1). There was also no effect on overall
uptake (unadjusted OR 0.93, 95% CI 0.81 to 1.06; p = 0.3; adjusted OR 1.00, 95% CI 0.96 to 1.03;
p = 0.8). The median number of days to return the test kit was 26 in both arms.
In the GPE trial, there was a slight differential change: –0.8% and +1.4% in the least and most deprived
groups. There was also a trend towards a modest SEC gradient in effect; however, this heterogeneity was
not significant (unadjusted ORs 0.97, 1.02, 1.06, 1.06, 1.06; p = 0.3; adjusted ORs 1.04, 1.06, 1.08, 1.09
and 1.07 for the least to most deprived quintiles respectively; p = 0.5). Although the unadjusted OR
indicated little effect for overall uptake (unadjusted OR 1.03, 95% CI 0.95 to 1.11; p = 0.5), the effect
became significant after adjustment for other factors (adjusted OR 1.07, 95% CI 1.04 to 1.10;
p = 0.0001), mainly owing to differences in effect sizes between arms by screening episode (first time,
prevalent, incident). The median number of days to return the test kit was 23 for the intervention and
22 for the control arm.
SCIENTIFIC SUMMARY
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In the ER trial, the difference in uptake between the intervention and standard arm was –0.2% and
+0.8% in the least and most deprived groups, respectively. There was a significant interaction with IMD
quintile (least to most deprived quintiles after adjustment for other factors: unadjusted ORs 0.99, 1.05,
1.10, 1.05, 1.07; p = 0.3; adjusted ORs 1.00, 1.04, 1.13, 1.09, 1.11; p = 0.005) with a greater effect in
the most deprived quintile (adjusted OR 1.11, 95% CI 1.04 to 1.20; p = 0.003) than the least deprived
(adjusted OR = 1.00, 95% CI 0.94 to 1.06; p = 0.98). The unadjusted OR did not indicate a statistically
significant difference in overall uptake between intervention and control arms (unadjusted OR 1.04,
95% CI 0.95 to 1.14; p = 0.4), but the effect became significant after adjustment (adjusted OR 1.07,
95% CI 1.03 to 1.11; p = 0.001). The median number of days to return the test kit was 11 in both arms.
The average marginal costs per person screened of providing the gist and narrative leaflets were £0.04 and
£0.05, respectively. The GPE and ER trials incurred a one-off cost to modify the standard invitation and
reminder letters within the NHS BCSP information technology system of £78,000, but this cost would not
be incurred again if the interventions were implemented. The average marginal cost per person screened
with these interventions was therefore zero.
Conclusion
Three out of four trials of interventions aimed at tackling inequalities in screening uptake failed to reduce
the SEC gradient. An ER letter was the only strategy to significantly reduce the gradient, while GPE
increased overall uptake. Given their minimal cost, these interventions could be implemented immediately
to support the enhanced and equitable delivery of cancer screening within the NHS BCSP. The results of
these trials are testament to the difficulty of modifying inequalities in screening within an organised
programme, but they highlight the importance of continuing to research effective strategies to achieve
equity in early diagnosis of cancer.
Trial registration
This trial is registered as ISRCTN74121020.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research.
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Chapter 1 Overview of the ASCEND programme
In this chapter, we describe the background to, and rationale for, our research programme – ASCEND –the first major research programme to focus specifically on tackling socioeconomic inequalities in uptake
in an organised cancer screening programme.
Background
Burden of disease and NHS context
Bowel cancer constitutes a significant public health burden in the UK. It is the fourth most common cancer
(approximately 41,600 cases annually) and the second leading cause of cancer death (15,700 deaths
annually).1 Its incidence rises with age2 and early diagnosis is vital to improve outcomes: 93% of patients
with early-stage disease (Dukes A) survive for 5 years, compared with 6.6% of those with late-stage
(Dukes D) disease.3
Randomised controlled trials (RCTs) have demonstrated that bowel cancer mortality can be reduced by
screening using the guaiac faecal occult blood test (gFOBt).4 Following successful pilots (the first conducted
in two English health authorities and three Scottish health boards; the second conducted in the English
sites only),5,6 the NHS Bowel Cancer Screening Programme (BCSP) began in England in 2006.7 Reduction in
mortality as a consequence of population screening is dependent on participation. Thus, the combined
results of four international RCTs (including the UK’s Nottingham Trial8) showed that participation rates of
> 50% in biennial population screening reduced mortality by 16%,9 saving up to 2500 lives a year.10
The Nottingham Trial, which began in 1981, reported uptake of 57%, and a 13% reduction in bowel
cancer mortality at 11-year follow-up.11 Subsequently, the first and second NHS BCSP pilots reported initial
and ongoing uptake of 58.5% and 51.9%, respectively.5 Data from the first 2 years of the English NHS
BCSP showed uptake of 54%.12 Further decreases in mortality can be achieved through improvements in
the population participation rate.9,13
The NHS BCSP offers the gFOBt every 2 years to 60- to 74-year-olds. Five hubs covering England
co-ordinated a call/recall programme and were also responsible for analysing the gFOBt kit samples.
Further details of the screening programme are provided in Chapter 2.
Relevance to priorities and needs of the NHS
A commitment to improve health and reduce inequalities in health and health care forms the cornerstone
of the government’s public health and health-care policies.14,15 Organised screening programmes have
been assumed to be superior to opportunistic screening in terms of socioeconomic equity, because they
use population lists to ensure that all eligible individuals are invited and call/recall systems to avoid under-
or overscreening. Direct financial barriers are also avoided in the UK because the screening programmes
are run by the NHS and, therefore, individuals incur no costs either for the primary screening test or for
follow-up investigations or treatment. In addition, bowel cancer screening with the home-based gFOBt kit
avoids barriers associated with travelling to a medical facility or interacting with health professionals.
Nonetheless, striking gradients in uptake across levels of deprivation were reported in the two pilot studies
and the first 2 years of the national screening programme.5,12,16 The initial pilot reported 61% participation
in the most socially advantaged areas, falling to 37% in the most deprived areas,5,12 and this gradient
persisted in the beginning of the national programme, when participation was 61% in the least deprived
areas and 35% in the most deprived areas.12
Identifying effective strategies to achieve equity in uptake is vital to avoid exacerbating inequalities in mortality.
Our research programme focuses on reducing the socioeconomic gradient in uptake without compromising
uptake in any socioeconomic circumstance (SEC) group. In contrast with most inequalities research, we address
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the gradient in uptake rather than the gap between the most and least socioeconomically advantaged, in
order to take account of the stepwise relationship between SECs and health, whereby more socioeconomically
advantaged individuals have better health and better access to health care.17 Thus, the costs of inequalities are
borne not only by those at the bottom of the SEC hierarchy but at every level. Policies that target the most
disadvantaged subgroups only, or which aim to narrow the gap between the most and least disadvantaged,
underestimate the pervasive effect across the SEC hierarchy and exclude those in need in the intermediate SEC
groups. This research programme was therefore designed to focus on reducing the socioeconomic gradient in
uptake, which entails designing interventions that increase uptake to a greater extent in lower than higher SEC
groups. Our approach reflects the concept of proportionate universalism whereby actions are universal, but
with a scale or intensity proportionate to the level of disadvantage.18
This programme was developed to contribute directly to the following three additional national initiatives:
1. The Department of Health’s target for cancer mortality, which includes a target to reduce the
inequalities gap.19
2. The Cancer Reform Strategy,20 which began the National Cancer Equality Initiative to focus on
improving collection of data to improve understanding about current inequalities, promoting research
to fill knowledge gaps about inequalities, and spreading good practice.
3. The Marmot Review of Health Inequalities which highlighted the need for ‘bespoke initiatives’ to reduce
the socioeconomic gradient in bowel cancer screening uptake and which championed proportionate
universalism.18
Need for research in this area and rationale for our research programme
We have previously examined whether or not the socioeconomic inequalities identified during the Bowel
Cancer Screening Pilot persisted once the NHS BCSP was rolled out. We analysed national uptake for the
smallest geographical unit that is routinely recorded by the NHS BCSP, namely postcode sector, each of
which contains an average of 3000 addresses. We found that between October 2006 and January 2009,
overall screening uptake was 53% but it varied from 61% in the least deprived quintile of postcode
sectors to 35% in the most deprived quintile.12
As further evidence of the need for this research, and as part of the ASCEND programme, we undertook a
new study to evaluate the extent of and factors associated with socioeconomic-related inequality in bowel
cancer screening uptake in England using individual-level data from the English Longitudinal Study of
Ageing (ELSA). We used data from the fifth wave of data collection of ELSA for 1833 participants who
were eligible for at least one NHS BCSP invitation. Our outcome measure was completion of a gFOBt
home testing kit. We ranked the sample using a composite measure of socioeconomic status, predicted
from net non-pension wealth and a number of individual-level socioeconomic and sociodemographic
characteristics and plotted the cumulative uptake of bowel cancer screening against it using a
concentration curve. We then derived the concentration index, which provided a measure of
socioeconomic-related inequality in screening uptake. We then fitted univariate probit models for the
association between a number of sociodemographic (age, gender, ethnicity, marital status, education),
socioeconomic (quintiles of net non-pension wealth, housing, vehicle ownership, economic activity, social
class) and health-related (self-reported general health, long-standing illness, difficulties with daily activities
and using the toilet, health literacy, partner screening status) variables and the probability of screening.
Variables showing significant associations were included in a multivariate model and in a decomposition
analysis of the Concentration Index.21,22 This provided a measure of socioeconomic inequality by
accounting for the probability of screening and the distribution of each variable across different levels of
SEC. We found a significant pro-rich gradient in screening uptake [concentration index +0.06, 95%
confidence interval (CI) +0.04 to +0.09] with 41.7% of individuals in the poorest and 65.5% in the richest
quintiles of predicted non-pension wealth participating in screening. Socioeconomic-related inequalities in
screening were mostly explained by differences in education (19.6%), partner screening status (17.4%),
disability (14.3%) and health literacy (8.7%). The findings suggest that interventions for reducing the
gradient in bowel cancer screening participation should aim to increase acceptability and comprehension
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of the screening test among those with lower levels of literacy and emphasise the social implications of
screening and its benefit not just to the individual but also to their family and friends.23
In other work,24 we have also demonstrated that the low uptake and striking socioeconomic gradient is
not seen among people with a positive gFOBt kit result who are invited for further investigation (usually
colonoscopy). Overall, colonoscopy uptake is 84% with little variation between socially advantaged and
disadvantaged areas (86–80%).12 The high uptake of colonoscopy regardless of SEC indicates that
addressing the gFOBt uptake gradient should improve subsequent uptake of effective treatment and,
therefore, contribute to reducing inequalities in survival.
Prior to the establishment of the NHS BCSP, there was evidence that more disadvantaged patients with
bowel cancer tended to present as emergency admissions and at a later disease stage25,26 and their outcomes
are poorer. Furthermore the deprivation gap in survival is widening, reaching 7% for colon cancer and 9%
for rectal cancer.27 These findings further demonstrate the need to devise strategies to achieve early diagnosis
among all social groups as well as reduce inequalities, if we are to improve survival across the board.
Previous research into improving uptake of cancer screening has focused primarily on factors such as
ways of establishing contact.28 Although this approach can help reach screening targets, it is unlikely to
reduce inequalities and may even increase them if more socioeconomically advantaged individuals are
more responsive.
A few studies have specifically addressed socioeconomic inequalities in uptake, but often by focusing on
underserved groups, for example by providing community support workers.29 Even if they are successful,
these initiatives serve only one group in the population and do not address the gradient. In addition, they
are often highly intensive and therefore impractical for wide-scale implementation.
Therefore, we set out to design and evaluate effective interventions which focus specifically on the
socioeconomic gradient in uptake. Multiple potential causes for lower uptake of screening in more
socioeconomically deprived groups include general factors (e.g. stress caused by lack of financial resources,
reduced subjective life expectancy) which limit ability to engage in future-focused health protective
actions30,31 and more specific factors, such as greater concern about the negative aspects of the test itself
(e.g. embarrassment, contact with faecal material).32,33 Health literacy limitations are also implicated in
comprehension of the screening information materials34 and recognition of the organisation that sends the
screening invitations. All these factors may have their upstream roots in the more stressful, constrained
lives of people with fewer social and economic resources.30 In addition, life stress may directly affect
screening uptake if ‘passive’ barriers in the form of competing priorities reduce translation of screening
intentions into action.35 The four interventions that we tested addressed some of these barriers to uptake.
We were required to design interventions that could easily be added to (rather than replace) existing
invitation and information materials (which had been through formal approval procedures).
Aim and objectives
Our aim was to reduce socioeconomic inequalities in bowel cancer screening uptake in England without
compromising uptake in any socioeconomic group.
In order to achieve this, we set out the following objectives:
1. to explore psychosocial and cultural determinants of low uptake of the gFOBt
2. to develop and test four theoretically based interventions to reduce the socioeconomic gradient in
screening uptake
3. to undertake RCTs to evaluate the effectiveness and cost-effectiveness of each intervention within the
NHS BCSP.
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
3
ASCEND workstreams
Our programme was divided into three workstreams to address our objectives.
Workstream 1
In order to explore the psychosocial and cultural determinants of low uptake of gFOBt, we conducted
18 focus groups and 16 key informant interviews. These generated rich qualitative data, which are
reported in Chapters 3 and 4 and which were used to inform workstream 2.
Workstream 2
We developed and piloted four interventions designed to reduce inequalities in uptake of bowel cancer
screening. Two of the interventions consisted of provision of additional information leaflets designed to
meet the information preferences of individuals with lower SECs; one provided a simplified version of
the screening information focusing on the ‘gist’ of the message and one provided personal narratives
describing the screening experience. The third intervention added an endorsement of the programme
from a familiar health professional [the individual’s general practitioner (GP)] to circumvent lack of
recognition of the NHS BCSP – a strategy that has been shown to improve screening uptake in those with
lower SECs.36,37 The fourth intervention provided an enhanced ‘cue to action’, designed to help bridge
the ‘intention–behaviour’ gap by briefly restating the screening offer and adding a ‘reminder’ label to the
reminder letter sent to individuals who had not responded within 35 days of their initial invitation. The
interventions are described individually in Chapters 5–8.
Workstream 3
Each of the four interventions developed in workstream 2 were tested in separate two-arm, cluster
randomised trials targeting all individuals who were routinely invited for bowel cancer screening in the
NHS BCSP in England over each study period. The RCTs took place between November 2012 and August
2013. We hypothesised that each intervention [the ‘gist’ leaflet, the ‘narrative’ leaflet, the general practice
endorsement (GPE) and the enhanced reminder (ER)] would be low cost and progressively more effective
at improving screening rates across increasing levels of deprivation. We also undertook a national survey of
research activities and health promotion activities to ascertain usual practice during the trial period. This
workstream is described in Chapters 9–11.
Workstream 4
We planned to combine the successful components from workstream 3 into a complex intervention for
experimental evaluation; however, the results of the trials of the individual interventions did not justify this.
Conclusions
We draw conclusions from the study and make recommendations for future research and practice in Chapter 12.
Patient and public involvement and engagement
Our first ASCEND patient representative, Mr Fuller, contributed expertise from a patient perspective during
the drafting of the original application, particularly regarding workstream 2 and the planning of the
development of the interventions. Unfortunately, Mr Fuller was unable to offer further support following
the grant being awarded owing to ill health. We recruited another patient representative (Mr Band), who
reviewed some of the ASCEND development work (namely the narrative leaflet) and attended our Advisory
Group meeting prior to the start of the national trials. In addition, we worked with individuals from a
number of charity and community groups and organisations, Primary Care Research Networks and faith
settings who helped us to identify specific groups of people to take part in the development stages of the
study (see Chapters 3–6 for further details).
The research team also undertook engagement activities, presenting information about the study at conferences
and to other groups, as well as publishing peer-reviewed papers of the study findings.
OVERVIEW OF THE ASCEND PROGRAMME
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Chapter 2 Overview of Bowel Cancer Screening
Programme usual practice
Introduction
The NHS BCSP, established in England in 2006, offers bowel cancer screening every 3 years to adults
aged 60–69 years (inclusive) using a gFOBt kit that is completed at home. Between 2008 and 2014, the
programme was gradually extended to include subjects aged 70–74 years. Primary endoscopy screening is
now being added to the programme following the UK Flexible Sigmoidoscopy Screening Trial,38 with a
single flexible sigmoidoscopy (FS) offered at 55 years. FS screening started after the completion of the
ASCEND programme.
Bowel Cancer Screening Programme hubs
Five NHS BCSP hubs provide the ‘call and recall’ service for the screening programme in England: London,
Southern England, Eastern England, Midlands and North West England and North East England (Figure 1).
This involves the use of the Bowel Cancer Screening System (BCSS) database to invite the eligible
population as their screening becomes due. To support this process, all hubs offer a helpline service to
provide advice and a laboratory service to test all returned kits.
Screening pathway
A detailed diagram of the NHS BCSP screening pathway is included in Appendix 1. In brief, each hub
sends an initial invitation (‘pre-invitation’) pack to all eligible people in their area describing the programme
and its objectives. The pre-invitation pack contains a letter (see the S1 letter, Appendix 2) and ‘The Facts’
booklet (see Appendix 3). A week later, the hub sends out the gFOBt kit (Figure 2) with a formal invitation
letter (referred to as the S9 letter; see Appendix 4) and a leaflet explaining how to do the test (the
screening instruction test kit leaflet; see Appendix 5). The test kit includes the gFOBt card, cardboard
spatulas for sample collection and a reply-paid envelope in which to return the test for analysis at the NHS
BCSP hub laboratory. There are three flaps on the test kit, each of which covers two sample application
‘windows’. Two tiny samples are taken from a bowel motion and spread onto each of the two windows
using the cardboard spatulas provided. The flap is then sealed and dated and the process is repeated for
the second and third bowel motions (using the windows under the second and third flaps, respectively).
Once all six windows have been used, the test kit is returned to the laboratory for analysis. The test kit must
be received by the hubs within 21 days (subjects are told 14 days, to allow time for return postage) of the
first sample being taken to ensure that a valid test result can be obtained. The hubs process the completed
gFOBt kits in their laboratories and send out result letters to participants within 2 weeks of receiving a
completed test kit. If a test kit has not been returned within 4 weeks of the date it was sent, the hub sends
out a reminder letter (referred to as the S10 letter; see Appendix 6).
The possible test results for kit 1 are described in Table 1. Up to three test kits may be needed to reach a
‘definitive’ test result of ‘normal’ or ‘abnormal’. If none of the six windows is positive for blood in the
faecal sample on the first test kit, the test result is normal and the participant will be invited to be screened
again in 2 years’ time (if they remain within the eligible age group). If five or six windows test positive on
their first kit, the result of the screening test is abnormal and the participant is offered an appointment
with a specialist screening practitioner (SSP). If between one and four windows are positive on their first
kit, the result of that test is ‘unclear’ and the participant will be asked to repeat the test. If one or more
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FIGURE 2 The gFOBt kit.
FIGURE 1 Map of England showing the five Bowel Cancer Screening hubs.
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windows test positive on a second test kit the definitive test result is abnormal (‘weak positive’) and the
participant is referred to a SSP. If no windows are positive on the second test kit, a third test kit is sent and
any positive windows result in referral to SSP. Participants will be asked to repeat the test if a test was
completed incorrectly (‘spoilt’) or there was a problem in the laboratory during processing (‘technical failure’).
General practitioners are not directly involved in the delivery of the NHS BCSP but the practice receives
written (or electronic) notification of the screening results for their patients including a notification of a SSP
appointment and colonoscopy outcome. Practices are also informed about subjects who have not taken
part in screening.
Each NHS BCSP hub provides a freephone helpline service. Helpline staff are not medically trained but
have received training on common diseases of the bowel and have a sound knowledge of the screening
pathway. Helpline staff provide guidance on how to complete the test kit, are able to answer queries
about the appropriateness of screening (complex clinical queries are passed to the hub management team)
and can reschedule clinical NHS BCSP appointments etc.
Individuals who receive an abnormal test result are invited to attend an appointment with a SSP at a local
screening centre. The SSP will discuss a follow-up investigation and arrange a colonoscopy, if appropriate.
There are 60 screening centres across England (between 6 and 18 per hub area). Colonoscopy is an invasive
procedure that involves passing a thin, flexible tube with a tiny camera attached through the rectum and
around the bowel to look directly at the lining of the large bowel. Preparation for colonoscopy requires the
subject to use a self-administered laxative for thorough bowel cleansing and a sedative is sometimes used
during the procedure. If polyps are found in the bowel, most can be removed painlessly using a wire loop
passed down the colonoscope tube. These tissue samples are then checked for any abnormal cells that might
be cancerous. On average, for every 10 people undergoing a colonoscopy following an abnormal gFOBt kit
result, five will have a normal result (or non-cancerous/non-polyp abnormality), four will have a polyp (which, if
removed, may prevent cancer developing) and one will have cancer.
TABLE 1 Possible gFOBt kit results and implications
gFOBt kit result
Spoilt kitNormal Unclear Abnormal
Technical
failure
Explanation 0 positive spots 1–4 positive spots 5 or 6 positive
spots
Technical
problem in the
laboratory’s
processing of
the kit
Unreadable test kit
owing to incorrect
use, out-of-date
sample or no
readable date
Action Participants are
sent a discharge
letter. The letter
also contains a list
of the symptoms of
bowel cancer to
promote awareness
between screening
episodes and after
the age of 74 years.
The gFOBt is
offered again in 2
years if < 75 years
Participants are sent a
covering letter and
another kit. If the
second kit gives an
abnormal or unclear
result, participants
are offered an
appointment to see a
specialist nurse. If the
second kit is normal,
participants are sent
another kit to confirm
a definitive result
overall
Participants are
sent a covering
letter containing a
clinic appointment
to see a specialist
nurse within
2 weeks of the
gFOBt kit being
processed
Participants
are sent a
covering letter
and one
further kit
Participants are
sent a covering
letter with an
explanation of why
the kit could not
be processed and
a replacement kit
Reproduced from NHS Bowel Cancer Screening Programme. Information for Primary Care. London: NHS; 2012.39
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Screening ‘episodes’
For screening participants, a screening episode refers to the period of time from when an S1 pre-invitation
letter is sent to an eligible individual to when they receive a definitive normal test result or to an outcome
from colonoscopy for those referred for further investigation. If a subject has not responded by returning a
test kit or contacting the hub to opt out of screening within 18 weeks of the initial pre-invitation letter
being sent out, the screening episode is closed and the subject will receive another invitation to take part
in screening 2 years after their previous screening due date, if they are still within the age group to be
screened (60–74 years).
Subjects are first invited to take part in screening within approximately 6 weeks following their 60th
birthday and may then be invited to take part in screening every 2 years, depending on test results,
outcomes from any follow-up and age, and regardless of whether or not they have taken part in the past.
Individuals aged ≥ 75 years can request a test kit every 2 years from the NHS BCSP if they wish to
be screened.
The first time an individual is invited to be screened is referred to as the prevalent screening episode
(‘prevalent previous non-responders’ refers to subjects invited to be screened at least once previously but
who have not participated). ‘Incident’ screening is the term used for episodes of repeat screening (i.e. in
the case of subjects who have participated in screening previously).
Initiatives to promote the Bowel Cancer Screening Programme
A number of organisations promote awareness of the NHS BCSP. Clinical Commissioning Groups [and
formerly primary care trusts (PCTs)] fund a variety of local initiatives to promote uptake of screening, including
promotion of screening at flu vaccination clinics, placing posters in general practices and providing information
stands at health fairs, general practices, libraries, conferences and hospital open days, as well as various GPE
strategies and targeted recruitment of individuals not taking part in screening. The Southern Hub is piloting a
new approach to increase participation by working in partnership with general practices and sending a second
reminder letter using the surgery letter head and a local GP signature. The National Awareness and Early
Diagnosis Initiative also co-ordinates and provides support to activities that promote the earlier diagnosis of
several cancer types in England, including breast, bowel and lung cancer.
Several charities, including Beating Bowel Cancer (Teddington, UK), Bowel Cancer UK (London, UK) and
Cancer Research UK (London, UK), also fund campaigns to promote uptake of bowel cancer screening.
OVERVIEW OF BOWEL CANCER SCREENING PROGRAMME USUAL PRACTICE
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Chapter 3 Workstream 1: focus group study
A version of this chapter has been published as Palmer et al.32 This work is licensed under the CreativeCommons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.
Introduction
In workstream 1 we explored the psychosocial and cultural determinants of low uptake of gFOBt.
In this chapter, we describe how we carried out focus groups with men and women from different
socioeconomic backgrounds in London and South Yorkshire in order to identify specific barriers to
screening uptake.
Uptake of bowel cancer screening in South Asian communities is particularly low, at 31.9% in the Muslim
community, 34.6% in the Sikh community and 43.7% in the Hindu community, compared with average
uptake across the whole population (53%).12,40–42 Low uptake of colorectal cancer (CRC) screening in the
UK has continued to be identified in areas with higher ethnic diversity,5,12 and within all South Asian
religiolinguistic groups even when age, deprivation and gender are adjusted for.40,43 We therefore also
explored culturally specific barriers to uptake in South Asian communities to identify additional appropriate
methods which could be specifically targeted at minority ethnic groups who speak English. To do this,
we carried out interviews with 16 participants acting as ‘key informants’ on behalf of their communities.
This interview study is described in Chapter 4.
The current research evidence in this area includes qualitative explorations of attitudes towards bowel
cancer screening. Most of these studies were conducted in the USA or report insights relating to a range
of screening methods including gFOBt, colonoscopy and FS.44–47 This limits their applicability to the UK NHS
BCSP. The sparse literature focusing on gFOBt33,42,48–52 has identified reasons for non-uptake including
feeling healthy and having no bowel symptoms, fear of the outcome of screening and ‘not wanting to
know’, which was often linked to doubts about the value of screening to detect health problems.
Difficulties in understanding the kit instructions, concerns about hygiene and storage of the kit, avoiding
or delaying decision-making, intention to take part but failure to do so owing to practicalities, and the
preference for a doctor to do such tests have also been identified as reasons for not completing
screening.33,42,50,51,53 An association between being invited to be screened and entry into ‘old age’ has also
been identified as a factor influencing the decision to be screened.52 The need to deal with faeces to
complete the test has not been reported as a major barrier to participation in screening, with previous
studies42 reporting that the majority of respondents have not tended to express disgust or reluctance to
handle faecal matter. However, the material realities of the gFOBt do constitute a barrier to participation
for some individuals.42,45,50
Few qualitative studies have focused on the English NHS BCSP. Two studies carried out during the NHS
BCSP pilot phase explored the acceptability of gFOBt with individuals who had not yet been invited to take
part in the NHS BCSP.42,51 Findings from these studies were therefore based on participants’ hypothetical
commentaries regarding the acceptability of the programme design and screening process. Recruitment of
participants with actual experience of being invited to the NHS BCSP is limited to three qualitative studies.
In one, the majority of the participants had completed the gFOBt kit50 and the other two report on small
samples, each restricted to one geographical area in England.33,52 The experiences of individuals who have
been invited to the NHS BCSP and have not taken part, who might be expected to offer the richest
insights into screening non-uptake, have been largely absent from the research literature to date.
Furthermore, the beliefs of individuals who do not take part in one round of screening but subsequently
take part in another round is limited to one recent study which describes how beliefs, awareness and
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intention change over time.33 These participants are of particular interest because of their potential to
explain why people make different uptake decisions on separate screening rounds.
Finally, research exploring the views and experiences of ethnic minority participants to an invitation to the
NHS BCSP is, with the exception of Szczepura,42 extremely limited, despite ethnic diversity in the UK
population and variation in screening uptake linked to ethnicity.12,40,54
A single study on FS screening (an invasive form of bowel cancer screening not routinely used in the NHS BCSP
at the time this research was conducted) identified specific cultural barriers associated with the threats to
masculinity in African Caribbean men.55 However, it is not known whether such barriers are also present in
relation to gFOBt or if there are any culturally specific issues related to gFOBt screening among African
Caribbean women.
The research presented here therefore adds to the literature in two important respects. First, we explored
non-uptake decisions in a socially and ethnically diverse sample of individuals with experience of non-uptake
within the English NHS BCSP. Second, we included participants who made different uptake decisions on
separate screening rounds. This allowed us to identify ‘tipping points’, that is, the factors that changed an
individual’s mind about screening.
Aims
1. To explore psychosocial determinants of bowel cancer screening uptake with an attention to the
possible differences between socioeconomic and ethnic groups.
2. To explore the reasons for participating in screening following non-participation in a previous
screening round.
Objective
To understand determinants of initial non-uptake and reasons for subsequent participation in gFOBt
screening using focus groups, homogeneous with respect to gender, SECs and ethnicity.
Methods
Theoretical underpinnings
Our study is rooted in the interpretivist tradition of qualitative social research and thus focuses on the
subjective understandings and meanings held by the participant.56 An attention to participants’
interpretations and meanings provides a context to their actions, from which explanations for particular
actions and behaviours may be derived.57 We used a focus group design to explore the experiences of
people invited to take part in the NHS BCSP and we used the rich textual data generated therein to
illuminate the meanings, interpretations and influences that underlie participants’ decisions not to undertake
screening. Focus groups are of particular value when exploring reasons why people choose not to do
something, or what Barbour terms ‘why not?’ questions.58 We took a nuanced view of the data we
collected, accepting that while they may reveal aspects of the actual experience of receiving an invitation to
screening, they also comprise ‘accounts’ that are produced within, and shaped by, the social setting of a
focus group, and in which particular behaviours are likely to be framed in certain ways.56
Recruiting participants
To explore sociocultural differences in barriers to uptake, we purposively sampled participants from two
distinct geographical areas: inner-city London and two towns in South Yorkshire (Barnsley and Doncaster).
In each setting we sampled individuals from a diverse range of SECs. We aimed to recruit participants who
WORKSTREAM 1: FOCUS GROUP STUDY
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had not taken up screening on at least one occasion. We also purposively sampled participants of African
Caribbean ethnic minority background owing to the dearth of research examining ethnic minority
experiences of bowel cancer screening and following the finding of a study on FS that specific cultural
barriers associated with threats to masculinity were experienced by African Caribbean men.55
Inclusion and exclusion criteria
Our inclusion criteria were:
l individuals who had been invited to participate in bowel cancer screening but who did not take part on
at least one occasion
l individuals who had a good understanding of, and who were able to communicate in, English.
Our exclusion criteria were:
l individuals who did not wish to provide informed consent for the study
l individuals who had a known previous cancer diagnosis.
Focus groups benefit from being organised around the homogeneity of the participants.58,59 This may be
especially pertinent when the research topic is of a potentially sensitive nature. Therefore, we planned to
establish separate focus groups for men and women and to group participants based on their ethnic and
occupational backgrounds where possible.
We planned to convene seven all-female and seven all-male English-language focus groups. Groups were
to be single sex owing to the sensitive and personal nature of the topic to be covered. Two of these
groups (one male and one female) would comprise African Caribbean participants to ensure ethnic
diversity in our sample.
We initially planned to recruit participants through general practice lists and via community settings
assisted by our charity partners Age UK (London, UK), Beating Bowel Cancer and ContinYou (London, UK).
However, we encountered difficulties with these approaches, which we describe below.
Difficulties in convening focus groups
Through general practice lists
We anticipated that some focus groups would be convened through general practices serving (1) relatively
affluent resident populations, (2) relatively disadvantaged populations and (3) a high prevalence of African
Caribbean individuals. We planned to identify appropriate practices using routinely available data on
deprivation (derived from practices’ postcode) and ethnicity from the Public Health Observatories. We
established relationships with research officers at the local Primary Care Research Networks in London and
the South Yorkshire and Bassetlaw Bowel Screening Health Promotion Group, which agreed to assist us in
recruiting participants. However, we soon found that, although general practices held information on their
patients’ bowel cancer screening uptake status, it was not held on easily searchable databases; therefore,
this approach would require a great deal of effort and expense in order to identify potential participants.
Through charity partners (Age UK, Beating Bowel Cancer and ContinYou)
Our three charity partners, Age UK, Beating Bowel Cancer and ContinYou, volunteered to help recruit
participants via their networks and community groups; however, although each charity offered valuable
insights and expertise to the research team, particularly during the initial planning stages of our research, it
soon became clear that they would not be able to assist with identifying relevant individuals or convening
appropriate focus groups. Age UK tend to have contact with people who were older than the screening age
or who had already positively engaged with the NHS BCSP. Beating Bowel Cancer has a well-established,
extensive network of community, health promotion and district nurses; however, it transpired that its
contacts were mainly with younger people who had developed and overcome bowel cancer, but were too
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young for their cancer to have been identified through screening by the NHS BCSP. The charity ContinYou
is a community learning organisation that focuses on engagement with socially excluded groups, including
those with lower levels of educational attainment and poor health literacy, and minority ethnic groups.
However, during the period between the grant proposal being submitted and the grant being awarded,
ContinYou shifted its focus to deliver education services for young people and, therefore, contacts with
individuals eligible for bowel cancer screening (aged 60–69 years old) had ceased.
Through community settings
Owing to the lack of research exploring the experiences of minority ethnic communities to bowel
screening, we wished to maximise our opportunity to explore specific ethnic issues related to non-uptake,
particularly among the British South Asian and African Caribbean communities. In order to achieve this we
took account of previous studies which found that alternative recruitment strategies to those used to recruit
white European origin participants may be required.60,61 Therefore, we attempted to opportunistically sample
people of African Caribbean origin through community settings. However, despite contacting 12 community
groups (seven in London and five in South Yorkshire), all of which were enthusiastic to assist us, we were
unable to recruit enough men who met our inclusion criteria. This was because very few men attended
these groups and those who did were commonly older than the screening age range or had taken part in
screening. We did, however, recruit a focus group comprising women of African Caribbean origin from a
church-based exercise group in North London. This group was arranged without reference to occupational
background.
The difficulties we faced recruiting non-white British participants through community groups, in
combination with advice received from a bowel cancer improvement practitioner working with Muslim
South Asian communities in Manchester, informed the decision to use key informant interviews in place of
focus groups for the study exploring experience and access to bowel cancer screening among UK South
Asian communities. This aspect of workstream 1 was redesigned and accepted by the National Institute for
Health Research (NIHR) following peer review.
Alternative methods of recruitment
Convening focus groups through the Bowel Cancer Screening Programme
In response to the difficulties we encountered with recruitment, we approached the London NHS BCSP
Hub and the North East of England NHS BCSP Hub to help with recruitment. The two hubs agreed to act
as patient identification centres, enabling us to target our recruitment at participants who had not taken
up screening on at least one occasion. Therefore, we identified postcodes in areas of London and South
Yorkshire, within which the hubs were asked to invite people to participate in focus groups on our behalf.
We did this by identifying lower-layer super output areas (LSOAs) that encompassed a range of Index of
Multiple Deprivation (IMD) scores, including those in the least deprived and most deprived quintiles.62 We
then mapped LSOAs on to postcode maps, which enabled us to identify postcode sectors from which we
wished to invite participants to participate in the study. We supplied hubs with these postcode sectors and
they invited a total of 5100 eligible participants living in addresses in these areas, during two periods of
recruitment to the study. In order to achieve our objectives, the hubs invited individuals with a variety of
uptake experiences, including individuals who had never taken part in screening, individuals who had
taken part in one round of screening but not in a subsequent round, and individuals who had not taken
part in initial screening but then gone on to take part in a subsequent round.
We prepared focus group invitation packs that the hubs sent out to 2560 and 2540 potential participants
from across areas in the first and second wave of recruitment, respectively. The pack contained a letter of
invitation to the study signed by the hub director and the study chief investigator (see Appendix 7), an
information sheet (see Appendix 8), a consent form (see Appendix 9) and a return stamped addressed
envelope. Potential participants were invited to telephone or e-mail the researchers to further discuss the
study if they wished. The researchers had contact only with participants who returned a consent form and
expressed an interest in taking part in focus groups; all non-responders remained anonymous.
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Using this method of recruitment through the NHS BCSP, we were successful in recruiting enough
participants to establish 16 focus groups (four male and four female in London, and four male and four
female in Yorkshire).
Convening a focus group through a market research recruitment agency
Finally, we approached an external market research recruitment agency to assist in the recruitment of a
focus group with men of African Caribbean origin.
Overall we established 18 focus groups, of which eight were conducted in Yorkshire and 10 were
conducted in London (Table 2).
Composition of each focus group
In addition to organising separate focus groups with male and female participants, we also used
participants’ occupational background to group them by broadly similar SECs.
Although we invited individuals from the least deprived and most deprived areas (as defined by IMD
quintile, i.e. based on postcode), we also needed to take account of the possibility of ecological fallacy
(defined as ‘an error of deduction that involves deriving conclusions about individuals solely on the basis of
an analysis of group data’), in this case, IMD derived by postcode rather than individualised data63 when
grouping individuals of broadly similar socioeconomic backgrounds.64
TABLE 2 Focus group composition
Focus group Location Gender Occupation Number of participants/ethnicity
FG01 London Male Professional White European, n= 11
FG02 London Male Non-professional White European, n= 5
FG03 London Female Professional White European, n= 7; South Asian, n = 1
FG04 London Female Non-professional White European, n= 5; African Caribbean, n= 1
FG05 South Yorkshire Male Professional White European, n= 7
FG06 South Yorkshire Male Non-professional White European, n= 8
FG07 South Yorkshire Female Professional White European, n= 7
FG08 South Yorkshire Female Non-professional White European, n= 6
FG09 South Yorkshire Male Non-professional White European, n= 7
FG10 South Yorkshire Male Professional White European, n= 8
FG11 South Yorkshire Female Non-professional White European, n= 6
FG12 South Yorkshire Female Professional White European, n= 6
FG13 London Male Non-professional White European, n= 6
FG14 London Male Professional White European, n= 7; West African, n= 1
FG15 London Female Non-professional White European, n= 4; African Caribbean, n= 2
FG16 London Female Professional White European, n= 6
FG17 London Female Not recorded African Caribbean, n= 9; South Asian, n= 1
FG18 London Male Not recorded African Caribbean, n= 6; West African, n = 1
FG, focus group.
Reproduced from Palmer et al.32 This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike
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A standard measure for occupational background was not used. Instead, we used a consensus method
between two researchers to group participants by ‘professional’ or ‘non-professional’ occupational
background. This pragmatic approach was taken in the spirit of the qualitative research design adopted for
this study in which flexibility and responsiveness to the emerging research context are required.
The two groups comprising majority African Caribbean participants were not grouped by reference to
occupational background. This information was not available owing to the recruitment method used for
these focus groups.
Generation of the topic guide
We developed a topic guide to ensure that key topics were covered in each focus group (see Appendix 10).
We used the existing literature to inform the questions included on the guide, including questions to
explore previously unreported areas of interest with our focus group participants. Iterations of the topic
guide were discussed among the team to ensure that topics of importance for the study were covered and
that these questions were framed to enable detailed and unstructured responses.
Running the focus groups
The first eight groups were conducted during July 2011 and a further 10 were conducted during April
2012. We elicited participants’ availability to attend a focus group on several dates and ran the groups at
the times when the majority of participants were able to attend. We conducted all the London-based focus
groups at university meeting rooms, apart from the female African Caribbean group, which was conducted
at the church where the group met for other purposes. We identified conference centres and community
spaces in South Yorkshire at locations that would be convenient for focus group participants to reach.
Each group lasted approximately 1 hour and one facilitator (CP or CvW) ran the group while another
member of the research team took detailed notes (MT or SS). Each group was audio-recorded with
consent from each participant. We provided refreshments and at the end of the focus groups each
participant was given £20 to thank them for taking part and to cover travel expenses.
Ethics
The study received ethics approval from South East London research ethics committee five (reference
11/H0805/7) and NHS trust research governance was obtained at the relevant sites. Written informed consent
was obtained from all participants.
Patient and public involvement and engagement
We collaborated with community groups to recruit potential focus group participants. In Doncaster we
worked with three community centres (contact details were provided by ContinYou colleagues), an indoor
bowls centre and a men’s 60+ social group, supported by AgeUK (found through our own research).
ContinYou also put us in touch with three community centres in London. In addition, we approached
an over-50s exercise group at a London sports centre, a ‘men’s shed’ group and an over-50s library group,
inviting them to take part in our research. AgeUK worked with us in London, for example, inviting us to a
black and minority ethnic elders meeting in London, where we made a contact who arranged a focus
group with Caribbean women based at a church exercise group in North London. All of these groups
were extremely willing to help but, unfortunately, we often found that many of the people available were
outside the age bracket we were seeking and, if they were of screening age, they tended to be positive
about screening.
Following the publication of our results in the British Journal of Cancer,32 we produced an information
sheet summarising the findings and posted this to all participants who expressed an interest in receiving
them.
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Data management and analysis
After each focus group, the audio-recording was sent securely to a third-party transcription agency and
transcribed verbatim. The research team members who led each focus group (CP or MT) then checked
the transcripts for accuracy in comparison with the audio-recordings and written notes and removed any
identifying information. Transcripts were not returned to participants for comment or correction.
Audio-recordings and electronic transcripts were saved on a secure password-protected drive. Paper
transcripts and written notes were kept in locked office cabinets.
An inductive analytical approach was used to generate themes from the data. During the first stage of
analysis, two members of the research team (CP and MT) working with hard copies of the data
descriptively coded each transcript as it was generated; this was done in a grounded way, meaning that all
data were closely and repeatedly read and coded without reference to ‘a priori’ topics linked to the
research questions of interest to the study. During this initial open and grounded coding stage, the
researchers would meet regularly to discuss the emerging codes and areas of commonality and difference
between each researcher’s codes. As further transcripts were coded, the researchers coidentified patterns
of repeating or similar codes across the data, which they clustered into early themes and wrote brief
descriptive summaries of each. There was little disagreement between the researchers when clustering
codes into early themes; however, the labelling and descriptions of early themes were discussed and
revised collaboratively to agree on wording that was acceptable to both researchers.
Following grounded coding of the first eight focus group transcripts, these data and associated codes and
preliminary themes were entered in to NVivo version 10 (QSR International, Warrington, UK) to increase
data manageability and retrieval. The researchers had regular meetings in which early themes and their
associated data extracts were printed out and discussed with reference to the data extracts to within the
theme and against other early themes. During these discussions, themes were refined and the changes
saved within NVivo. The associated summaries of the early themes were also extended and refined and
saved within Microsoft Office® 2010 (Microsoft Corporation, Redmond, WA, USA) documents with the
associated data extracts coded within that theme. At this point, the researchers considered all thematic
categories and began to jointly identify the thematic areas that were emerging to be most relevant to the
research questions of interest. The researchers presented the developing themes and associated data
extracts to the wider research team at frequent intervals in order to inform, when possible, the content
and development of the gist, narrative, GP and ER letter interventions.
Following the identification of key themes, the researchers created a framework grid in which the data
extracts illustrating each emerging key theme were inserted alongside the focus group number and
participant from which they had originated. This allowed the researchers to easily identify the individual
focus groups from which data extracts had been categorised and, importantly, allowed the researchers
to identify the ‘spread’ of emerging key themes across the eight focus groups. This revealed that the
coidentified key themes were present and repeated across the majority of the focus groups.
As the remaining 10 focus groups were completed and transcribed, the data were coded by the same
two researchers using the thematic framework developed during analysis of the first eight groups. The
researchers also undertook some open coding for which data did not fit into a pre-developed theme.
The themes were revised and refined with reference to these data when necessary, as were the thematic
summaries. The thematic framework was barely changed with the addition of the second phase of focus
group data indicating that the key themes relating to gFOBt non-uptake had reached saturation. However,
analysis of these data did lead to the generation of new codes relating to ‘tipping points’ to screening,
which were clustered into themes following the same processes described above and saved as word
documents comprising a descriptive summary below which all the relevant data extracts were saved.
The identification of these new themes was due to the inclusion of participants in the second phase of
focus groups who had changed from non-uptake to uptake of gFOBt on a subsequent invitation to the
NHS BCSP. The framework grid of key themes and illustrative data extracts was extended with data
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extracts and the new ‘tipping point’ themes from focus groups 9–18. Our analysis produced detailed
summaries of the key themes accompanied by extensive illustrative empirical material, which were written
up for publication.
Once all focus group data had been analysed, the researchers undertook additional comparative analyses
to determine if themes could be identified that were specific to focus groups clustered by gender,
occupational background, ethnicity or geographical location. Only one such theme was identified, which
related to the way in which participants with ‘professional occupations’ described ‘delay’ as a key
component of their gFOBt non-uptake. However, in the vast majority, the key themes relating to gFOBt
non-uptake were present and repeated in each focus group. The key theme relating to ‘tipping points’ to
screening was present and repeated across groups 9–18 because these were the groups containing
participants with experience of taking part in a subsequent screening round.
Throughout the analytical process, emerging themes and their associated illustrative quotations continued
to be presented to the wider research team for discussion and to inform intervention development. The
key themes were also presented to study coapplicants present at the ASCEND steering group.
Results
Participant characteristics
In the first wave of recruitment, 2560 participants were invited (1280 from areas served by each hub). We
anticipated a 2.5% response rate, which would equate to approximately 32 responders in each hub area.
We estimated that we should be able to convene two focus groups of between 6 and 12 participants in
both areas with this level of response. Our response rate was actually nearer 5% and, therefore, we were
able to convene four focus groups in each area. In the second wave of recruitment (and in order to
achieve at least a further six focus groups), the hubs posted invitations to 2540 individuals (1270 from
areas served by each hub).
As a result of these two separate waves of recruitment via the NHS BCSP, we received 243 completed
consent forms from 129 men and 114 women. A total of 111 individuals subsequently attended a focus
group. We intended to run 14 focus groups but were able to hold 16 owing to higher than anticipated
response rates. We paid attention to ensuring the sample included a balance of men (n = 60) and women
(n = 51), and individuals with reported professional (n = 61) and non-professional (n = 50) occupational
backgrounds (see Table 2). Reported professional occupations included teacher, local government officer,
solicitor, civil servant, nurse, dentist, journalist, artist and social worker, and non-professional occupations
included sales assistant, cook, cleaner, carer, builder, miner, driver, waitress, postman and carpenter.
Recruitment using a market research company resulted in one focus group of seven primarily African
Caribbean men and the approach by the research team to the north London church exercise group
resulted in one focus group of 10 primarily African Caribbean women. In common with the purposively
sampled focus groups, the two opportunistically recruited focus groups comprising individuals of African
Caribbean origin also included participants who had and had not taken part in bowel cancer screening;
however, these two groups were not organised with reference to occupational background.
In total, 18 focus groups were held with a total of 128 participants (Figure 3). The majority of participants
recalled receiving invitation(s) and gFOBt kit(s) from the NHS BCSP. One hundred participants reported
gFOBt non-uptake on at least one occasion, of whom 31 went on to complete the gFOBt kit when they
were invited to take part in a subsequent screening round. Nine participants had not completed the gFOBt
owing to ‘alternative uptake’ of bowel cancer screening, such as colonoscopy, endoscopy or gFOBt kit
completion in primary or private care. Our comparative analyses found high consistency in accounts for
non-uptake regardless of gender, ethnicity, occupational background or geographical location.
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Themes
We present our findings as a series of six themes described below. To ensure anonymity, the identity of
participants who provided the selected direct quotations is limited to focus group attended (i.e. FG01) and
assigned participant number within this group (e.g. P1).
Themes common across non-professional and professional occupational groups
Risks posed by faeces
Participants in all focus groups explained their aversion to completing a gFOBt kit by reference to the
perceived risks that collecting, storing and posting samples of faeces posed to hygiene. These risks were
heightened by the requirement to complete the kit with samples from three separate bowel movements,
which meant that the kit had to be stored over several days. Participants reported that the completion of
the gFOBt kit threatened to physically pollute them or their environment and that they would need to go
to extreme lengths to manage these perceived threats:
People’s hands have to handle this yes? You don’t know how strong germs get . . . so I don’t fancy it
going through the post.
FG17P1
It’s like sort of not flushing, only worse, it’s sort of not nice . . . I wanted to scrub the bathroom down
every day, so I thought it’s not worth the hassle.
FG03P5
Invitations sent by the NHS BCSP 
to eligible individuals inviting 
them to take part in a focus group
(n = 5100)
Participants (all male)
recruited purposively 
by market research agency
(n = 7)
Participants (all female)
 recruited opportunistically 
through approach to 
community organisations
(n = 10)
Participants who returned a
completed consent form 
indicating willingness to take
part in a focus group
(n = 243)
Participants who 
returned a consent 
form without adequate 
contact information
(n = 16)
Professional
occupation
(n = 34)
Non-professional
occupation
(n = 26)
Male
(n = 60)
Professional
occupation
(n = 27)
Non-professional
occupation
(n = 24)
Female
(n = 51)
Participants who 
attended a focus group
(n = 111)
FIGURE 3 Recruitment of focus group participants.
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Completion of the gFOBt kit was considered to pose serious and fundamental threats to notions of socially
acceptable and proper behaviour. Participants reported discomfort at the idea of handling faeces because
this was an activity that was abnormal, broached a cultural taboo or could cause embarrassment
and shame:
You wouldn’t normally leave faeces in your bathroom for 3 days.
FG07P3
FG08P5: It’s just not the done thing is it?
FG08P6: No – to mess about with it.
What will happen in the bathroom with it . . . you know the whole complication of where to put it
and if someone else walks in and finds it.
FG16P4
The perceived taboo of interacting with faeces was further illustrated by participants’ concerns about being
‘found out’ to have completed the gFOBt kit. Being found to have stored or posted faecal samples was
believed to be potentially socially and personally damaging, in that it could reflect badly on the individual
and undermine them in the eyes of others. Some participants described the requirements of the gFOBt as
‘offensive’ and ‘degrading’. The use of the term ‘degradation’ is of particular significance, because it
carries ideas of personal cost in that it compromises the individual. Thus, completing the kit raised the
threat of being at best embarrassed and, at worst, disgraced and discredited:
Put your poo in the post . . . I thought oh god, y’know it’s got your name on it and what if they
open it.
FG15P5
I’ve had two I’ve sent them both in the dustbin. I won’t discuss it but I were a bit offended.
FG09P6
I’ve had one and I ain’t done it, I just felt degraded to tell you the truth.
FG11P5
The aversion to dealing with faeces that emerged in participants’ accounts of non-uptake is underpinned
by deeply ingrained definitions of faeces as a taboo substance65 and rigid social rules surrounding how it is
appropriately dealt with.
Detachment from familiar health-care settings
Participants reported discomfort with the detachment of the gFOBt from ‘usual’ health-care settings and
professionals. They expressed a preference to attend a health setting such as a general practice or hospital
and for ‘someone else’ to undertake the screening on their behalf:
Why don’t they send you t’doctors or hospital to have it done there? . . . if the doctor sent for me and
said I want to do so and so for you I’d go, or the hospital but doing that meself, I didn’t like it at all.
FG09P6
On one level, participants linked their desire to ‘go somewhere’ such as a general practice or hospital with
the avoidance of having to collect and sample their faeces. However, participants’ references to medical
settings as ‘preferred’ also revealed that the invitation to the NHS BCSP was out of context and unsettling,
because it required them to undertake a health procedure outside the settings in which health care is
usually practised. Further linked to this was a perception of ‘self-testing’ as unusual and unexpected,
WORKSTREAM 1: FOCUS GROUP STUDY
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particularly in comparison with other screening experiences or medical interactions where ‘a professional’ is
involved in the procedure:
I thought ‘oh my god now we are asked to be doctors’.
FG16P6
I threw mine away, I’d rather have it done for me.
FG04P5
I’d rather go somewhere and have it done to be quite honest.
FG04P6
Participants emphasised that it was unusual to play an active role in a health procedure, when the norm in
medical encounters was for them to be the passive ‘receiver’ of care. They also disliked the impersonal
nature of home testing:
I would prefer my doctor to have some obvious interaction with me in the actual process rather than it
being done with an anonymous third party.
FG01P8
By extension, it was noteworthy how many participants claimed that, had they been given an appointment
to attend, or been told by their GP to complete a gFOBt kit, they would have done so. Therefore, it
appeared that the detachment from clinical settings and professional roles may have reduced the perceived
importance of the offer of screening:
The message that was communicated to me was that this was hardly urgent or serious because if it
was they would send me off to have a clinician do it.
FG01P1
If the letter had come from my GP . . . I would have taken it more seriously.
FG18P6
The prospect of self-sampling at home inhibited rather than facilitated uptake.
The implications of knowing the screening results
The most complex theme to emerge related to the implications of knowing the screening results.
Participants preferred not to be in possession of this information for several reasons. First, they commonly
referred to the undesirable implications of a positive result. Thus, they expressed unwillingness to undergo
the recommended procedures that may follow a positive gFOBt kit result, such as colonoscopy or
bowel surgery. These participants often referred to previous experiences (their own or those of family
members) of bowel investigations or treatment for gastroenterological problems and described their
negative consequences:
It’s the after effects, if they do find something, that would put me off taking the test in the first place
. . . it’s the colonoscopy, the treatment of the colonoscopy.
FG10P3
Non-uptake was therefore a means to protect oneself from the possible unpleasant consequences of a
positive test.
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Second, participants distinguished between ‘being unwell’ and ‘knowing about being unwell’. A positive
screening result meant that they would need to ‘redefine’ themselves as being unwell, which they did not
wish to do because they believed it was unnecessary:
If there’s something the matter with me now, and I don’t know about it, I’m fine. If somebody says
I’ve got a problem, I’m going to worry about it, and I don’t want that, you know you live life as it is
now and I don’t want people finding things.
FG10P6
Thus, there emerged from participants’ accounts an alternative reading of screening as an activity that,
rather than maintaining good health, may actually be complicit in generating ill health. By presenting
screening as a process that could undermine health and questioning the value of the knowledge offered
by screening to the maintenance of good health, participants pointed out that the benefit of declining to
complete the gFOBt kit allowed one to ‘get on with life’:
This is just like sticking your head down the loo and thinking you’ve got cancer all day, you know
there’s a balance of how much ‘into’ things you should get.
FG03P3
To me it’s like mollycoddling yourself so everything working right, don’t mess about with yourself.
FG05P1
Finally, the possibility that screening might identify cancer and result in subsequent interventions was
described by some participants as too frightening to contemplate. The knowledge offered by screening
was, for some, a stressful and frightening prospect, to the extent that actively choosing not to be in
possession of this information was preferable:
I’m scared, simple as that . . . it’s the test coming back positive that worries me, so I tend to ignore it
and hope it goes away.
FG02P2
Researcher: What’s frightening?
FG13P3: What actually might be discovered, what I don’t know is not there like, if you know what
I mean.
Thus, some participants demonstrated an ambivalence towards, or overt rejection of, the knowledge
offered by screening. Analysis of the accounts of participants who ‘didn’t want to know’ found that it was
also common for such participants to describe cancer as a particularly serious and frightening diagnosis for
which treatment was unpleasant and often futile. Participants’ attitude towards cancer treatment further
underpinned their rejection of the knowledge offered by screening because, if there was perceived to be
little benefit associated with treatment, there was little point in taking part in screening:
[A friend] went through all that chemotherapy and all that suffering it didn’t make a . . . difference.
FG08P6
Judgements of good health and low relevance of screening
Many participants believed that the gFOBt was irrelevant because they were certain that they did not have,
and were unlikely to get, bowel cancer. The evidence they cited included a lack of symptoms, being
physically active and having no family history of bowel cancer:
I’ve got no symptoms so I’m all right, y’know, I go to the toilet regular and y’know, I exercise and I’m fit.
FG09P1
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Descriptions of being in good health were often interwoven with other themes of non-uptake.
Themes present among professional occupational groups only
Delaying uptake, leading to non-uptake
No themes emerged solely from participants with non-professional backgrounds; however, we identified
one theme associated with non-uptake which was discussed only by participants with professional
backgrounds. These respondents commonly described their non-uptake in terms of delay, rather than
outright rejection. Participants reported that the gFOBt kit was ‘put to one side’, or ‘put in the in-tray’
implying some degree of intention to participate, but ultimately kits were not completed. Delay was often
linked to descriptions of the complexity of the instructions for completing the gFOBt kit and also the
time-consuming nature of kit completion:
You’ve got to really sit down and read it, you can’t, it’s not just something you can pick up and say
‘oh I’ll go and do that now’, you’ve got to study it.
FG12P4
It’s quite a long-winded, drawn out thing I just kept putting off doing it.
FG03P8
There was a common misconception among participants in all focus groups that samples had to be taken
on three consecutive days. Respondents from professional backgrounds cited this rigid, 3-day ‘window’ for
test completion as a cause of delay and subsequent non-completion because it was not possible to fit the
test requirements in with their bowel movements or routine and lifestyle:
If I start it on one day I’ve got to remember then to do it for the next 2 days and that was a big block
for me because I’m very rarely in the same place for 3 days in a row.
FG14P8
Non-uptake followed by uptake in a subsequent screening round: the power
of talk – a key ‘tipping point’
Participants from all occupational backgrounds who reported that they had not initially participated in
screening and had then completed the gFOBt kit in a subsequent screening round described being
influenced by discussions with family members, friends and health professionals. They reported being
questioned about their initial refusal to complete the test or being told outright to take part in bowel
cancer screening. They also recalled supportive discussions in which their concerns about or aversions to
the gFOBt kit were discussed and challenged. Participants reported that becoming aware that their partner
or friends had already completed the gFOBt kit was influential. In addition, they reported that becoming
aware that a family member or friend had developed bowel cancer influenced them to take part in screening:
My brother-in-law was diagnosed with bowel cancer after I’d had the first request which I totally
ignored . . . my wife did [her gFOBt kit] and she got her results back which were clear, peace of mind,
I thought well you silly bugger, you know, why didn’t I do [it].
FG09P4
A friend also had it and she was telling me about how she did it and I thought gosh it’s not as
complex as I think.
FG16P2
Discussions in which other individuals championed participation in screening or revealed their own gFOBt
kit uptake were repeatedly implicated by participants as the key tipping point to a decision to undertake
screening on a subsequent occasion. Through talking with others, participants described themselves as
‘nagged’, encouraged and reassured to undertake the gFOBt. Furthermore, through talking with others
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and becoming aware of others’ completion of the gFOBt kit, uptake was repositioned as a normal activity.
The particular power of talk appeared to normalise the unusual, unexpected and potentially taboo aspects
of the gFOBt kit:
I think as well it’s a critical mass isn’t it, so you discover your friends are all doing it or whatever so
then it does become a slightly normal thing to do.
FG16P1
Discussion
Our analysis of participants’ accounts has identified key themes that inform understanding of why
non-uptake of bowel cancer screening occurs. Furthermore, our comparative analysis of focus group data
by area (inner-city London, Doncaster and Barnsley), gender, occupational background and ethnicity found
few differences in the ways in which participants accounted for non-uptake. In common with previous
studies,45,50,51 we have identified the threats to hygiene posed by completion of a gFOBt kit. However, our
analysis extends the understanding of the problems posed by faeces with the concept of ‘social pollution’.
Taboos surrounding interactions with faeces65,66 mean that completion of a gFOBt kit may be considered
‘improper’ in addition to unpleasant. The troubling nature of faeces is therefore a key element in
participants’ non-uptake of the gFOBt. In addition, we found that the requirement to undertake the gFOBt
kit oneself and in one’s own home represented a detachment from familiar medical settings and roles,
which, in turn, impersonalised or devalued screening as a valid health endeavour. The prospect of
self-testing at home was for some unsettling rather than facilitating of uptake. This finding is unreported
elsewhere in the literature.
Ambivalence about the value and benefit of the knowledge offered by screening, and of medical
intervention more generally, has been identified previously.47,50,51 Participants confidently articulated the
negative implications of participation in screening and emphasised the benefits of not being in possession
of such knowledge. Non-uptake was therefore presented as having protective and beneficial effects. In
addition, we found that participants described delay and non-uptake of the gFOBt kit owing to its
prolonged and complex nature, and identified misconceptions about correct test completion that may
contribute to perceptions of complexity. We further identified the well-documented misconception that
having no symptoms meant that screening was not needed.44,47,49,50 Finally, we have identified the
influence of talking with others as a tipping point to uptake of screening. We suggest that it is through
talk that completion of a gFOBt kit may be ‘reformed’ as a normal and culturally appropriate activity, and
that concerns about its unexpected and potentially inappropriate aspects may be alleviated.
Strengths and weaknesses
This study adds significantly to the qualitative literature exploring gFOBt non-uptake and offers unique
insights relating to the NHS BCSP in England. The strength of the study lies in our grounded and inductive
analysis of an extensive qualitative data set generated through focus groups with participants who had
actual experience of screening non-uptake within the NHS BCSP. Moreover, this is the first study, to our
knowledge, to have explored changes of uptake decision at a subsequent screening round to generate
insights into the ‘tipping points’ for uptake of gFOBt. Importantly, our analysis has identified the ‘faecal
factor’ to be a key element in non-uptake of screening, differing somewhat from previous studies that
have found such concerns to be downplayed.45,50,51 However, in these studies, the majority of participants
had undertaken screening and, therefore, such concerns were likely to have been minimised.
Our data comprise the accounts of participants who recalled an invitation to screening, who knew they
had not taken part and were, as such, able to report on the experience in a focus group. However, there
were a small number of participants who exhibited little knowledge or recollection of being invited to
screening. These participants illustrated that it is possible to be unaware of one’s non-uptake, possibly
because the invitation to screening or purpose of the gFOBt has made little or no impression (or may never
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have been received). Low literacy on the part of a participant may render the entire experience of being
invited to screening inaccessible and unknown67 and, thus, ‘unreportable’ in the context of a focus group.
We therefore acknowledge the limitations, as well as the utility, of insights based on participants’
accounts. Finally, we acknowledge that our sample excluded participants who required care owing to
dementia, stroke or learning difficulties because of challenges for such participants to take part in a
focus group.
A further strength of the study is the unique method of recruitment, which was largely achieved through
direct invitation from the NHS BCSP. This enabled us to ensure that our sample included a majority of
individuals who had not taken part in screening. It further enabled composition of the focus groups which
maximised the potential for comparative analyses of the data by reference to gender, area (inner-city
London and two towns in South Yorkshire) and SECs of participants. However, we were not able to
specifically recruit low-literacy adults (one of the groups we had intended to recruit via ContinYou) using
this method, as we might have been able to had we been able to recruit participants through our charity
partners and community settings. Indeed, inviting people by a written letter may have positively excluded
low-literacy individuals.
Some participants reported a screening history that did not match the hub’s records. The hub invited to
focus groups only those individuals who had not responded to a screening invitation on at least one
occasion. However, a small number of participants reported never having been invited to screening or
always having taken part when invited to be screened. This discrepancy may be secondary to incorrect
NHS BCSP records, invitations being lost in in the post or sent to an incorrect address (addresses are
supplied to the NHS BCSP by the individual’s GP), participants’ forgetfulness or unwillingness to admit to
non-uptake within the focus group. In the London hubs’ experience, invitations are particularly likely to be
lost in the post if individuals live in blocks of flats where the postal officer leaves all the post in the hallway
of the block rather than in individual letter boxes.
In our first wave of NHS BCSP recruitment, a number of participants reported having previous experience
of ‘alternative’ bowel screening through colonoscopy or gFOBt in primary or private care. These
participants were positive about screening and uptake, and simply had not taken part in the NHS BCSP
offer of screening because they already had recent information about their bowel cancer status. Therefore,
in our second wave of recruitment we elicited whether or not participants had previous experience of
‘alternative uptake’ of bowel screening and did not invite people in this category, in order to maximise the
number of participants who did not take up screening for reasons other than receiving surveillance outside
the screening programme.
Previous/current occupation was used as a pragmatic indicator of SECs to allocate participants into groups
with others of similar occupational background and, therefore, SECs. It is possible that organising
participants by a different classification system may have produced different results. However, owing to the
large number of focus groups undertaken, and the homogeneity of results across all groups regardless of
occupation, it is unlikely that this would have been the case.
Conclusion/summary
Our focus group study provided insights into why people do not take part in bowel cancer screening and
why people participate in one round of screening but not in another. The findings from this study were
used specifically to inform the design of ASCEND intervention 4, described in Chapter 8. Although not
intended to be used directly to inform the design of intervention 2 and 3, it emerged from the focus
groups that learning of other people’s views and screening experiences could act as a decision ‘tipping
point’ and that input from a GP would influence people’s intention to take part in screening, further
emphasising the potential impact of these interventions.
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Chapter 4 Workstream 1: key informant study
Introduction
In workstream 1 we explored the psychosocial and cultural determinants of low uptake of the gFOBt. In
this chapter, we describe how we undertook interviews with ‘key informants’ representing South Asian
Muslim, Sikh and Hindu faith communities in London, in order to explore culturally specific barriers to
uptake in South Asian communities and to identify appropriate strategies to increase uptake which could
be specifically targeted for minority ethnic groups who speak English.
Uptake overall within the NHS BCSP is about 56%, but this figure masks much lower rates in South Asian
communities, which vary from 31.9% in the Muslim community, through 34.6% in the Sikh community to
43.7% in the Hindu community, than in ‘non-Asians’.40–42 South Asian minority ethnic communities
(comprising Indian, Pakistani and Bangladeshi groups) make up 7.5% of the population of England and
Wales.68,69 Low uptake of bowel cancer screening in the UK has continued to be identified in areas with
higher ethnic diversity5,12,54 and within all South Asian religiolinguistic groups, even when age, deprivation
and gender are adjusted for.40,43 A study of participation in bowel cancer screening using FS (an internal
examination undertaken by a medical professional) similarly found lower uptake by South Asian
participants after socioeconomic status had been controlled for.70 Inequalities are also present in the
longer-established UK breast and cervical screening programmes.40,43,69,71–73 Uptake across screening
programmes has consistently been lower in London than in the rest of the country, and this has in part
been attributed to its diverse population.73–75
Many of the studies which have sought to explain reasons for ethnic disparities in screening uptake
originate from the USA and present insights relating to black American, Hispanic, Latino and other ethnic
groups. Importantly, many of the structural and financial barriers exposed in US studies do not apply to the
English health-care system, in which health care is free at the point of access and bowel cancer screening
is made available through a nationally organised screening programme.44,76–78 Their findings therefore offer
limited scope for comparison with the UK setting.
A number of UK studies have found that reasons for low or late uptake of breast and cervical screening by
minority ethnic women include low knowledge and awareness of these cancers and related screening
services;75,79–81 inaccurate screening registers;82 misconceptions about the smear test; fear; embarrassment
and negative previous experience;75,81 language, literacy and administrative difficulties; cultural values and
beliefs; misconceptions about perceived risk; concerns about surgery hygiene; and poor attitudes of
GPs.73,74 Reasons for non-uptake of bowel cancer screening are likely to include some of those identified
for breast and cervical screening programmes, but may also relate to the way in which bowel cancer
screening is offered by written invitation requiring home-based self-completion of the gFOBt, with no
face-to-face contact with a medical professional.
Research exploring acceptability of the gFOBt among minority ethnic communities is limited to a single
study undertaken prior to the initiation of the NHS BCSP involving participants from diverse minority ethnic
groups, most of whom had not yet been invited to bowel cancer screening.42 The study found that
although people supported the principle of screening and completing a gFOBt once it had been explained
to them, many participants would not respond to postal invitations without prior warning being given,
preferably by trusted local sources, invitees would require support from family members to translate
information materials and translated materials could pose problems owing to poor literacy in their first
language and limitations of translations because of dialects spoken.42 Two studies exploring low uptake of
bowel cancer screening by FS in diverse minority ethnic groups reported low knowledge and awareness of
bowel cancer, anxiety about test invasiveness, fear of cancer, language difficulties, religious sensitivities
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and embarrassment as barriers to participation.55,70 However, the relevance of these findings to low uptake
of gFOBt is limited owing to differences in screening test procedures. Importantly, no studies have explored
explanations for the differences in gFOBt uptake identified in the Muslim, Sikh and Hindu faith communities.42
The UK South Asian community comprises multiple ethnic groups with a diversity of religious, linguistic,
cultural and geographical origins, and there have been calls for greater attentiveness to this heterogeneity
in health research involving participants of South Asian origin.83,84
Aims
1. To explore reasons for the variations in bowel cancer screening uptake between South Asian Muslim,
Sikh and Hindu faith groups.
2. To explore reasons for low uptake of bowel cancer screening in all South Asian communities and
identify possible methods by which uptake might be improved.
Objective
To understand reasons for low uptake of gFOBt screening by UK South Asian communities using key
informant interviews with participants representing Muslim, Hindu and Sikh faith groups in London.
Methods
Theoretical and methodological underpinnings
This study used interviews with key informants to generate insights regarding acceptability and accessibility
of an invitation to the NHS BCSP among a number of South Asian minority ethnic communities. The key
informant approach originates within the anthropological ethnographic tradition in which members of a
particular culture or community facilitate access to, and understanding of, features of their community on
behalf of a researcher. Key informants are individuals who, owing to their position and immersion in a
particular community, can provide information and insight regarding the experiences and needs of the
community they represent.85 Key informant interviews have been successfully used across a number of
social research disciplines to generate contextually detailed and culturally informed knowledge about
community members’ use (or non-use) of health services.86 We have taken a realist view of the data
generated during interviews with key informants.
Recruiting key informant participants
We aimed to recruit key informants from the three largest South Asian faith communities in the UK.
Approximately half of the UK South Asian minority ethnic population lives in London,68,87 and we recruited
key informants via direct approaches to 26 London-based faith and community organisations that provide
services specifically to South Asian communities. Organisations were identified via internet searches and
professional and personal contacts. Potential participants were contacted by e-mail or telephone, provided
with information about the study and invited to participate. Key informants were purposively sampled to
ensure that they held an embedded role within an organisation serving one of the three main South Asian
faith communities (Islam, Hinduism and Sikhism) and that they spoke English at a level suitable for
interview. A snowball technique was used to generate further contacts for possible participation.
In addition, we recruited GPs working in areas with large South Asian populations via two Comprehensive
Local Research Networks (North West London and East London) and personal contacts. Populations
represented by GPs comprised mixed faith, ethnic and linguistic groups. Interviews were arranged for a
time and place convenient to each participant.
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Final key informant participant sample
A total of 16 key informants participated in the study, of whom 12 held roles across a total of 10
community or faith organisations that served people of South Asian minority ethnic origin as follows: four
informants representing the Sikh community held roles in Gurdwaras or community groups based in West
London, four informants representing the Hindu community held roles in Mandirs or community groups in
West and North London, four informants representing the Muslim community held roles in third-sector
organisations that support the Bangladeshi community in East London and, therefore, represented a
specific Muslim ethnocultural group originating from the Sylhet region of Bangladesh and the final four
key informant participants were GPs serving areas with a large South Asian minority ethnic population in
the London boroughs of Barnet, Tower Hamlets, Harrow and Redbridge (Table 3). Fifteen participants were
of South Asian minority ethnic heritage and one was white European.
Topic guide
We used a short topic guide (Box 1) to ensure coverage of relevant questions.
Undertaking the interviews
Between May and December 2013, semistructured face-to-face interviews were undertaken with 16 key
informants. All interviews were undertaken at the organisation from which the key informant had been
TABLE 3 Key informant participant sample
Interview
number
Organisation key
informant recruited
from Area
South Asian community
represented Sex
1 Social/community group
linked to Gurdwara
Southall, West London Sikh community Male and female
2 Mandir Neasden, North West
London
Hindu community Female
3 Community health
charity
Tower Hamlets, East
London
Muslim community
(Bangladeshi)
Female
5 Community centre Tower Hamlets, East
London
Muslim community
(Bangladeshi)
Male
6 Community charity Tower Hamlets, East
London
Muslim community
(Bangladeshi)
Female
7 Mandir Wembley, North West
London
Hindu community Female
8 Community charity Tower Hamlets, East
London
Muslim community
(Bangladeshi)
Female
9 Gurdwara Hounslow, West London Sikh community Male
10 Social/community group Barnet, North London Hindu community Male
11 Mandir Southall, West London Hindu community Male
12 Gurdwara Ealing, West London Sikh community Male
13 GP Barnet, North London Mixed with large Indian
Gujarati-speaking population
Female
14 GP Tower Hamlets, East
London
Bangladeshi largely
Sylheti-speaking population
Female
15 GP Harrow, North West
London
Mixed with large Indian
Gujarati-speaking population
Female
16 GP Redbridge, Essex Mixed Pakistani, Indian and
Bangladeshi population
Male
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recruited and were conducted in English by a female researcher (CP). Interviews began with a brief
explanation and presentation of the NHS BCSP invitation materials, which formed the starting point for
participants’ comments and reflections about the accessibility and acceptability of an invitation to the NHS
BCSP for members of the communities they represented. Interviews lasted between 25 and 40 minutes
and were audio-recorded with the permission of the participant. A donation was made to the key
informant participant’s organisation in recognition of their time. Donations were not made to the
GP participants.
Data management and analysis
Following each interview, the audio-recording was transcribed verbatim using a professional transcription
service. Transcriptions were checked and amended for accuracy against the audio-recordings and interview
notes, and any identifying information was removed from the transcripts. Transcripts were not returned to
participants for comment or correction.
We undertook an inductive analytical approach to generate themes from the data.57 Each transcript was read
and coded by at least two out of three team members (CP, MT and LM) and the data were initially analysed
separately by reference to faith community. Authors met to generate preliminary themes using the codes
and compared themes to identify commonalities and differences between data generated across the three
faith communities. Key themes were then refined and defined in relation to the areas of research interest.
Ethics
Ethics approval for this study was granted by the National Research Ethics Service Committee London-Bromley
(reference 11/H0805/7). NHS research and development approvals were gained for interviews undertaken
with GP informants. Written informed consent was obtained from all participants.
Results
Key informants provided detailed commentaries about how their communities would be likely to respond
to an invitation to take part in the NHS BCSP. Results are presented as three main themes relating to low
uptake of bowel cancer screening that were described across faith groups: limitations posed by the written
word, low awareness of bowel cancer and screening, and difficulties around faeces and gFOBt completion.
Within each theme we also report suggestions to increase accessibility and uptake. Finally, we present
reasons for low uptake specific to Muslim Bangladeshi and Sikh faith groups. Data extracts are identified
by community represented and interview number (see Table 3).
BOX 1 Key informant interview topic guide
l What do you think might happen when this invitation and test kit comes through the door?
l Would it be easy for people to take part in bowel cancer screening offered in this way? (Why/why not?)
l Why might people not take part?
l Why do you think uptake of screening for bowel cancer is lower in South Asian communities/the (specific)
South Asian community you work with?
l (Other than what you have already described) are there any other reasons why you think uptake of bowel
cancer screening is lower in South Asian communities/the (specific) South Asian community you work with?
l Are there ways in which uptake of bowel cancer screening could be increased in South Asian communities/
the (specific) South Asian community you work with? (How do you think this could be done?)
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Themes
Limitations posed by the written word
Unanimously, key informants described how many South Asian elders eligible for bowel cancer screening
would not be able to engage with the letter and accompanying information that is sent by the NHS BCSP,
because they did not read or had limited ability to read and speak in English:
They don’t speak English, they don’t read English.
Muslim community informant 8
Some of the elderly [. . .] don’t necessarily have English as their first language.
Hindu community informant 2
. . . quite a lot of the older people don’t speak English very well.
Sikh community informant 9
Key informants across faith communities reported that it was common for sons and daughters to translate
and interpret written materials for older members of the family, and that support of this kind would be
required for the NHS BCSP invitation materials. Informants therefore suggested that the ability of those
invited to participate in screening may be heavily mediated by younger family members, who may further
make their own judgements about the importance and relevance of the screening invitation:
In terms of letters and stuff they won’t read them. They’ll get the kids to read it.
Sikh community informant 9
She [my mum] said to me, there’s a letter for me from the doctor. I came and looked at it but I didn’t
put that much emphasis on the importance, I didn’t encourage her to take up.
Muslim community informant 3
In recognition of the language needs of the population, the NHS BCSP offers translated materials, which
are available on request by telephoning the helpline. However, calling the helpline to request a translation
was perceived to require additional effort and motivation, potentially in the absence of knowledge
regarding what the recipient is seeking information about:
So what kind of person would ring [the NHS BCSP helpline], it would be someone who is very
motivated to want to do it. Or very interested in these letters coming through but they don’t
understand it.
GP informant 14
You’ve got to have some understanding of English to be able to say ‘I’ve got this letter, what shall
I do’.
Hindu community informant 2
Therefore, although translated materials were offered, informants identified that variable proficiency in
reading English would make accessing these challenging and, again, would require reliance on a family
member to mediate.
Indeed, the written word (whether in English or translated) as a medium for communication was
repeatedly described by key informants as unappealing and lacking impact and importance within their
communities; for these reasons, postal communications were often overlooked. Moreover, informants
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perceived that the NHS BCSP invitation letter and materials comprised too many words and too much
information, even for those who do read English:
I think they would probably get lost in these words.
GP informant 16
It’s a lot to take in [. . .] It’s just too much, to be honest.
Hindu community informant 2
Although several key informants suggested there may be some value in offering translated written
materials, it was noteworthy that, across all faith communities, human interaction involving face-to-face
discussion, verbal descriptions and demonstrations was the favoured means of communication to
effectively share information:
Our people are more visual learners [. . .] they rather see and hear before they make any decision.
Muslim community informant 6
They’ll need support, someone needs to show them what to do [. . .] it will require a conversation,
because otherwise I don’t see how they would understand how to do it.
Muslim community informant 8
Somebody who is like 60 or 65, English is not their first language, they probably need some human
touch where people can come and explain to them.
Hindu community informant 11
Key informants emphasised that these interactive approaches would be particularly useful within places of
worship or other settings in which community members gathered communally. Approaching community
members in a familiar place and at the group rather than individual level was strongly endorsed as a
means of increasing the understanding and confidence of community members, enabling them to more
readily engage in screening:
I think it’s coming into the community [. . .] at our Mandir it works really well because you’re capturing
the audience in their home, as it were, and they feel comfortable [. . .] as long as, of course, it’s in
their language as well.
Hindu community informant 2
Go into the community, showing them, telling them the importance.
Muslim community informant 3
Low awareness of cancer and screening
Informants reported that there was low awareness of bowel cancer and bowel cancer screening within
their communities. This was partly linked to the limitations of written invitation materials to enable
understanding as described previously. Informants suggested that participation in screening would increase
if communities were given information about the purpose and value of screening in culturally accessible
ways, as well as how to undertake the practical side of gFOBt kit completion:
Unless they understood how important it was, they wouldn’t do it. [. . .] you would need to tell them
what the facts and figures are, why it’s important for them to do it, what the risks are.
Muslim community informant 8
Explain to them properly if you send that kit back and if you have any problem then [. . .] they will be
treated in early stages they will be fine.
Sikh community informant 1
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Informants also identified low awareness of cancer being potentially curable and reported that cancer was
perceived to be serious, frightening and final. Informants suggested that such perceptions could
undermine engagement with screening:
Cancer is one of those things that everyone regards as you can’t do anything about it, once you get it
you get it, and that’s end of.
Muslim community informant 8
Most people think if they find they have the cancer, that’s it, that’s the end of the story. They’re too
scared to know the word, hear the word . . .
Hindu community informant 11
Informants across faith communities suggested that owing to low awareness of screening, the invitation to
be screened was likely to be perceived as having come ‘out of the blue’ and unsolicited because it comes
from a national source, rather than from a local familiar person (e.g. a GP) or organisation. Informants
suggested using media other than the written word, such as television or radio, to raise people’s
awareness of the NHS BCSP and to prepare and familiarise them for the forthcoming invitation and
gFOBt kit:
I would get something on radio and that would get the message across and then at least then they’ll
be looking out for the letters.
Sikh community informant 9
So you could almost do like a description of what might happen [on Asian radio and Asian television
Sky channels] and then they’d at least have an idea of what it is.
Hindu community informant 2
Informants suggested that awareness-raising should include positive information about early diagnosis and
cancer curability to counteract some of the fear surrounding cancer. Informants recommended that
information be provided ‘in language’ to groups within faith and community settings, incorporating
demonstrations of the gFOBt kit, face-to-face explanation and the opportunity to ask questions. Indeed,
informants reported health awareness activities were already taking place within a number of the
community and faith settings represented.
Difficulties associated with faeces and test completion
Informants suggested that the requirement to complete the kit with samples of faeces and to store the kit
over a period of days would be considered unpleasant and compromising to hygiene. They also considered
that community members would require help with how to collect and sample faeces but that, because of
the personal nature of the test process, younger family members would be less able to assist:
Doing something like this and having it out for 3 days with faecal matter on it is totally abhorrent to them.
GP informant 13
I see not many people doing this to be honest, especially because they don’t want to go around
sneaking their own poo.
Muslim community informant 8
This is something very personal you know toilet is something you don’t dare – even dare to ask
children you know ‘can you do that?’
Hindu community informant 10
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Informants suggested that a simplified test procedure that required a one-off sample might help overcome
some difficulties with test completion. They also suggested that community members be given the option
to take the gFOBt to their GP or practice nurse to seek explanation and practical instruction.
Reasons for low uptake specific to faith groups
Offering screening using written materials in any language was described as being a particularly ineffective
way to communicate with the Bangladeshi Muslim faith community owing to its largely oral (non-written)
culture. The majority of this community speak Sylheti, which is rarely used in its written form, and
community members were unlikely to be able to read in Bengali, meaning that written translations of
screening information would be of no use:
They don’t function in a written way [. . .] written information does not give people the ability to go
and do what needs doing.
GP informant 14
Most of these people, even in this age, they even don’t know how to read Bangla [Bengali].
Muslim community informant 5
Informants representing Sikh faith communities described a particular reluctance to disclose a cancer
diagnosis or talk about cancer more generally. This was explained in terms of a social stigma surrounding
cancer and fear of the potentially negative reactions from the wider community that may be elicited in
response to cancer:
. . . within the family someone will get cancer and they don’t talk about it. It’s just a social stigma on
things [. . .] they think that ‘what will other people think?’
Sikh community informant 9
People don’t want to talk, disclose their own thing. If even they do find out [they have cancer] they
don’t want to tell other people.
Sikh community informant 1
Discussion
We identified common reasons that may explain ongoing low uptake of bowel cancer screening across
South Asian faith groups. In all three faith communities, the delivery of bowel cancer screening using a
written approach directed at the individual was considered likely to be inaccessible to a significant number
of South Asian people of screening age. We also identified low awareness of the existence and purpose of
bowel cancer screening and of cancer curability. In addition, there were potential difficulties with gFOBt kit
completion linked to the requirement to deal with faeces and test complexity.
This study is the first, to our knowledge, to explore differences between South Asian faith groups in the
reasons for low uptake of bowel cancer screening. Uptake of bowel cancer screening within England’s
South Asian population is lowest in the South Asian Muslim community.42 This may, in part, be explained
by our finding that communication via written materials is particularly inappropriate for the London
Bangladeshi Muslim community owing to the largely oral culture of this community. The second lowest
uptake of bowel cancer screening in the South Asian population is reported among the Sikh community.42
Our finding that reluctance to talk about cancer is linked to social stigma surrounding cancer within this
community may go some way to explain the poorer uptake in this faith group.
Our findings that written invitation materials may pose particular challenges and that, even when
translated, written invitation materials are of limited value owing to widespread low literacy specifically
among older members of South Asian communities (to whom bowel cancer screening is offered) are in
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common with previous research.42 Difficulties related to language have also been found in relation to low
uptake of other screening programmes.73–75
Although previous studies have identified reluctance to talk about cancer linked with fearful perceptions of
cancer in mixed South Asian minority ethnic groups, these studies have not attempted to distinguish
between faith groups regarding the specific experience and impact of social stigma surrounding cancer.42,81
Our finding of low awareness of the purpose and value of bowel cancer screening across South Asian faith
communities confirms previous findings.42,55,73,75,81 A number of studies also found low knowledge and
awareness of cancer and fearful perceptions of cancer in minority ethnic groups,42,55,70,73,75,80,81 which
mirrors our finding that awareness of cancer curability was perceived to be low across South Asian faith
communities. Finally, we found perceived difficulties associated with the sampling and storage of faeces in
order to complete the gFOBt kit, including limitations on getting help from family members owing to the
personal nature of the test, which were also experienced within the majority (white European and African
Caribbean) population.32,50,51
We identified agreement across faith communities in the preferred approaches to increase accessibility and
awareness of bowel cancer screening offered by the NHS BCSP. In common with previous studies, we have
identified an overwhelming preference for face-to-face, verbal and interactive approaches in order to
provide information and raise awareness about the availability and purpose of bowel cancer screening.42,74
We also identified a desire for the provision of information to take place ‘in language’ within community,
faith and/or social settings;42,55,73 and the potential value of ethnic community media to publicise the NHS
BCSP and gFOBt completion.42,55 A simplified test kit and the option to seek screening guidance from the
GP or practice nurse were noted as further potential strategies to increase uptake. Our findings reiterate
existing evidence regarding strategies to improve accessibility and uptake of health services more generally
for South Asian communities, but we have also demonstrated that specific South Asian ethnocultural
groups may have distinctive features and needs.
Strengths and limitations
Interviews with key informants generated culturally and contextually informed knowledge about how an
invitation to the NHS BCSP may be received within faith communities. However, limitations exist in the
approach used because informants were expected to speak ‘on behalf of’ communities but may have
given their own personal views on bowel cancer screening as well as reporting more general cultural
issues. Furthermore, key informants are likely to have had a less detailed understanding of the NHS BCSP
invitation and test completion than participants with personal experience of being invited to screening.
Although we aimed to recruit informants to ensure representation of the three main South Asian faith
groups, we acknowledge that there is further diversity within each group that our sample was not able to
include owing to the scope of this particular study. Specifically, we were unable to recruit participants
representing the Pakistani Muslim ethnocultural group. We further acknowledge that the number of
informants representing each individual faith community was small and this may have meant that further
subtle differences between faith communities in their likely responses to an offer of bowel cancer
screening remained unexamined. Although our study sample was limited to London, the shared ethnic and
religious origins of South Asian communities across the UK are likely to mean that our findings have wider
relevance. Finally, we acknowledge that the language the interviews were conducted in (English) and the
gender and ethnicity of the researcher conducting the interviews (white European and female) is likely to
have had an impact on the sample of informants recruited to the study and the generation of data therein.
Conclusion
Our findings identify barriers to bowel cancer screening uptake in the UK for many people within South
Asian communities that persist despite being first identified over a decade ago.42 Design and evaluation of
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interventions to increase accessibility and awareness of bowel cancer screening are required and should
incorporate verbal and interactive approaches in the appropriate language for the target community in
order to address the limitations of written correspondence. An encouraging recent intervention study
tested the provision of health promotion information either face to face or by telephone through general
practices with a large minority ethnic population and found that these approaches led to significant
improvements in the likelihood of bowel cancer screening uptake.88 Approaches should further be
delivered within community and faith settings in partnership with representatives from these settings, and
be backed up with the use of local ethnic media. Given the role of children in mediating access to health
for older people across South Asian communities, it may also be beneficial to raise general and practical
awareness of the NHS BCSP across all age groups. Interventions involving GPs opportunistically offering
screening to low uptake groups could be explored. Design and delivery of interventions may need to be
further tailored to the distinct needs of specific South Asian minority ethnic and faith groups, for example,
by devising ways to tackle the social stigma associated with cancer in the Sikh community.
Reasons for low uptake of bowel cancer screening are predominantly shared across South Asian faith
communities. However, specific cultural issues such as non-written culture or social stigma surrounding
cancer may further explain low uptake in individual faith groups. Strategies to increase access to screening
should move away from the use of written messages mailed directly to individuals. Locally targeted efforts
using verbal and face-to-face approaches delivered in community settings, and backed up with the use of
local ethnic media, should be developed to enable people from South Asian communities to make an
informed choice about what screening can offer.
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Chapter 5 Workstream 2, intervention 1:
developing and piloting a ‘gist’ leaflet
Introduction
The first ASCEND intervention to be evaluated nationally in workstream 3 involved the inclusion of a ‘gist’
leaflet with the invitation letter and materials sent out by the NHS BCSP. In this chapter, we will first
describe the theoretical background to this intervention and we will then report how we carried out a
think-aloud study, which describes how the current NHS BCSP materials are received and how we then
developed the leaflet and tested it for comprehension with people with low levels of literacy. Finally, we
provide details of a pilot study that tested if the leaflet would influence people’s intention to take part in
screening. The results of the national RCT of the ‘gist’ intervention are reported in Chapter 10.
Theoretical background
Fuzzy trace theory (FTT) is a theory of judgement and decision-making.89,90 It has recently been applied to
the field of medicine and health91 and is a dual-processing theory which proposes that information is
encoded into memory in two parallel forms: a gist representation and a verbatim representation. Gist
representations are defined as vague, qualitative concepts capturing the bottom-line meaning of
information. As such, they are subjective to the individual and affected by a range of different core values.
In turn, these core values are influenced by factors such as emotional state, general world view, literacy and
numerical ability. In contrast, verbatim representations are precise and quantitative and said to capture the
surface form of the information (i.e. they are literal). For example, an individual reading ‘The Facts’ booklet
would first read about the efficacy of gFOBt screening in reducing bowel cancer deaths. A verbatim
representation of this would be ‘gFOBt screening reduces my chances of dying from bowel cancer by 16%’
and a gist representation might be ‘my chances of dying would be lower if I take part in gFOBt screening’.
Gist representations are formed along a continuum, which ranges from the simplest to most complicated.
People exhibit a consistent preference to use the simplest form of gist available when making a judgement
or decision89,92 particularly at older ages.93 For example, in a sample of students and physicians making
judgements on the cardiac risk of nine hypothetical patients, better discriminatory decisions resulted from
processing information in an ‘all-or-none’ fashion, as opposed to weighing up several details at once.94
Fuzzy trace theory argues that by presenting information in a format more closely aligned with preferred
processing styles (i.e. gist), retrieval will be improved and the cognitive burden placed on the reader will be
reduced.95 This will be particularly true for people with lower levels of health literacy and numeracy.96–98
It has therefore been suggested that pre-formulated gist-based information may improve gist extraction,
reduce cognitive burden and improve public understanding of screening.95 As such, FTT provides an
elegant theoretical model on which to base a cancer communication intervention that aims to reduce
socioeconomic inequalities in screening.
Study A: a ‘think-aloud’ study
A version of the ‘think-aloud’ study has been published in Smith et al.99 This is an open access article
under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
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In order to inform the design and content of our ‘gist’ leaflet, we carried out a ‘think-aloud’ study to
provide detailed commentary on how individuals process the information contained within the NHS BCSP
‘The Facts’ booklet. We set out to identify areas of the existing booklet (‘The Facts’) that were difficult to
read, confusing to the reader or detrimental to motivation in order to quantify them within a typology of
utterances. Furthermore, we sought to identify additional responses to the information using a more
in-depth qualitative analysis.
Methods
Participant recruitment
We recruited participants through two community organisations: Social Action for Health (SAfH) and
ContinYou. Additional individuals who had previously agreed to take part in studies with the University
College London (UCL) Health Behaviour Research Centre Panel were also recruited. Individuals were
purposively sampled from disadvantaged groups, because of the established link between literacy100,101 and
CRC screening uptake.12 A total of 21 eligible participants were identified and were sent an information
sheet and consent form to be returned to the study team via a freepost return envelope.
Inclusion and exclusion criteria
Inclusion criteria were being aged 45–60 years (i.e. before the age at which CRC screening is offered in
England) and no previous diagnosis of CRC.
The exclusion criteria were not being able to speak or read English, having previously participated in the
NHS BCSP and having severe cognitive impairment.
These criteria were chosen to ensure that individuals were relatively naive to the processes of CRC
screening and the accompanying information materials. Three participants completed interviews but were
subsequently excluded because one was illiterate and two had cognitive impairments. Participants were
paid £20 for their time and travel expenses. Interviews took place in the community or in university
meeting rooms.
The think-aloud method
The ‘think-aloud’ method entails the verbalisation of a person’s thoughts that would normally be silent,
while enabling the individual to continue with the primary task (such as completing a puzzle, calculating
a mathematical sum or reading textual information). The verbalised thoughts represent the current
contents of short-term memory, providing access to cognitive processes that occur during a task.102
A recent meta-analysis has demonstrated that the method is empirically and conceptually distinct
to introspection.103,104
Our study used a ‘marked protocol’ in which participants were prompted to make a comment every time
they encountered a small red dot in the leaflet. There were a total of 66 prompts that were placed by a
researcher at the end of bullet points and short paragraphs (i.e. two short sentences). When lengthy
paragraphs were included (i.e. two or three longer sentences), a prompt was placed after each sentence in
the paragraph. A marked protocol was used in this study as this approach has previously been shown to
elicit more instances of confusion and miscomprehension, which were primary aims of the study.105
Participants were asked to complete a brief sociodemographic questionnaire (see Appendix 11) on arrival
followed by the structured interview. In line with best practice for reporting think-aloud studies,103 the
statement below was read to participants prior to beginning:
In this exercise we are interested in what you think about when you read information. In order to do
this I’m going to ask you to THINK ALOUD as you read through some information. What I mean by
think aloud is that I want you to tell me EVERYTHING you are thinking from the time you reach a red
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dot. I would like you to think aloud CONSTANTLY from the time you reach a red dot until you have
finished telling me what you are thinking. I don’t want you to plan out what you say or try to explain
to me what you are saying. You may want to make predictions about what you are reading, rephrase
what you think the text is saying, share a story that describes something in the text that you’re familiar
with, remark on something in the text that is confusing, or say something else that helps you
understand the text you’re reading better. Just act as if you are in the room speaking to yourself. It is
most important that you keep talking. If you are silent for any long period of time I will prompt you by
saying ‘please carry on thinking out loud’.
Adapted from Ericsson and Simon102 and Crain-Thoreson et al.105
Participants were asked to practise thinking aloud on a control leaflet (‘Recycle to Save the Environment’),
which contained three prompts, before going on to read ‘The Bowel Cancer Screening Programme “The
Facts” Booklet’ (see Appendix 3). After participants had completed three successful utterances, they were
deemed ready to participate. If they did not reach this threshold during the practice session, the procedure
was explained again and they were given additional time to practise.
Sample size
When determining the sample size for think-aloud studies, it has been argued that a single test subject
yields up to one-third of usability problems, and after as few as five participants most issues are
identified.106 Therefore, we aimed to recruit a sample of 15–20 participants to ensure that the aims of our
study were met. Saturation (i.e. when no new themes or information was gained after several consecutive
interviews) was used as the marker at which recruitment ceased.
Measures of participant characteristics
The following participant characteristics were recorded: age, gender, marital status, first language, living
arrangement, employment status, education level, screening history (women only) and experience
with cancer.
Data analysis
Interviews were audio-recorded and transcribed. Occasions when participants deviated from the text (i.e.
failed to read the text or misspoke) were coded as reading mistakes. After this, prompted and unprompted
utterances (any statements made following a passage of text) were coded. Participants were not instructed
to make unprompted utterances prior to starting the interview. However, there was author consensus that
unprompted utterances, when made, were not substantially different from prompted utterances. All
utterances were therefore collapsed and analysed together. Analyses were performed in NVivo 9 (QSR
International, Warrington, UK).
We used a mixed-methods approach to analyse the data. First, a coding framework was developed in
consultation with previous literature105 and the research team (Table 4). We then performed a content
analysis, with utterances allocated to at least one theme. An utterance could be coded into several themes
if deemed necessary; however, when possible, multiple coding was kept to a minimum. An utterance
could also be split into several sections if the participant was discussing several aspects of the text. Two of
the transcripts (> 10% of the data) were second coded by an additional researcher to assess inter-rater
reliability. Reliability was found to be adequate to excellent (κ = 0.5–1.0).
In addition to the content analysis, we conducted an in-depth thematic analysis to provide insight into the
subthemes contained within the framework. Thematic analysis is used to identify, analyse and report
patterns (themes) within data.107 Although the majority of the comments were brief and provided little
insight past surface-level meaning, a thematic analysis allowed exploration of deeper-level meanings of
some comments. We used this approach because the aims of the study were to extract general
perceptions about ‘The Facts’ booklet, rather than understand individual experience with the information.
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To increase the validity of the thematic analysis, two researchers were responsible for analysing the
transcripts and identifying and categorising themes within each interview. These themes were analysed
across all transcripts using the constant comparison method.108 To increase the validity further, the wider
study group was responsible for suggesting alternative themes within the data and asked to assess
whether or not the suggested themes were adequately represented by the quotations.
Results
Participant characteristics
A total of 18 participants [mean age 55 years (range 48–60 years)] took part. As indicated in Table 5, the
sample was mixed. Participants predominantly spoke English as a first language and were of white
ethnicity: their level of education was mixed, and most had experience of cancer in some form.
Content analysis
In the 18 interviews, 270 reading mistakes were recorded (mean 15 per person; range 0–59). The
interviews yielded 776 coded utterances (mean 43.1 per person; range 8–95), which were analysed within
the predetermined framework.
TABLE 4 Coding framework
Name of theme Description
Deep processing An inference based on the text, which goes beyond repetition
Rephrasing of the text, which goes beyond repetition
An anecdote which explains the text
Surface processing Repetition or very near repetition of the text
Self-reported learning
Self-reported previous knowledge
Miscomprehension Confusion about a statement
An incorrect statement following a passage of text
Asserts that factual information is opinion
Emotional (negative) A negative reaction with at least one emotion in the sentence
Person mentions the information makes them feel the opposite of a positive emotion
Emotional (positive) A positive reaction with at least one emotion in the sentence
Person mentions the information makes them feel the opposite of a negative emotion
Unanswered questions An individual has unanswered questions following a passage
Layout An individual comments on the layout of the information
Unnecessary information Comments that indicate the information is unnecessary
Decrease motivation An individual remarks that something in the text would be demotivating to screening participation
Increase motivation An individual remarks that something in the text would be motivating to screening participation
Reproduced from Smith et al.99 This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
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TABLE 5 Study 1: participant characteristics
Characteristics n (%)
Gender
Male 7 (39)
Female 11 (61)
Marital status
Married/living with partner 6 (33)
Single/divorced/separated 9 (50)
Widowed 3 (17)
English as first language 18 (100)
Living arrangement
Own home/mortgage 9 (50)
Renting/other 9 (50)
Employment
Currently employed 10 (56)
Unemployed/disabled or too ill to work 6 (33)
Retired 2 (11)
Education
≤GCSE or O-level 4 (22)
>GCSE or O-level 14 (78)
Health literacy
Adequate 16 (89)
Inadequate/marginal 2 (11)
Ethnicitya
White 15 (83)
Non-white 2 (11)
Cancer experienceb
0 2 (11)
1 13 (72)
2 3 (17)
Breast screening historyc
Yes 11 (100)
No 0 (0)
Cervical screening historyc
Yes 10 (91)
No 1 (9)
GCSE, General Certificate of Secondary Education; O-level, ordinary level.
a One person elected not to answer this item.
b Cancer experience was quantified by assessing personal diagnoses of cancer (1 point) and/or knowing someone who
had been diagnosed with cancer (1 point).
c Women only.
Reproduced from Smith et al.99 This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
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There was substantial variation in the types of comments made by participants (Figure 4). The
comprehension theme was largely made up of comments that implied higher-level understanding (i.e.
deep processing, 17.9% of all comments) or repetitions of the text and unsubstantiated self-reported
knowledge (i.e. surface processing, 15.2%).
Responders were significantly more likely than non-respondents to be female [χ2(1) = 16.09; p < 0.001],
older [t(4401) = 6.16; p < 0.001], from an affluent neighbourhood [χ2(1) = 115.07; p < 0.001] and be in a
home with two or more invitees [χ2(1) = 4.05; p = 0.044].
Miscomprehension was less common (6.2%); however, this still amounted to 48 instances of mistakes or
self-reported lack of understanding. There were a high number of comments in the emotional theme.
Emotionally negative statements were three times more common than emotionally positive statements
(18.0% and 5.7%, respectively). The information preferences theme suggested that people desired further
information on specific aspects of the booklet (unanswered questions: 15.2%), while others suggested
improvements to the style and layout of the booklet (layout: 13.1%). A minority of statements questioned
the necessity of certain information that they had just read (unnecessary information: 4.8%) and
utterances rarely alluded to whether the participant felt motivated (1.4%) or demotivated (2.5%) by
information in the booklet.
Thematic analysis
Difficulties with numerical information
The use of numbers to convey risk information in ‘The Facts’ booklet was common, which participants
often considered to be unnecessary. For example, one participant preferred to think categorically about the
efficacy of screening to reduce CRC deaths (i.e. anything is better than nothing), rather than in verbatim
terms (i.e. a 16% reduction):
I know we have to have . . . the evidence and that, but I think if I hadn’t done research myself . . . I
would just find that got in the way really. This thing about 16%. What’s 16%? What does it mean to
the person on the street? I know anything is better than nothing for reducing the risk of dying, but
surely it should be a lot more percentage than that, but is it something that I want to know about?
QE, 50 years, female, degree-level education
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FIGURE 4 Typology of participant utterances. Reproduced from Smith et al.99 This is an open access article under
the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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The use of numerical information to convey the lifetime incidence of CRC as 1 in 20 led to confusion.
For example, one participant overestimated the likelihood of being diagnosed with CRC as a result of an
information-processing error:
That’s about, yeah, that’s one in four of the population isn’t it?
IT, 51 years, male, higher educational qualifications
The prevalence of screening outcomes proved difficult to interpret. The booklet explains that, following a
gFOBt, approximately 98 out of 100 individuals will receive a normal result (no blood found), 4 out of 100
will receive an unclear result (a small amount of blood), and 2 out of 100 receive an abnormal result
(blood was found, further investigation is required). However, there was confusion as to whether or not
the normal prevalence figure includes those who have previously received an unclear result:
Does that equate with the 98 out of 100 in the previous paragraph? Something, somewhere doesn’t
seem quite. Four people out of 100 and then we had 98 out of 100, anyway, not quite sure about that.
WW, 56 years, female, degree-level education
As with the gFOBt kit results section, colonoscopy outcomes were misinterpreted. The booklet explains
that 1 person out of 10 will be diagnosed with cancer, 4 people out of 10 will have a polyp removed and
5 people out of 10 will have nothing found. In this instance, the participant appears to discount the
number of people receiving a polyp diagnosis, thus overestimating the prevalence of cancer following an
abnormal gFOBt kit result:
Half of people that go for these colonoscopes [sic] don’t have cancer? And the other half do? Hmm.
IT, 51 years, male, higher educational qualifications
Unfamiliar topics and complex terminology
Participants questioned whether or not it was necessary to have such a long and complex booklet to
inform people about the screening programme:
This is an awful lot for people to read, this is just handed out? Hell of a lot to read isn’t it?
OU, 54 years, female, degree-level education
Comments were often made about the introduction of unfamiliar topics and scientific terminology:
A bit difficult to understand, if you’re not up to date with those kind of informations.
RT, 58 years, female, no formal qualifications
Participants argued that a leaflet that aims to provide complex and technical information would benefit
from the use of vernacular language as opposed to scientific terminology:
. . . I would prefer a more high-level definition of what the bowel is actually. This just seems to provide
too much detail . . .
SM, 51 years, male, degree-level education
There was also difficulty when describing the difference between the possible outcomes of a gFOBt.
Despite the bold text within this paragraph describing the exact meaning of abnormal, it was easily
misinterpreted as the definite identification of a malignancy or polyp:
So that’s good, it gives you all of the different results of the testing . . . normal, you’re not going to
have any more tests for 2 years. If it’s unclear you have another one to make sure it’s nothing
suspicious and if it’s abnormal you’ve definitely got something that needs further investigation.
CW, 56 years, female, degree-level education
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This and other complex areas of the booklet were improved by the provision of summary boxes and
diagrams. To improve the booklet further, it was recommend that, when technical phrases are introduced,
the most familiar word should be used first and the more technical phrase included within brackets
that follow:
I’m wondering sometimes with these things whether it isn’t better to have the common word before
the technical, so piles (haemorrhoids), just because seeing those words that are hard to pronounce can
put you off.
OU, 54 years, female, degree-level education
Emotional responses
As demonstrated by the quantitative analysis, there was a mixture of emotionally negative and positive
comments. For example, some participants found the scientific explanations of cancer interesting and
somewhat reassuring:
Yeah that’s interesting, I’ve never really known an awful lot about cancer, and how it spreads and
what happens so that again seems to make it quite sensible and slightly not too scary. Because
obviously everybody talking about cancer, everybody gets very ‘the big C’.
WW, 56 years, female, degree-level education
Despite the reassurance offered by these explanations, the colonoscopy risk information frequently led to
negative emotional responses. In particular, the risk of death (1 in 10,000) led some to question why this
may occur:
Oh oh that is shocking. That is shocking. I’d like to know more, now that’s been said . . . what on
earth would they have had to do for that to happen – whether a heart attack, or a shock to the body
or you perforate the liver or something that’s vital to keep you alive.
CW, 56 years, female, degree-level education
Others questioned the necessity of including such information, preferring instead to supply it on a ‘need to
know’ basis or in a less prominent position:
I’d write it in small and I’d write it at the end . . . It wouldn’t be something massive, I don’t think it,
anything put there to make people more worried about the procedure, the procedure’s
complicated enough.
JS, 52 years, male, A-level education
The nature of the test was often considered to be distasteful:
Yeah I think that probably, there’s nothing else you can do about it but it is rather embarrassing
and unpleasant.
BD, 56 years, female, no formal qualifications
One individual commented that the description evoked unpleasant images about the procedure that may
induce aversion to participation:
OK, yeah, wipe the samples on a special card . . . I’m getting a bit unpleasant mental images of
that procedure.
SM, 51 years, male, degree-level education
Summary
This think-aloud study of 18 adults who were naive to CRC screening explored how people interpret the
current information booklet that is provided to invitees of the English NHS BCSP (‘The Facts’; see Appendix 3).
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Despite the extensive testing process the information went through,109 and its approval by the plain English
campaign, our study suggests that it may not always meet the information needs of some older adults.
Furthermore, this gap in understanding is not filled by health-care professional counselling, suggesting
that communication inequalities may be created through the introduction of home-based organised
screening programmes.110
The study enabled us to successfully identify specific areas of ‘The Facts’ booklet that were difficult to read,
confusing to the reader and detrimental to motivation to be screened. We also observed strong emotional
responses to some aspects of the screening process. We were able to address some of these findings in
further adaptations of the gist leaflet, with the consideration that this may aid knowledge translation and
reduce the cognitive burden placed on individuals when deciding whether or not to take up the offer of
CRC screening.
Designing the ‘gist’ leaflet
The Department of Health policy for screening communications endorsed in the UK cancer strategy is to
‘empower the greatest number possible . . . to make an informed choice to participate in cancer screening’
(© Crown copyright 2010; contains public sector information licensed under the Open Government
Licence v3.0).111 We therefore needed to ensure that the gist leaflet would be accommodated within this
policy context.112 The NHS BCSP specified that our leaflet must be provided in addition to, rather than
instead of, the existing booklet. Although this is not the ideal situation according to FTT, it represents a
compromise for using psychological theory within the constraints of an organised health-care system.
Consultation of best practice
Best practice guidelines from the fields of information design, cognitive psychology and health literacy
were used to complement a theory-based approach during the design phase.113–115
Expert input
Prior to starting the design process, we interviewed 11 SSPs to discuss their views on the development of
the gist leaflet. These interviews focused on the following areas: (1) what parts of ‘The Facts’ booklet they
felt members of the public found difficult to understand, (2) what information contained in ‘The Facts’
booklet they felt was essential to know prior to making a decision about bowel cancer screening
participation, (3) how acceptable they found the idea of providing supplementary information to the public
as part of their invitation and (4) whether or not they had any advice on ways in which to provide
this information.
During development of the leaflet, members of the research team with expertise in health services
research, epidemiology, public health, behavioural science, decision-making, communication and literacy
provided continual feedback. This panel met frequently throughout the design process, using their specific
area of expertise to make suggestions in response to public feedback.
In addition, a version of the leaflet was presented at the ASCEND advisory group meeting in September
2012. This provided an opportunity to receive feedback during the design phase and ensure that the
leaflet would be acceptable to those administering it (i.e. the hub directors) as well as the target audience.
Factors considered in the design of the leaflet
The following is a description of the factors that were considered in the design of the gist leaflet.
Numerical information
Evidence suggests that attempts to encourage further understanding of risk information through the
provision of numbers may be misguided.116 The empirical evidence to support the provision of numerical
information for improving medical decision-making is scarce. Furthermore, it is possible that the provision
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of excessive numerical information can ‘hurt rather than help’ this process.92,117–121 Specifically, in a bowel
cancer screening context, it has been shown to increase the prevalence of negative attitudes about bowel
cancer screening.122 At the same time, it is important that information is not so oversimplified that it is no
longer accurate or fails to enable people to make an informed decision about screening.123 Concerns that
simplifying health information might disadvantage certain groups are alleviated by the finding that low
literacy messages can improve knowledge even among more educated samples.124
To overcome difficulties with processing numerical information, we attempted to encourage gist-based
processing by providing a verbal description (i.e. gist) of the number [e.g. ‘most people (98 out of 100)’].
This approach has been used successfully in previous research.125–127 Findings broadly indicate that
comprehension of the information is improved, particularly for people with low numeracy.128 Furthermore,
the same study suggested that evaluative categories can increase deliberative processing of the numerical
information. Numerical descriptors may also increase perceptions of risk and, as a result, may be more
effective at altering behaviour than numerical information in isolation.127 In line with current evidence,
natural frequencies with the same denominator were used to present key numerical information.129
Reduction of concepts
In keeping with the ‘less-is-more’ approach, the leaflet was designed to encourage gist-based processing
by removing specific concepts which were deemed ambiguous in the think-aloud study. This resulted in
four pages of text being used for the gist leaflet, compared with 15 pages in ‘The Facts’ booklet. An
example of information that was streamlined was the role of gFOBt screening in preventing bowel cancer
(by removing polyps detected at follow-up colonoscopy). This was justified because of the unconvincing
evidence that gFOBt-based screening reduces bowel cancer incidence.130 The leaflet therefore focused on
the primary mechanism by which gFOBt screening works: the early detection of colorectal adenomas.
A further example of streamlining was the removal of academic references from within the text to
accommodate the preferences of people with low health literacy.131
After consultation with the wider research team, a decision was reached to remove any mention of
‘unclear’ results. This decision was made because ‘unclear’ was considered confusing to the reader in
the think-aloud study, without any additional benefit of its inclusion. Its removal also fits with providing
information in the simplest gist format (i.e. nominal), without overlapping categories.91
Navigation
Guidelines on the layout of health information designed for groups with low health literacy suggest
providing essential information at the beginning of the text.115 This has been shown to improve
comprehension and decision-making.121 To identify what was considered to be essential information, we
searched the relevant literature to identify aspects of screening that are considered essential to make an
informed decision.112,132 We also drew on the interviews with the SSPs to inform this process.
Information that was deemed essential to making a screening decision was presented on the front page.
This included (1) the prevalence of the cancer, (2) how the test works, (3) the efficacy of the test and
(4) who is invited. To avoid the front page becoming too dense with information, additional essential
information that could not be explained succinctly (i.e. in a single sentence) was contained in subsequent
pages. This information included (1) the disadvantages of screening, (2) the possible outcomes, (3) practical
aspects of screening and (4) where more information could be found.
After providing the essential information on page 1, we aimed to improve the navigability of the
information by providing ‘sign-posting’ to direct the reader to the location in the leaflet where more
detailed information could be found (i.e. pages 2 and 3).133 Page 4 was devoted to ‘sign-post’ other
information sources (i.e. Bowel Cancer Screening: The Facts). As such, the booklet was designed to be a
cascade of information formats ranging from the simplest gist-based information through to more detailed
information for those who wanted it.
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Language
Health literacy, European Union and NHS guidelines suggest that vernacular rather than formal language
should be used when possible in cancer communication materials.114,115,123,134 The use of words with
multiple definitions (e.g. spot) may be confusing for the reader; however, this was accounted for by testing
the comprehensibility of the leaflet (described in Study B: user testing the ‘gist’ leaflet). These guidelines
also recommend that information should be written in short sentences and bullet point lists. Evidence from
cognitive psychology suggests that this reduces the cognitive burden of information by enabling
participants to ‘chunk’ information and retain more in short-term memory.135,136 This is particularly
important for people with poor basic skills owing to the strong association between health literacy and
cognitive ability.137 Importantly, reducing the cognitive burden of information can increase subsequent
recall and this is apparent for all health literacy groups.138
Aesthetic appeal
European Union guidelines suggest that information materials should be appealing to the recipient.134
The aim of this is to encourage engagement and processing of the information and reduce immediate
defensive reactions such as avoidance. In response to the guidelines, a blue background was used because
experimental evidence has demonstrated that it invokes a lower disgust response,139 which is a frequently
cited barrier to bowel cancer screening participation.50,140–142
The research team produced a version of the ‘gist leaflet’ which aimed to provide a simple summary of the
essential information required to understand the offer of bowel cancer screening and to address issues
around non-uptake (see Appendix 12). In order to test the comprehensibility of the leaflet, we carried out
a series of user tests, described below in Study B: user testing the ‘gist’ leaflet.
Study B: user testing the ‘gist’ leaflet
A version of the user testing study has been published in Smith et al.143 © 2013 The Authors. Published by
Elsevier Ireland Ltd. Open access under CC BY license.
Methods
Recruitment of participants
We recruited 28 participants, some of whom were recruited via postal invitation through two of our
charity partners, SAfH and ContinYou. SAfH is a non-governmental organisation involved in health
promotion within disadvantaged areas of London and ContinYou is an adult education organisation that
works with children and adults in deprived communities across the UK. We also recruited participants from
the established research panel in the Health Behaviour Research Centre, Department of Epidemiology and
Public Health, UCL.
By recruiting participants through community organisations, we were able to target and include the
perspective of individuals who may struggle to access and use health information owing to limited health
literacy and numeracy skills. A number of barriers exist to the recruitment of such individuals and we were
mindful of these in our approach.144
We used a mixed-methods, user-testing approach to assess the comprehensibility of the information
leaflet.145–147 In rounds of approximately 8–10 people at a time, we identified problems with the gist-based
leaflet. Both quantitative (face-to-face administered questionnaire) and qualitative (brief semistructured
interview) methods were used to achieve this purpose. Retesting assessed the impact of revisions on a new
set of participants and was repeated as necessary.
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Inclusion and exclusion criteria
Inclusion criteria were people aged 45–59 years (i.e. before the age at which bowel cancer screening is
offered in England) and with no previous diagnosis of bowel cancer.
Exclusion criteria were not being able to speak or read English, having previously undergone bowel cancer
screening and having severe cognitive impairment.
The study was approved by the UCL research ethics committee (reference 2247/002).
Process of user testing
Participants were asked to complete a brief sociodemographic questionnaire on arrival, followed by a
standard health literacy assessment. They read through the gist-based leaflet for as long as they wanted
and completed a researcher-led comprehension test. The participant had access to the gist-based leaflet at
all times. This was followed by a brief (5- to 10-minute) semistructured interview at which participants
were asked to comment on the following: overall impressions of the leaflet, use of language, order of
information, use of headings, use of the word ‘poo’ within a health context, missing information, size of
the print, ways to simplify the information and any other changes that they would like to see.
Measures of participant characteristics
Participants were asked to provide the following information: age, gender, marital status, first language,
employment status, education level, amount of experience with written documents and whether they
had a previous cancer diagnosis or knew someone else that has been diagnosed with cancer. (For the
sociodemographic questionnaire, see Appendix 11.)
Health literacy was assessed using the UK version of the Test of Functional Health Literacy in Adults
(UK-TOFHLA)100 which has numeracy and literacy sections. The numeracy section involves tasks relating to
date and time calculation, computation of medication dosage, and patient navigation, and this section
takes approximately 10 minutes to complete. The literacy section is based on the ‘cloze’ procedure.
Three passages of text (instructions on how to prepare for an X-ray, eligibility for NHS prescriptions and
a consent form for surgery) of increasing difficulty are given to the participant and every fifth word is
missing. When a word is missing, a blank line is drawn and four possible words that could be used are
provided. This section takes approximately 12 minutes to complete. A score of 100 points is calculated,
with each section having a maximum score of 50 points. Scores are converted into three groups:
inadequate (0–59 points), marginal (60–74 points) and adequate (75–100 points) health literacy.148
Tested materials
The Flesch Kincaid formula149 was used to calculate the reading ease of the gist-based leaflet. Scores range
from 0 to 100 points, with higher scores indicating greater reading ease. The readability scores for version
1, 2 and 3 were 82.1, 79.4 and 81, respectively. This corresponded to a US grade level of 4–5 (equivalent
to age 9–10 years).
Outcome
The primary outcome was the percentage of participants correctly responding to eight true or false
statements about bowel cancer and bowel cancer screening. In line with European guidelines for medicinal
package testing,150 each statement had to be answered correctly by at least 80% of participants for our
leaflet to be deemed legible, clear and easy to read.
Data analysis
We calculated the total number of individuals who answered each statement correctly (statement totals) as
well as the mean number of statements correctly answered per participant (individual totals). Data from
the semistructured interviews were digitally recorded, transcribed verbatim and analysed using thematic
analysis, which is a qualitative technique for identifying patterns (themes) within data.107 The purpose of
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the thematic analysis was to pin-point the particular areas of the gist-based leaflet that caused difficulties
with comprehension.
Results
Participant characteristics
The majority of participants were female (75%), employed (54%), and white (54%), had a General
Certificate of Secondary Education (GCSE) level of education or below (57%), were adequately literate
(82%), were without a partner (68%), spoke English as a first language (75%) and had either received a
cancer diagnosis themselves (11%) or knew someone that had (82%). The majority had used written
documents in their current of previous employment at least some of the time (75%). As rounds
progressed, more individuals had a lower level of education, marginal or inadequate health literacy scores,
spoke English as a second language or were from a minority ethnic group.
Round 1
As demonstrated in Table 6, the majority of the statements were answered correctly by at least 80% of
participants. However, two statements {‘The FOB [faecal occult blood] test is done at home’ (true) and
‘People with an abnormal result always have cancer’ (false)} were answered correctly by < 80% of
participants. At an individual level, participants were able to answer a mean of 7.2 out of 8 statements
correctly (range 5–8).
In response to the threshold not being met for the statement that ‘the FOB test is done at home’, we
changed the sentence ‘A FOB test kit with instructions is sent through the post’ to ‘A FOB test kit with
instructions is sent through to the home’ in order to clarify where the test was completed.
More than 20% of individuals did not correctly answer the statement that an abnormal test result does
not necessarily mean cancer has been found. One participant commented that:
I do wonder about the fact that if you have an abnormal test that it doesn’t necessarily indicate that
you’ve got cancer. That’s inferred but it doesn’t necessarily say that.
AL, 55 years, female, degree-level education
TABLE 6 Participant responses in rounds 1, 2 and 3
True/false statement
Round
1: correct n (%) 2: correct n (%) 3: correct n (%)
1. Doing the FOB test lowers the risk of dying from bowel
cancer (true)
6 (100) 11 (100) 11 (100)
2. The FOB test is done at home (true) 4 (67) 10 (91) 9 (82)
3. Most people who do the FOB test will receive an abnormal
result (false)
5 (83) 9 (82) 9 (82)
4. Only women are sent a FOB test (false) 6 (100) 11 (100) 11 (100)
5. Bowel cancer is a common cancer in people over 60 (true) 6 (100) 10 (91) 10 (91)
6. People only need to do the FOB test once in their life (false) 6 (100) 10 (91) 11 (100)
7. The FOB test can miss bowel cancer (true) 6 (100) 9 (82) 9 (82)
8. People with an abnormal result always have cancer (false) 4 (67) 8 (73) 9 (82)
FOB, faecal occult blood.
Reproduced from Smith SG, Wolf MS, Obichere A, Raine R, Wardle J, von Wagner C. The development and testing of a brief
(‘gist-based’) supplementary colorectal cancer screening information leaflet. Patient Educ Couns 2013;93:619–25.143 This is an
Open Access article published under a Creative Commons licence (CC BY 3.0; https://creativecommons.org/licenses/by/3.0/).
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To improve comprehension of the meaning of an abnormal result, we added the following sentence:
‘An abnormal result does not always mean cancer has been found’. Our interviews demonstrated that
the language used was easy to understand for the audience:
It’s quite well set out, and it’s readable and gives you basically all the information.
WG, 58 years, female, no formal qualifications
However, further changes were identified by participants that could make it more accommodating for low
literacy groups:
There were a couple of words in it that I thought might need thinking about . . . ’discuss’, I wonder
whether ‘talk about’ would be more appropriate?
AL, 55 years, female, degree-level education
Changes were also made to the spacing between and within lines to improve readability.
Round 2
Nearly all statements were answered correctly by at least 80% of the participants (see Table 6); however,
the statement on the meaning of an abnormal result remained problematic [‘People with an abnormal
result always have cancer’ (false)]. At a participant level, a mean of 7.1 out of 8 statements were answered
correctly (range 4–8).
Changes to the layout of the leaflet were made in response to difficulties with participants remembering
all of the information that they had just read:
I think it’s OK, but it’s remembering what you read. If you read something and don’t remember, it
doesn’t do you any benefit does it?
DW, 52 years, female, no formal qualifications
Changes included placing boxes around text that related to each subheading, reducing the number of
bullet points on the final page, changing the colour of the background and increasing the size of the font
on the front page to increase the readability of the text for individuals with eyesight difficulties.
It’s very clear. Maybe I would say, it could be done in more bigger letters, you know if somebody’s old
or something.
SF, 51 years, female, no formal qualifications
These changes were particularly apparent on the final page, which assisted participants when searching for
the correct answer to the statement that did not meet the threshold. The text relating to the statement
‘For most people, the follow-up test will show there is no bowel cancer’ was altered in an attempt to
improve comprehension. Participants reported being confused about the age of eligibility for screening.
To reduce this confusion, sentences discussing the age extension were removed:
That’s all clear and it’s explained further, all very simple. But this I couldn’t get [age extension]. That’s
like a random statement. It’s not really backed up or [explained] why.
VY, 45 years, male, advanced high school qualifications
Participants also wanted reassurance that the test was simple, as some felt that it might be complicated
and that people may be less likely to participate as a result. This resulted in changes to the text regarding
the age that people are invited to screening, as well as an additional sentence highlighting ‘The FOB test is
easy to do’. The title of the booklet (‘A two minute guide’) was changed to ‘The essentials’ as the former
may have been perceived as intimidating by less literate and slower readers.
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This is meant to be a 2-minute guide. Well people read at their own pace and you know they might
think well, oh. A simple guide? Or is that being patronising . . . or the essentials?
FV, 55 years, female, degree-level education
Finally, the full title of the FOB test was added in response to comments questioning the phrase, FOB test:
I think the only thing is, FOB, what does that stand for?
WF, 58 years, male, no formal qualifications
Round 3
As demonstrated in Table 6, all statements were answered correctly at least 80% of the time. The
predefined threshold was therefore met and the leaflet was considered fit for purpose. At a participant
level, individuals were able to answer a mean of 7.2 out of 8 statements correctly (range 6–8).
Summary
In this study we user tested our ‘gist-based’ CRC screening information leaflet, which promotes
comprehension of the screening offer. We used principles of FTT and best practice guidelines from the
fields of information design, cognitive psychology and health literacy to provide accessible information
about the aims, benefits and disadvantages of the English NHS BCSP. Readability scores indicated that the
leaflet was suitable for individuals with low literacy (e.g. reading age of 9–10 years) and may therefore
increase the accessibility of the programme to disadvantaged groups. User testing indicated that the leaflet
was well comprehended in all rounds and, after three rounds of testing, the pre-defined threshold was
reached and the leaflet was considered fit for purpose. The final version can be seen in Appendix 13.
Study C: a pilot study to evaluate the ‘gist’ leaflet
A version of the gist evaluation RCT has been published in Smith et al.151 Parts of this text have been
reproduced from Smith SG, Kobayashi LC, Wolf MS, Raine R, Wardle J, von Wagner C. The associations
between objective numeracy and colorectal cancer screening knowledge, attitudes and defensive
processing in a deprived community sample. J Health Psychol 2016;21:1665–75,151 with permission
from Sage.
We used a RCT design to compare sociocognitive outcomes with the ‘gist’ leaflet as a supplement to
standard information (gist + facts) and standard information alone (facts). Interactions with levels of
numeracy were also examined. In keeping with FTT, we hypothesised that the ‘gist’ leaflet would increase
knowledge and screening intentions and that the difference between conditions would be stronger among
low-numeracy individuals.
Methods
A multicentre parallel randomised trial design was used. Participants were allocated to two groups
(‘facts only’ or ‘gist + facts’) on a 1 : 1 allocation ratio.
Participants and setting
General practices in the North of England were identified. Using the IMD (a neighbourhood deprivation
score based on several socioeconomic markers), three practices in deprived areas and one practice in an
affluent area were recruited. IMD is a well-validated marker of socioeconomic status and is linked to bowel
cancer screening uptake.54,152,153
Inclusion and exclusion criteria
Staff at the general practices produced a list of all men and women aged between 45 years and 59.5 years.
This age group would not yet have been invited to bowel cancer screening and, therefore, had no direct
experience with the procedure or the information materials. GPs were invited to exclude patients who had
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severe cognitive impairments, were vulnerable (e.g. had had a recent diagnosis of cancer or other significant
illness), were under bowel cancer surveillance or were registered as not speaking English.
Randomisation and blinding
Eligible patients at each practice were randomised to intervention or control groups, with all members of a
household allocated to the same study group to limit contamination. Random number generation software
(version 1.0; Random Allocation Software, developed by M Saghaei, Department of Anesthesia, Isfahan
University of Medical Sciences, Isfahan, Iran) was used to generate a restricted randomisation sequence
for participant group allocation. Blocking was used to ensure evenly balanced group sizes, which limits
the unpredictability of randomisation; however, this bias was reduced by the use of random blocks.154
A researcher posted the study materials from the practice. Group allocation was not concealed at any
stage after the random sequence was generated; it was not possible to be blind to the group allocation at
data entry or analysis stages because some questions were included for only one study group. Participants
were not aware of a comparator group. Randomisation occurred prior to consent, which was assumed
based on the return of a completed questionnaire.
Study groups
In the ‘facts-only’ group (control), each participant was provided with a study invitation letter from their GP,
a questionnaire and an example ‘screening pack’ consisting of a NHS-marked envelope with a mock NHS
screening invitation letter (watermarked ‘example’) and the standard patient information booklet (‘Bowel
Cancer Screening: The Facts’). The packs were as similar as possible to a real screening invitation to increase
ecological validity of the study. Reminders were sent to non-responders after approximately 3 weeks.
The ‘gist + facts’ group (intervention) were sent the same as above as well as the ‘gist’ leaflet. The
questionnaire was a little longer because it also contained questions relating to the ‘gist’ leaflet (see both
questionnaires, in Appendices 15 and 16).
Outcome measures
Outcome measures included level of gist knowledge, degree of intention to be screened, level of numeracy
and acceptability of study materials, as well as a range of demographic characteristics (i.e. age, gender,
marital status, ethnicity, employment status, level of education).
Sample size
This study aimed for a 5% difference in intention between the study groups. To detect this size of effect
(Cohen’s w = 0.12), 818 respondents were needed assuming 80% power and p = 0.05.
Analysis
Respondents were compared with non-respondents using data that had been provided by the participant’s
GP on gender, age, deprivation and number of people in the household, using chi-squared tests and t-tests,
as appropriate.
Analysis included all individuals returning a questionnaire with primary or secondary outcome data. The
extent to which participants read the assigned information materials was monitored using descriptive
statistics and chi-squared tests. Study outcome variables were described using means, standard deviations
(SDs) and percentages, when appropriate. Differences between intention and gist knowledge between
the study groups were assessed using the chi-squared test. Independent t-tests were used to test for
differences between study groups on the perceived risk and bowel cancer worry items. To investigate
condition by numeracy interactions, logistic regression (LR) was used. Data were analysed using Statistical
Product and Service Solutions (SPSS) version 21 (IBM Corporation, Armonk, NY, USA).
Missing data
Missing data for outcomes (except gist knowledge) were considered to be missing at random, justifying
the use of pairwise deletion. Missing gist knowledge data were considered to be missing not at random if
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the individual had responded to at least five items out of a possible nine. Individuals who answered fewer
than five items (n = 6) were excluded for all gist knowledge outcomes. Missing data for the remaining
individuals were dealt with by transforming total scores to account for the number of items that participants
responded to, which enabled participants with a small number of missing data to be allocated a score from
0 to 9. In total, 10.5% of the numeracy data were missing. These data were also considered to be missing
not at random. We coded missing numeracy data as incorrect but sensitivity analyses were carried out,
excluding individuals with missing data and yielded similar results.
Results
The study ran between July 2012 and March 2013, with questionnaires returned up to May 2013 (Figure 5).
Individuals (n = 4452) were randomised by household (n = 3706), with 2216 allocated to the ‘facts’ group
and 2236 to the ‘gist + facts’ group (Table 7). A total of 3631 (81.6%) individuals were sent a reminder [the
‘facts-only’ group = 1808 (81.6%); the ‘gist + facts’ group = 1823 (81.5%)] approximately 3 weeks after
the initial invitation (median 22 days, range 22–41 days).
Respondents were excluded from analysis if questionnaire data on age and gender did not match GP
records (n = 26) or if the study materials were not delivered as intended (n = 23). Exclusions were
approximately equal for both study groups. A sample of 4403 individuals remained and this figure was
used as the denominator for calculating a response rate. A total of 1269 questionnaires were returned, of
which 964 were completed and provided outcome data, giving a response rate of 21.9%. The response
Study invitation letters mailed 
to eligible individuals
(n = 4452)
Allocated to ‘facts-only’ group
(n = 2216)
Received allocated intervention
(n = 2203)
Returned questionnaires
(n = 478)
Analysed
(n = 466)
• Incorrect address, n = 12
• Deceased, n = 1
Did not receive
allocated intervention
• Discrepancy between practice
   and questionnaire data, n = 12
Excluded from analysis
Allocated to ‘gist + facts’ group
(n = 2236)
Received allocated intervention
(n = 2226)
Returned questionnaires
(n = 512)
Analysed
(n = 498)
• Incorrect address, n = 10
Did not receive 
allocated intervention
• Discrepancy between practice
   and questionnaire data, n = 14
Excluded from analysis
FIGURE 5 Numbers of participants in control ‘facts-only’ and intervention ‘gist+ facts’ groups.
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rate varied between the practices (Manchester, 13.0%; Liverpool a, 18.1%; Liverpool b, 19.6%; Stockport,
31.8%) and these differences were statistically significant [χ2(3) = 128.76; p < 0.001].
Questionnaire data indicated that a high proportion of participants were married (66.9%), white (83.8%)
and in employment (72.2%) and had either some formal education (49.9%) or a degree-level education
(36.5%) (Table 8). The sample was well distributed by gender (51.4% female) and age group (45–49 years,
32.7%; 50–54 years, 34%; 55–59 years, 33.3%). Despite the educated sample, a high proportion
answered the numeracy item incorrectly (35.3%) or did not provide an answer (10.5%).
Respondents had a high level of knowledge (mean 7.70, SD 1.74 out of a possible 9) and a large
proportion (93.1%) were classified as having ‘adequate’ gist knowledge. Individuals in the ‘gist + facts’
group were more likely to have adequate knowledge (95.2%) than those in the ‘facts-only’ group [90.9%;
χ2(1) = 6.74; p = 0.009] (Table 9). Low-numeracy individuals were less likely to have adequate knowledge
[89.0% vs. 96.6% (7.6% difference) χ2(1) = 21.34; p < 0.001], but there was no significant group by
numeracy level interaction [odds ratio (OR) = 0.42; p = 0.130].
A large proportion of the sample said they would ‘definitely’ (74.7%) or ‘probably’ (22.9%) participate in
screening and very few reported that they would ‘probably not’ (1.6%) or ‘definitely not’ (0.8%) participate.
There were no significant differences between the two groups in the proportion of individuals who definitely
intended to participate [χ2(1) = 0.45, p = 0.50] (see Table 9). Low-numeracy individuals were less likely to say
they would ‘definitely’ participate in bowel cancer screening [71.2% vs. 77.7% (6.5%); χ2(1) = 5.40;
p = 0.020], but there was no significant group by numeracy level interaction (OR = 1.02; p =0 .936).
In the whole sample, 81.7% reported reading all of the information at least once, but those with poor
numeracy were less likely to have read them [74.4% vs. 88.0% (13.6% difference); χ2(1) = 29.56;
p < 0.001]. There was no significant group by numeracy level interaction in terms of reading the
information (OR = 1.37; p = 0.367).
TABLE 7 Characteristics of randomised individuals using GP records (n= 4452)
Characteristics All (%), n= 4452 ‘Facts-only’ group (%), n= 2216 ‘Gist+ facts’ group (%), n= 2236
Gender
Male 2420 (54.4) 1194 (53.9) 1226 (54.8)
Female 2032 (45.6) 1022 (46.1) 1010 (45.2)
Number in household
1 2984 (67) 1476 (66.6) 1508 (67.4)
2 1400 (31.4) 714 (32.2) 686 (30.7)
3 60 (1.3) 22 (1.0) 38 (1.7)
4 8 (0.2) 4 (0.2) 4 (0.2)
IMD score quintiles
1 (low deprivation) 996 (22.4) 473 (21.4) 523 (23.5)
2 794 (17.9) 412 (18.7) 382 (17.1)
3 930 (21.0) 462 (20.9) 468 (21.0)
4 834 (18.8) 420 (19.0) 414 (18.6)
5 (high deprivation) 884 (19.9) 441 (20.0) 443 (19.9)
Age 51.1 (4.1) 51.2 (4.1) 51 (4.2)
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TABLE 8 Participant characteristics for respondents using questionnaire data
Characteristics n (valid %)
Gender
Male 466 (48.6)
Female 493 (51.4)
Age (years)
45–49 313 (32.7)
50–54 325 (34.0)
55–59 319 (33.3)
Marital status
Married 640 (66.9)
Unmarried 317 (33.1)
Ethnicity
White 799 (83.8)
Black 42 (4.4)
South Asian 58 (6.1)
Other 55 (5.8)
Education
No formal education 128 (13.6)
Some formal education 471 (49.9)
Undergraduate or higher 345 (36.5)
Employment status
Employed 689 (72.2)
Unemployed 95 (10.0)
Full-time homemaker 44 (4.6)
Retired 37 (3.9)
Student 5 (0.5)
Disabled 84 (8.8)
Numeracy
Correct 523 (54.3)
Incorrect 340 (35.3)
Missing 101 (10.5)
The total number may not round to 964 owing to missing data.
TABLE 9 Differences between study groups on outcome measures
Variable ‘Gist+ facts’ group (%) ‘Facts-only’ group (%) Significance
Intention 75.7 73.8 χ2(1)= 0.45; p= 0.50
Gist knowledge 95.2 90.9 χ2(1)= 6.74; p= 0.009
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The ‘gist + facts’ group were marginally less likely to have read the materials than the ‘facts-only’ group
[79.7% vs. 83.9%; χ2(1) = 2.83; p = 0.093]. Within the ‘gist + facts’ group, participants were more likely
to read at least some of the ‘gist’ leaflet (88.6%) than ‘The Facts’ booklet (80.5%). Figure 6 shows that
participants in the ‘gist + facts’ group with low numeracy were slightly less likely to read the ‘gist’ leaflet
[84.5% vs. 92.5% (8.0% difference); χ2(1) = 7.86; p = 0.005] and even less likely to read ‘The Facts’
booklet [72.2% vs. 88.5% (16.3% difference); χ2(1) = 21.07; p < 0.001]. There was also a significant
difference in reading between the low- and high-numeracy groups in the ‘facts-only’ group [79.1% vs.
88.1% (9.0% difference); χ2 = 8.56; p = 0.003] (see Figure 6).
Summary
This multicentre parallel RCT found that the inclusion of a supplementary gist-based leaflet alongside
the usual materials sent out with the invitation to take part in bowel cancer screening by the NHS BCSP
increased knowledge but did not increase intention to participate in screening. This finding has to be
tempered by the very high intention levels among the study respondents.
Patient and public involvement and engagement
At each stage of the leaflet development, we sought input from members of the public as well as from
individuals specifically identified to have low health literacy.
The charities ContinYou (then specialising in working with adults with low literacy nationally) and SAfH
(a London-based organisation working alongside marginalised local people and their communities in order
to improve health and well-being) assisted the research team in recruiting individuals with low literacy for
the development of the gist-based information leaflet.
Primary Care Research Networks in Manchester and Liverpool assisted the research team in identifying GPs
situated in areas of high deprivation in order for us to undertake a RCT via a postal questionnaire survey
regarding intention to participate in bowel cancer screening.
We described the development of the gist leaflet and the results of the primary care-based pilot study
were presented to an advisory meeting comprising the study team, representatives from third-sector
organisations and patient representatives. At the meeting, copies of the gist leaflet were also provided and
additional input was given before the final version was tested in the RCT.
Summaries of the findings of the trial carried out through GPs were sent to participants who ticked a box
requesting that details were sent to them.
High numeracy
Low numeracy
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85
80
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Read both
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Read gist
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Read facts
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(F only)
FIGURE 6 Proportion of participants who reported reading at least some of their allocated materials by numeracy
group. F only, facts only; G + F, gist + facts.
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Conclusion
Following a consideration of acceptability of current NHS BCSP information materials, our research team
designed and user tested a simple gist-based leaflet, which aimed to provide information to help people
make an informed decision on whether or not to accept an offer of bowel cancer screening. This gist
leaflet was tested in a national RCT (intervention 1, workstream 3) in November 2012 and the results are
reported in Chapter 10.
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Chapter 6 Workstream 2, intervention 2:
developing and piloting a ‘narrative’ leaflet
Introduction
The second ASCEND intervention to be evaluated nationally in workstream 3 involved the inclusion of a
‘narrative’ leaflet with the invitation letter and materials sent out by the NHS BCSP. Support for this
intervention was obtained from the results of the focus group study described in Chapter 3. In particular,
the theme ‘the power of talk’, which described how learning of other people’s experience with bowel
cancer and bowel cancer screening helped normalise the screening process and ‘tip’ people into making a
personal decision to take part in screening. In the focus groups, this mostly referred to experience of family
and friends; however, as this was not possible in the format of a national leaflet, we attempted to simulate
this effect by using the stories of other people who had undergone CRC screening. Specifically, we tried
to appeal to a broad representation of people from the target age range by using a mixture of males
and females as well as individuals from ethnic minority backgrounds. In addition, focus group findings
concerning resistance to handling faecal matter and the implications of knowing gFOBt results were also
highly pertinent.
In this chapter, we will first describe the theoretical background to this intervention. Second, we will
describe how we collected the narratives for use in the leaflet and how we then developed and tested the
leaflet with several different groups, including experts and lay people. Third, we provide details of a pilot
study which tested if the leaflet could influence people’s beliefs about bowel cancer screening and
intention to take part in screening. The results of the national RCT of the ‘narrative’ intervention are
reported in Chapter 10.
Background
Cancer screening information is usually presented didactically (i.e. factual, statistical information)155 and the
information material currently delivered to individuals eligible for bowel cancer screening is no exception.
However, narrative based communication (i.e. stories with character and event examples) is suggested as a
format more attuned to engaging various audiences.156 Narratives are thought to reduce counter-arguing,
facilitate mental imagery and provide role models of behaviour, making them particularly useful for
enhancing health behaviours.156–158
The positive influence of narratives has been highlighted within a number of health-related behaviours,
including breast cancer screening, skin cancer prevention and hepatitis B vaccinations.159–161 Intentions to
take part in such health-promoting activities have been found to be higher after exposure to narrative
information compared with either statistical information or no information at all. In a US-based study by
Dillard et al.,162 incorporating narratives into information about bowel cancer screening increased perceived
personal risk of bowel cancer. This was a positive result in accordance with theoretical models of behaviour
change such as the Extended Parallel Processing Model163 and the Health Belief Model,164 which assert that
people need to consider themselves susceptible to a disease in order to ‘motivate’ preventative behaviours.
In addition, the inclusion of the narrative had the additional positive effect of reducing the impact of
perceived barriers which, in combination with perceived susceptibility, lead to positive behaviour change.
Consequently, narratives were found to significantly increase interest in receiving a colonoscopy.162 A more
recent US study165 reported that individuals presented with a bowel cancer screening information leaflet
containing a narrative were four times more likely to participate in bowel cancer screening than those
given information without a narrative. The impact of narrative information with regard to beliefs about
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bowel cancer screening, intention to do the gFOBt and actual screening behaviour has not previously been
investigated in the UK.
Accessing narrative health information is becoming easier owing to the array of online resources that are
now available. Healthtalkonline166 and Cancer Genetic Storybank167 are examples of websites dedicated to
using personal experiences to educate the viewer about selected health issues. However, the population
we are targeting with the gFOBt may have limited use of the internet. In a recent Ofcom report on media
literacy, ‘narrow’ users (i.e. use of the internet is limited) were more likely to be aged ≥ 55 years and in
lower SEC groups.168 Therefore, despite limitations of design (e.g. length and number of stories presented),
the written paper form remains an important medium, particularly to the age group served by the NHS
BCSP, and fits within the format of the current system.
Aims
1. To collect personal narratives from individuals who have experience of taking part in the NHS BCSP.
2. To develop a narrative leaflet, to supplement current information materials sent out by the NHS BCSP.
3. To test if the narrative leaflet had an impact on beliefs about screening, including intention to be
screened, among individuals of pre-screening age.
Collecting personal ‘narratives’ of screening
For the content of the narrative leaflet, individuals (n = 20) who had previously taken part in the NHS
BCSP were interviewed about their personal screening experience. Efforts were taken to ensure a mix of
screening outcomes. The interviews were transcribed and then each transcript reviewed with suitable
extracts highlighted for possible inclusion in the leaflet. The content of the leaflet was decided within the
ASCEND research group. A draft of the leaflet was presented to the Social Marketing Team at Stirling
University, Stirling, UK, and then evaluated via interviews and focus groups with pre-screening-aged men
and women, and further refinements were subsequently made. Finally, we evaluated the leaflet using the
Suitability and Comprehensibility Assessment of Materials questionnaire.169 These stages of development
are described in more detail below.
Participant recruitment
A variety of strategies were used to recruit individuals to take part in this interview study. A study
advertisement was placed on the Beating Bowel Cancer website and Twitter (Twitter, Inc., San Francisco,
CA, USA; www.twitter.com) asking those interested in telling their story to contact the research team. This
recruitment method was unsuccessful and so promotion of the research was e-mailed directly to eligible
candidates by our colleagues at Beating Bowel Cancer and we recruited six participants using this method.
The study was also advertised to individuals taking part in other research studies conducted by the UCL
Health Behaviour Research Centre or the UCL Department of Applied Health Research, which led to
recruiting an additional 13 participants. Finally, one individual was recruited by the research team during a
recruitment drive in a local library.
Inclusion and exclusion criteria
Inclusion criteria were:
l being of screening age (60–74 years)
l having taken part in bowel cancer screening
l being able to speak English.
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Wengraf’s Biographic Narrative Interpretive Method
The interviews followed a format described in Wengraf’s Biographic Narrative Interpretive Method170 and
lasted an average of 70 minutes (range 26–124 minutes). This interview format consists of three stages:
1. The researcher asks the participant to tell their story of screening. To do this, a single question aimed at
inducing narrative is asked of each participant. The single question aimed at inducing narrative used for
the purposes of this research was as follows:
i. Can you please tell me your story of how you came to do the bowel cancer screening test kit
and how it all turned out? Tell me the events and experiences which were important for you.
Begin wherever you like. Take all the time you need. I’ll listen first, I won’t interrupt. I’ll just take
some notes for after you’ve finished telling me about your experience.
ii. The researcher does not ask further questions or make comment at this stage, but rather listens
to the story told by the participant.
2. When the participant has finished telling their story, the researcher asks for more narration on relevant
topics brought up by the participant (topic question aimed at inducing narrative) using the words used
by the participant and in the order that the participant introduced them.
3. The researcher now has the opportunity to ask open-ended questions regarding topics of interest not
spontaneously addressed by the participant and, if necessary, to seek confirmation of any points raised
in the story.
Procedure
All 20 eligible participants were sent an information sheet (see Appendix 16) and consent form (see
Appendix 17) to be returned to the study team via a freepost return envelope. Participants elected to be
interviewed either in their own home (n = 7), in UCL offices (n = 7) or over the telephone (n = 6). Each
participant completed a demographic question sheet (see Appendix 18) on the day of their interview and,
at the end of the interview, was reminded of the possibility of including photographs of participants in the
leaflet. If agreed, the researcher took photos of the participant and a further consent form for the use of the
photo by UCL was signed (see Appendix 19). At the end of each interview, the participant was offered £20 for
their time and towards any travel expenses incurred. Each interview was transcribed verbatim, anonymised and
a copy sent to the participant for their review. A study debriefing form (see Appendix 20) was sent with the
transcript. A total of 19 out of 20 participants accepted the invitation to review their transcript.
Sample size
We aimed to interview 16–24 people, varying by gender, ethnicity, SECs and screening outcome.
Measures of participant characteristics
The following participant characteristics were recorded: age, gender, marital status, living arrangement,
car ownership, employment status, education level, ethnic background and religion.
Participant characteristics
The participants comprised 12 females and eight males with an average age of 66.5 years (range 60–73 years).
Out of the 20 participants, eight had been diagnosed with bowel cancer through the NHS BCSP, three had
received a normal gFOBt kit result and nine had benign polyps removed during colonoscopy. Table 10 gives
further characteristics of the participants.
Designing the narrative leaflet
We developed the narrative leaflet according to the principles set out by the Department of Health’s
Improving Outcomes: A Strategy for Cancer111 described in Chapter 5. As was the case for the first
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ASCEND intervention, the ‘gist’ leaflet, the ‘narrative’ leaflet was provided in addition to, rather than
instead of, the existing booklet. This was to ensure that every individual continued to have access to
information necessary for making an informed choice about bowel cancer screening participation.112
Our aim was to ensure that the narrative leaflet presented a variety of credible messengers with whom our
target population could identify, but without being overwhelmed by the amount of material provided. The
leaflet went through many iterations during the design process. Below, we summarise four iterations of
the leaflet that represent the main design changes, along with summaries of specific input for each design
and present the final leaflet used in the intervention.
TABLE 10 Narrative interview participant characteristics
Characteristics n (%)
Gender
Male 8 (40)
Female 12 (60)
Marital status
Married/living with partner 12 (60)
Single/divorced/separated 5 (25)
Widowed 3 (15)
Living arrangement
Own home/mortgage 18 (90)
Renting/other 2 (10)
Employment
Currently employed/self-employed 4 (20)
Retired 16 (80)
Educationa
No formal qualifications 6 (30)
A levels or Highers/vocational qualifications/other pre-degree qualifications 8 (40)
Degree 4 (20)
Ethnicityb
White 14 (70)
Non-white 3 (15)
Other 2 (10)
Religionb
None 3 (15)
Christian (Catholic or Church of England) 11 (55)
Other 5 (25)
A level, advanced level.
a Two participants elected not to answer this question.
b One participant elected not to answer this question.
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Managing interview data
Interviews were audio-recorded and transcribed. The narratives contained in the transcripts were reduced
for review in two ways: (1) four researchers independently highlighted pertinent quotations within each
narrative, which were then grouped together into topic themes (e.g. early diagnosis) and (2) each narrative
was individually summarised with key quotations included to illustrate points made. Suitable quotations
and summarised stories were selected through discussions with the research team and applied to various
iterations of the leaflet design.
Iteration 1
The first version of the leaflet was a trifold. We chose this format to make it stand out more from the
standard information booklet ‘The Facts’ (see Appendix 3). Following the leaflet proposal outlined in the
original research plan, the initial design included the summarised narratives of four participants, selected to
ensure variation in gender, ethnicity and screening experience (see Appendix 21). However, following
extensive discussion, it became clear that the leaflet was too text-heavy. Subsequently, a decision was
made not to focus on individual stories but rather to illustrate the ‘story’ of the bowel cancer screening
process with a variety of quotations. Telling the ‘story of screening’ allowed us to highlight key issues
involved in the decision to accept screening, such as the importance of early detection, the relative ease of
doing the test and the fact that most people receive a normal result, using the words of real people who
have taken part in the programme. This format also allowed more people to be represented in the leaflet,
increasing opportunities for the reader to identify with the ‘characters’ and further illustrating the normality
of receiving and completing the screening test.
Iteration 2
We presented this second version of the leaflet (see Appendix 22) to a team of experts in the Institute for
Social Marketing at the University of Stirling, Stirling, UK. Table 11 lists feedback from the Institute for
Social Marketing team which was discussed with the study team and the outcome agreed.
Iteration 3
The resulting leaflet (see Appendix 23) was tested with a sample of 45- to 63-year-olds, during three
telephone interviews and two focus groups. The participants who took part in telephone interviews (two
male and one female) had previously participated in a research study within the UCL Health Behaviour
Research Centre and had indicated interest in further research opportunities. The participants who took
part in two focus groups (N = 10: male, n = 4; female, n = 6) were recruited through the Camden Carers
Association, a local charity group that had previously assisted with recruitment to research studies. All
participants bar one (telephone interview; male) had not yet been invited for bowel cancer screening.
Telephone interviewees felt that the leaflet was ‘reassuring’, with genuine photos and a good selection of
comments that they could identify with. Each commented that the title was not clear and should include
‘bowel cancer screening’. Other minor comments relating to font, colour and wording were also taken into
consideration. When there were conflicting comments, the research team reached a consensus on the
preferred option.
The focus groups were more critical of the leaflet. Suggestions included having more information about
what bowel cancer is, diagrams of the bowel, information about the numbers of people who survive
bowel cancer, a number to call for more information and a link to a website at which more personal
stories could be accessed. Many suggestions were considered by the research team to be covered by ‘The
Facts’ booklet and, therefore, were not necessary or possible for this supplementary leaflet. Although the
addition of a website was an interesting idea, its development and maintenance was felt to be outside
the scope of this research project. Minor details relating to colour and font were considered and, when
possible, accommodated, but the most notable change made following the focus groups was the removal
of the map from the front cover. The majority of focus group participants found the map confusing and
misleading. A table with details of suggestions from the focus groups and interviews is presented in
Appendix 24.
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Iteration 4
This next version (see Appendix 25) was sent to all 20 participants who had been interviewed about their
screening experience and subsequently provided content for the leaflet. Telephone interviews with 14 of
the participants (six were not available and did not reply to the invitation to contact the researchers
directly) gave each person an opportunity to discuss how they had been represented in the leaflet.
All were pleased with the final result and were happy with how they had been portrayed.
In addition, this version of the leaflet was presented at the ASCEND Advisory Group meeting in September
2012. This provided an opportunity to receive feedback during the design phase and to ensure that the
leaflet would be acceptable to those administering it (i.e. the hub directors) as well as the target audience.
Positive feedback resulted in no further changes being made to the leaflet.
Suitability and comprehensibility assessment of materials
Finally, four researchers in the UCL Health Behaviour Research Group and a Health Promotion Specialist
working in North West London evaluated the leaflet using the Suitability and Comprehensibility
Assessment of Materials questionnaire.169 Completion of this questionnaire involves assigning a series of
scores to the following aspects of the leaflet: literacy demand; numeracy; graphic material; layout and
typography; and learning, stimulation and motivation. Scores are given as a percentage and a minimum
TABLE 11 Feedback from the Institute for Social Marketing, University of Stirling, Stirling, UK
Topic Comments, tips and suggestions Outcome
Layout People like diagrams and would help make
layout ‘more eye catching’
Diagrams to explain bowel cancer and
information related to FAQs were already
available in ‘The Facts’ booklet
Could include a section on FAQs Focus groups to discuss layout and style were
arranged
Colour and font style should be assessed with
focus groups
Inclusion of logos Add the NHS logo, a ‘trusted’ logo, on the front
of the leaflet
The NIHR logo, which incorporates ‘NHS’, was
added to the front of the leaflet and the UCL
logo kept out
Charity logos would have impact only if very
relevant to the reader
A University logo, in their experience, did not
tend to make an impact
Quotations Keeping character within the quotations was
deemed important
The leaflet was a national and not a local
intervention and so the language used had to be
modified to suit a varied UK audience. Some
character in quotations was therefore lost
Quality over quantity (i.e. one convincing
quotation is better than three short ‘average’
quotations)
One key quotation was selected for each point to
be made
Photographs A ‘disconnection’ between the photographs and
quotations was felt
Photographs were matched to quotations and
integrated into main text
Photos of participants in their homes or in the
street were taken where possible. Some
participants provided their own photographs
Fewer but larger, more naturalistic, photos were
recommended (i.e. something that places them in
the real world/community)
FAQ, frequently asked question.
WORKSTREAM 2, INTERVENTION 2: DEVELOPING AND PILOTING A ‘NARRATIVE’ LEAFLET
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
score of 40% is required for the leaflet to be considered adequate for use. The overall score for this leaflet
was 86%, deeming the leaflet to be of a ‘superior standard’ (> 70%).
A pilot study to evaluate the ‘narrative’ leaflet
A version of this study has been published in McGregor et al.171 © 2015 McGregor et al.; licensee BioMed
Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
A RCT was conducted to test the hypothesis that the inclusion of a narrative information leaflet would lead
to a positive shift in beliefs about bowel cancer screening, beliefs that have previously been found to be
predictive of health intention and behaviour.
The Extended Parallel Process Model163 predicts that positive behaviour change in response to a health
threat (i.e. cancer) will occur if there is a high level of perceived susceptibility to the disease, in addition to
a strong belief that the proposed behaviour can be successfully carried out and will successfully reduce the
threat. The narrative leaflet was designed with this in mind and, therefore, the presentation of various
people who had already successfully completed the test as well as selected quotations that illustrated
surprise at a diagnosis and relief at having cancer found and treated early were anticipated to increase
self-efficacy for test completion, perceived personal risk of getting bowel cancer and perceived response
efficacy of the test.
The Health Belief Model164 also suggests that, for a behaviour to be elicited, perceived barriers to the
behaviour should be low and the perceived benefits high. We included specific quotations in the narrative
leaflet to counter-argue known test barriers (i.e. disgust with test procedure and the belief that screening
is only for those with symptoms),172,173 hypothesising that endorsement of such barriers would decrease
and quotations portraying reassurance following participation would help enhance the perceived benefit of
peace of mind from doing the test.174
Methods
Design and study population
Adults registered at one of three GPs in England (two in London, one in rural North West England) were
invited to take part in this study. An age restriction of between 45 and 59.5 years was applied to ensure
that participants had not previously taken part in the NHS BCSP, but were approaching the age of
screening eligibility. Exclusion criteria included having had a recent diagnosis of cancer or currently
undergoing bowel surveillance. A total of 4125 eligible adults were identified and, using random allocation
software,175 were randomly assigned to one of two groups: ‘standard information only’ (SI) (n = 2067) and
‘standard information + narrative leaflet’ (SI + narrative) (n = 2058). To minimise crossover effects, eligible
invitees were clustered according to household before being randomised, to ensure that cohabiting
individuals were assigned to the same group.
Required sample size
The sample size calculation was based on the results reported in an article considering the impact of
narrative information on breast cancer screening attitudes and intentions.159 Assuming α = 0.05 and power
(1–β) = 0.90, the number of participants needed to find a significant between-group difference in intention
in the current study was 684 (342 per group). A low response rate was anticipated and, therefore,
approximately 4000 people were invited to take part.
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Procedure and materials
Each eligible participant was sent a covering letter along with an information pack, a questionnaire and a
freepost return envelope. The covering letter explained the purpose, process and voluntary nature of the study,
and was signed by a staff member from the individual’s general practice. The information pack resembled the
official invitation sent out as part of the NHS BCSP in England comprising a NHS-branded envelope containing a
sample screening invitation letter and the standard information booklet published by the NHS BCSP (‘Bowel
Cancer Screening: The Facts’, see Appendix 3). For those randomised to the SI+ narrative group, the
information pack also contained a copy of the narrative leaflet developed for this study, entitled ‘Bowel Cancer
Screening: People’s Stories’ (see Appendix 25). A statement explaining that this was a mock NHS BCSP invitation
letter was affirmed on the covering letter and on the front cover of the questionnaire. The questionnaire also
included a statement to confirm that consent to participate was presumed on its completion and return.
Individuals who did not respond within 4 weeks of the initial invitation received a reminder letter, again
signed by their general practice. A further copy of the questionnaire, information pack and freepost return
envelope were included with the reminder letter.
Data collection took place between June 2012 and January 2013. This study was granted ethics approval by
the National Research Ethics Service Committee, North East – Northern and Yorkshire and is a registered
trial (ISRCTN74502911).
Measures
The questionnaire booklet contained questions adapted from published studies that addressed beliefs
thought to influence uptake of bowel cancer screening: perceived risk, self-efficacy, test response efficacy,
anticipated disgust with the procedure, symptoms as a prerequisite to screening, peace of mind and
intention.162,172,174,176–178
An introductory question was asked to encourage or remind the participant to read the information
material sent to them prior to beginning the questionnaire: ‘Have you read the orange booklet, “Bowel
Cancer Screening: The Facts” found inside the NHS envelope?’. The intervention group were also asked
the same question in relation to the narrative leaflet. For both questions, responses were on a four-point
scale ranging from ‘no’ to ‘I have read it all more than once’.
A single item was used to measure perceived risk: ‘If I never do the FOB screening test, I would feel very
vulnerable to bowel cancer’.162 A five-point response scale from ‘strongly disagree’ to ‘strongly agree’
was provided.
Single items with a four-point response scale from ‘strongly disagree’ to ‘strongly agree’ were used to
measure self-efficacy (‘I would be confident that I could do the FOB test correctly’176), response efficacy
(‘Doing the FOB test would reduce my chances of dying from bowel cancer’177), anticipated disgust (‘Doing
the FOB test would be disgusting’172), symptom absence (‘I would only do the FOB test if I had symptoms
of bowel cancer’172) and anticipated peace of mind (‘Doing the FOB test would give me peace of mind’174).
Future intention to participate in bowel cancer screening was measured by a single item: ‘Imagine you
have just turned 60 and have received the bowel screening test kit (FOB test kit) in the post. Doing the test
involves taking small amounts of your stool (poo) on three different days and putting them on the FOB test
kit. Realistically speaking, how likely are you to do this?’.178 Responses were recorded on a four-point scale
ranging from ‘definitely not’ to ‘yes, definitely’.
Demographic information
Respondents were asked to give their age, gender and ethnicity. A composite score for socioeconomic
deprivation was calculated using three questions on current living arrangements (1 point for not owning a
home), education (1 point for having no formal qualifications) and car ownership (1 point for not owning
a car). Scores ranged from 0 (least deprived) to 3 (most deprived).179
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Data analysis
To analyse the data, SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) was used. Between-group
comparisons were conducted using independent-samples t-tests. A mediation analysis addressed the
impact that the bowel cancer screening beliefs had on the group and intention relationship. Mediation
was conducted using INDIRECT, a SPSS macro. See Appendix 26 for a correlation matrix of each belief.
Results
A total of 1256 people (SI = 606, SI + narrative = 650) returned a completed questionnaire (30.5%
response). Those who provided age information inconsistent with general practice records (n = 35) were
removed from the analysis. Therefore, the final sample consisted of questionnaire data from 1221
participants (SI, n = 590; SI + narrative, n = 631). The two groups were similar in terms of sociodemographic
characteristics (Table 12). Of those who answered the introductory question(s), the majority self-reported
that they had read at least some of the information materials provided (SI, 96%; SI + N, 94%; ‘The Facts’
booklet and narrative leaflet, 90%).
t-tests
The results of the t-tests are presented in Tables 13–15. The group that received the additional narrative
leaflet perceived themselves to be at higher risk of bowel cancer if they did not participate in bowel cancer
screening (p = 0.045) and were more likely to believe that doing the screening test would reduce their
chances of dying from bowel cancer (p = 0.008) (see Tables 13 and 15, respectively). In addition, the group
with the narrative leaflet were less likely to perceive doing the test as disgusting (p = 0.007) and more
likely to believe that doing the test would provide them with peace of mind (p = 0.002) (see Table 15).
The group who received the additional narrative leaflet also showed a significantly stronger intention to
take part in screening in the future [mean (SD) = 3.71 (0.53) vs. 3.64 (0.57); t(1208) = –1.98; p = 0.048].
Indeed, the proportion of participants who indicated that they ‘definitely’ intended to take part in
TABLE 12 Pilot study participant characteristics
Characteristic SI, N= 590 SI+N, N= 631
Age (years)
Mean (SD) 51.94 (4.31) 51.80 (4.16)
Missing – –
Gender, n (%)
Female 334 (56.6) 353 (55.9)
Male 256 (43.4) 278 (44.1)
Missing – –
Ethnicity, n (%)
White 513 (86.9) 547 (86.7)
Non-white 75 (12.8) 82 (13.0)
Missing 2 (0.3) 2 (0.3)
Socioeconomic deprivation score, n (%)
0 (least deprived) 326 (55.3) 362 (57.4)
1 145 (24.6) 147 (23.3)
2 71 (12.0) 77 (12.2)
3 (most deprived) 19 (3.2) 16 (2.5)
Missing 29 (4.9) 29 (4.6)
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screening in the future was 5% higher in the group who received the additional narrative leaflet (74% vs.
69%) (see Table 13).
Both groups generally agreed that they were confident to complete the gFOBt kit and correctly disagreed
that the test was only for those who had symptoms; however, there was no statistically significant
between-group difference on the strength of either belief (p > 0.05).
Mediation analysis
A mediation analysis was conducted to help explain how the narrative affected intentions by modifying
specific beliefs about screening. The direct effect of intervention on each belief, including intention, and of
each belief on intention was confirmed with multiple regression. The parallel multiple mediator model is
presented in Table 10. The model was based on a sample of 1106 people (SI, n = 529; SI + N, n = 577)
and accounted for 29.8% of the variance in intention.
TABLE 13 Between-group comparison of responses to question on perceived risk
Belief Group n
Response (%) Results
Strongly
disagree Disagree
Not
sure Agree
Strongly
agree Mean (SD) t-test
Perceived
risk
SI 583 4.3 23.2 35.7 29.2 7.7 3.13 (0.99) t(1208) = –2.00;
p= 0.045
SI+ N 628 5.3 20.3 30.0 33.5 11.0 3.25 (1.06)
TABLE 15 Between group comparison of responses to question on intention
Belief Group n
Response (%) Results
Definitely
not
Probably
not
Yes,
probably
Yes,
definitely Mean (SD) t-test
Intention SI 582 0.3 3.6 27.5 68.6 3.64 (0.57) t(1208) = –1.99;
p= 0.048
SI+ N 628 1.6 1.8 24.0 73.6 3.71 (0.53)
TABLE 14 Between-group comparison of responses to questions on beliefs about CRC screening
Belief Group n
Response (%) Results
Strongly
disagree Disagree Agree
Strongly
agree Mean (SD) t-test
Self-efficacy SI 584 0.7 2.9 62.7 33.7 3.29 (0.55) t(1208) = –1.92;
p= 0.055
SI + N 628 0.8 2.4 57.2 39.6 3.36 (0.57)
Response efficacy SI 582 2.2 8.1 60.0 29.7 3.17 (0.66) t(1201) = –2.64;
p= 0.008
SI + N 627 2.1 5.9 54.7 37.3 3.27 (0.66)
Anticipated disgust SI 584 28.9 52.2 15.9 2.9 1.92 (0.75) t(1204) = 2.69;
p= 0.007
SI + N 622 34.1 52.3 11.7 1.9 1.81 (0.71)
Symptom absence SI 577 44.0 49.0 4.2 2.8 1.67 (0.70) t(1196) = 1.39;
p= 0.165
SI + N 621 49.9 43.2 3.9 3.1 1.60 (0.71)
Peace of mind SI 582 1.0 6.7 61.0 31.3 3.22 (0.61) t(1199) = –3.15;
p= 0.002
SI + N 626 1.0 4.5 54.6 39.9 3.33 (0.61)
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Age, gender, ethnicity and socioeconomic deprivation were included as control variables in the model.
Older age was associated with stronger intention [β = 0.008, t(1095) = 2.55; p = 0.014], women were
more likely to intend to do the bowel cancer screening test than men [β = 0.066, t(1095) = 2.34;
p = 0.019] and a higher socioeconomic deprivation level (i.e. more deprived) was associated with lower
intention [β = –0.061, t(1095) = –3.43; p < 0.001]. There was no association between ethnicity and
intention (p = 0.135). The relationship between group and beliefs, beliefs and intention, and group
and intention were retained when controlling for gender, age, deprivation and ethnicity. The direct effects
are presented in Figure 7 and Table 16.
Importantly, the direct effect of group on intention reduced and became non-significant when the belief
variables were controlled for, indicating that the leaflet affected intention through beliefs (see Figure 7 and
Table 16).
Indirect effects were assessed using bias-corrected bootstrap CIs. Perceived peace of mind, vulnerability to
bowel cancer, anticipated disgust and perceived test efficacy all mediated the effect of group on intention.
The SI + N group had stronger intentions to be screened as a result of their tendency to, in order of strength
of influence, (1) more strongly believe that screening will provide peace of mind (β = 0.0167, 95% CI 0.0061
to 0.0319), (2) perceive themselves as more vulnerable to bowel cancer if they do not have screening
(β = 0.008, 95% CI 0.0014 to 0.0181), (3) consider the screening test as less disgusting (β = 0.006, 95% CI
0.0007 to 0.0143) and (4) more strongly believe that screening would reduce their chances of dying from
bowel cancer (β = 0.005, 95% CI 0.0004 to 0.0136) than the SI group. Examining the CIs for each mediator
contrast showed that the indirect effect of peace of mind was significantly stronger than the indirect effect
of response efficacy (β = –0.012, 95% CI –0.0275 to –0.0009). No other significant contrasts were found,
suggesting that each of the other mediator indirect effects were of comparable strength.
Discussion
The addition of a narrative leaflet to standard information material had a positive effect on a number of
beliefs about bowel cancer screening, which, in turn, significantly increased respondents’ intention to
participate in the screening programme.
The mediation analysis found that the narrative leaflet influenced intention to be screened predominantly
through its ability to strengthen the benefit of anticipated peace of mind from screening, enhance feelings
of vulnerability to bowel cancer without screening, reduce perceived disgust with the procedure, and
enhance the belief that screening could reduce your chance of dying from bowel cancer.
Although intention to be screened may not directly lead to screening behaviour (the ‘intention–behaviour
gap’), it remains an important prerequisite. Previous research has found that lower perceived barriers and
higher perceived benefits of screening are predictive of both intention to be screened and screening
behaviour itself180 and, therefore, the narrative leaflet’s ability to positively manipulate factors addressing
a selection of benefits and barriers suggest potential for an influence on screening behaviour.
A limitation of this study is the percentage of people who returned completed questionnaires (30.4%).
This may have subsequently added bias to the results. Within the SI group, a high percentage of respondents
(96%) said they would ‘probably’ or ‘definitely’ do the gFOBt and the variation of socioeconomic deprivation
was limited within groups; therefore, it could be suggested that the study failed to recruit the very people we
hoped the narrative leaflet would influence. Indeed, the socioeconomic deprivation measure used may have
overestimated the number of people in London within the more deprived groups; the selected measure was
itself a limitation because London is not a fair domestic representation of the UK, with car and home ownership
rates lower than in the rest of England due to circumstances not necessarily linked to deprivation.181,182
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A reason for the low participation rate may have been the subject matter. The leaflet was designed to help
reduce barriers to screening but the initial invitation cover letter introducing the topic of bowels (a topic of
conversation often regarded as socially unacceptable)183 may have put people off participating any further,
with the result that the mock NHS invitation envelope may not have been opened and the leaflet not seen.
Following on from this is the response burden associated with participation [i.e. reading a 16-page booklet
(‘The Facts’) and then completing and returning a questionnaire]. The multiple tasks involved may have
deterred participation, not only with respect to the length of time needed to participate but also the
additional onus on reading material. Although the leaflet fitted the format of the NHS BCSP, additional
reading material may not be an effective way of engaging people, especially those with low literacy levels.
The salience of the topic being investigated is also considered an important determinant of response
rates.184 Bowel cancer screening is currently offered to people aged 60–74 years as part of the NHS BCSP,
yet we purposively wanted to obtain the views of those naive to screening and, therefore, invited people
aged 45–59.5 years. As a result, it may be that the relevance of the topic to the invited individual was low
and, therefore, participation was not considered a priority.
TABLE 16 Regression coefficients, standard errors and model summary information for the parallel multiple
mediator model depicted in Figure 7
Variable βa SE tb p-value
Direct effect of group on each belief
Perceived vulnerability 0.135 0.062 20.19 0.029
Self-efficacy 0.047 0.033 10.44 0.150
Response efficacy 0.095 0.040 20.38 0.017
Anticipated disgust –0.093 0.044 –20.13 0.034
Symptom absence –0.047 0.041 –10.14 0.254
Peace of mind 0.107 0.036 20.97 0.003
Direct effect of each belief on intentionc
Perceived vulnerability 0.058 0.014 40.04 0.000
Self-efficacy 0.215 0.030 70.24 0.000
Response efficacy 0.051 0.024 20.13 0.033
Anticipated disgust –0.060 0.021 –20.93 0.004
Symptom absence –0.127 0.022 –50.67 0.000
Peace of mind 0.154 0.028 50.44 0.000
Total effect of group on intention
Group 0.067 0.032 20.08 0.038
Direct effect of group on intentiond
Group 0.016 0.028 0.578 0.564
a Unstandardised coefficient.
b Degrees of freedom = 1095.
c Holding all other beliefs and group constant.
d Holding beliefs about screening constant.
Reproduced from McGregor et al.171 © 2015 McGregor et al.; licensee BioMed Central. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
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Despite the limitation of a low response rate, this study has shown that the use of a paper-based narrative
leaflet, tailored only to the broad characteristics of the eligible population (i.e. men and women aged
> 60 years), has the potential to positively impact beliefs about bowel cancer screening and intention to
be screened.
Within a real-world situation, the NHS envelope containing the screening invitation and information
material will be delivered directly, with no additional research tasks requested, and to people within the
eligible age bracket. Consequently, more people are likely to engage with the narrative leaflet when it is
sent as part of the bowel screening programme and, therefore, it has the potential to heighten intention
to be screened at a more pertinent point in the decision-making process. As the leaflet was found to
enhance selected benefits and reduce selected barriers to screening, factors previously found to be
predictive not only of intention but also behaviour,180 a positive impact on screening uptake looks
promising. Further research in workstream 3 will assess the impact of the leaflet on actual behaviour.
Patient and public involvement and engagement
We were assisted by a number of different organisations in recruiting research participants to take part in
the narrative interviews. Some were identified following their response to a request advertised by Beating
Bowel Cancer, the UK’s leading charity working to promote awareness of bowel cancer. AgeUK invited us
to attend a local forum to promote the study but interested members were not found to be eligible for
participation. In addition, one participant was recruited when the researchers attended a health promotion
event at a local library. Verbal promotion of recruitment for the narrative interviews was also conducted
by the research team whenever opportunities arose within the public domain (e.g. when recruiting for
workstream 1).
A local carers centre recruited members of the public to take part in two focus groups in order to provide
feedback on the content and style of the narrative leaflet that was produced using the narrative interviews.
An additional three telephone interviews were undertaken with individuals recruited through ContinYou
(a charity working with adults with low literacy) and Groundwork (an organisation working in the most
disadvantaged areas of the UK, helping to create better environments to improve people’s prospects and
to promote environmentally responsible ways of living and working). The final draft of the leaflet was
then reviewed by those who had taken part in the original narrative interviews (including our patient
representative coapplicant).
The research team worked with primary care research networks in Cumbria and London in order to
identify general practices willing to assist with recruitment of participants to take part in a small RCT
concerned with assessing levels of intention to take part in bowel cancer screening.
We presented a summary of the development of the leaflet and the results of the primary care-based pilot
study to an advisory meeting consisting of the study team, representatives from third-sector organisations
and patient representatives. At the meeting, copies of the leaflet were also provided and additional input
was given, which informed the final version used in the RCT.
A summary of the pilot study results has been sent to those who completed a questionnaire and added
their contact details for the stated purpose of receiving a copy of the results. A similar summary has also
been sent to those who provided the narratives for the developed leaflet.
Summary
We interviewed a variety of individuals (n = 20) with real experiences of taking part in the NHS BCSP and
used these rich accounts to design a ‘narrative’ leaflet. We revised and refined the leaflet following
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feedback from a number of expert groups and focus groups with the general public and then evaluated its
impact on beliefs about screening in a small RCT with individuals of pre-screening age (Figure 8). Following
the positive results from this small RCT on screening intention, the leaflet was then tested in a national
RCT (intervention 2, workstream 3) in March 2013 and the results are reported in Chapter 10.
Interviews conducted with 
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ASCEND team
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FIGURE 8 Flow chart showing development of narrative leaflet. SAM + CAM, suitability assessment of materials and
comprehensibility assessment of materials.
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
71

Chapter 7 Workstream 2, intervention 3:
developing the general practice endorsement
intervention
Background
The results of workstream 1 highlighted the perceived detachment of the NHS BCSP from familiar
health-care settings and professionals; however, it has been demonstrated that a screening invitation from
a credible and trusted source, such as a GP, is more likely to be accepted185,186 and may have a specific
role in addressing low uptake in disadvantaged populations.187 Including the GP’s signature on the
screening invitation has been found to increase gFOBt uptake, but such active participation is costly and
time-consuming.188 A large Australian RCT (n = 2400) with 95% power to detect a difference in
participation rates found that a screening invitation naming the relevant general practice was almost as
effective at increasing uptake as having the letter signed by the GP.36 In a study by Cole et al.,36 letters
with GPE achieved a 6% higher participation rate than the regular screening invitation, although the trial
lacked the power to detect socioeconomic differences across groups. There is evidence to suggest that
endorsement by a GP might reduce the socioeconomic gradient in screening uptake. One study explored
predictors of participation via different methods of invitation for bowel cancer screening and reported that,
when deciding whether or not to take part in screening, participants with lower education relied more on
their GP’s advice than written information accompanying a mailed screening invitation.189 This suggests
that a letter including endorsement by a GP could potentially encourage participation in this population.
The NHS BCSP operates independently from general practices and, although GPs are notified about their
patients’ screening results or if their patients have not taken up the offer of screening, there is no
additional GP involvement. Reports from the NHS BCSP pilot studies, which included telephone interviews
and a focus group with individuals who had not responded to the invitation to be screened, indicate that
the perceived anonymity of the NHS BCSP pre-invitation and the lack of involvement of the GP are
significant barriers to uptake.190 However, GPs are generally positive about the NHS BCSP.190,191 The British
Medical Association also recommends that doctors should be more involved in research and interventions,
particularly those aimed at reducing the impact of social determinants on health.192
Therefore, the third ASCEND intervention tested in a national RCT was the addition of a GPE statement
appearing on the NHS BCSP pre-invitation (S1) letter. This was the first RCT to examine the effectiveness of
a simple endorsement by an individual’s general practice in the NHS BCSP invitation letter at a national
level. Adding the practice name to the pre-invitation (S1) letter was considered to have minimal cost once
GPs had agreed to their practice name being used. Some PCTs at the time of the development of this
intervention were introducing unevaluated GP interventions as part of their strategy to achieve the
Department of Health target for reducing cancer mortality, demonstrating that a simple practice
endorsement was likely to be welcomed by users and commissioners.
Development of the general practice endorsement
pre-invitation (S1) letter
Information provided by workstream 1 focus groups
During the workstream 1 focus groups, which explored reasons for non-uptake of bowel cancer screening
(see Chapter 3), many participants indicated their belief that GP involvement would be a facilitator of their
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taking part in bowel cancer screening; indeed actual or perceived GP support for the NHS BCSP appeared
to carry considerable power:
If the NHS wants me to do something, the only way to achieve it is to have my GP [XXX] tell me to
do it.
FG01 P1
I think if I had got it from my GP just saying your annual check is due I think that would have far
greater impact and almost be an obligation to do it.
FG01 P8
The lack of GP involvement in the NHS BCSP current pre-invitation process was reported by some
participants to contribute to it being regarded as an arm’s-length, ‘anonymous’ or unimportant process. It
appears that the lack of GP involvement in the current NHS BCSP pre-invitation approach contributes to its
interpretation by some as depersonalised and lacking in personal relevance. Several participants mentioned
that GP involvement would make the screening pre-invitation more personal and one even suggested
potential wording for the intervention:
. . . if it came from the GP rather than some anonymous NHS office or whatever, perhaps the letter
that goes out could say, ‘Your doctor has recommended that . . .’ or something like that . . .
FG01 P3
These initial impressions provided evidence that including an endorsement by the general practice in the
current pre-invitation (S1) letter had the potential to increase participation in the eligible NHS BCSP population.
Primary Care Advisory Group
A Primary Care Advisory Group (PCAG) including academic experts in screening and GPs working in
advantaged and disadvantaged areas was convened to aid the development of an effective GPE. This
group comprised five GPs, a practice manager, a NHS BCSP hub director and two clinical academics.
The PCAG helped to design the content of the GPE and various wordings were suggested and discussed.
Finally, ‘Your GP Practice [insert general practice name] supports the Bowel Cancer Screening Programme’
was agreed to be an effective endorsement, which could easily be incorporated into the screening
pre-invitation. During the PCAG meetings it became clear that the main difficulty with incorporating the
endorsement was working within the restrictions of the original format of the NHS BCSP pre-invitation (S1)
letter because the main body of the pre-invitation text could not be changed and space was limited.
Therefore, the endorsement needed to be short enough in length, once the general practice name had
been added, to fit onto a maximum of two lines. With these constraints in mind, the PCAG advised that
the endorsement should appear as a bold, stand-alone statement within a greyed out placeholder at the
top of the pre-invitation (S1) letter.
Practicalities of adding the general practice endorsement intervention
statement to the pre-invitation (S1) letter
Once the content and the format of the endorsement had been agreed by the research team, it was sent
to colleagues at the Health and Social Care Information Centre (HSCIC) responsible for the BCSS software
for formatting in preparation for implementation in the trials. We were informed by HSCIC that the GPE
placeholder in the format suggested by the PCAG could be incorporated into the screening pre-invitation
letter as long as the general practice name did not exceed 40 characters. As the general practice name
would be inserted automatically when letters were generated by the BCSS, they would appear on the
pre-invitation (S1) letter as they did when the practice became active on the system (i.e. not accounting for
any potential change to the practice name after that time). Permission to add the GPE to the screening
pre-invitation by willing general practices for the duration of the ASCEND programme was granted by
Professor Julietta Patnick, CBE (Commander of the Most Excellent Order of the British Empire) (Director of
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the National Health Service Cancer Screening Programmes). The final version of the GPE pre-invitation (S1)
letter can be found in Appendix 27.
Recruitment of general practices to endorse the screening offer
To prepare for this intervention it was necessary to seek permission from all current general practices with
screening-eligible participants in England (n = 8184) for the NHS BCSP to automatically add their practice
name to the pre-invitation (S1) letter received by their patients.
Previous research has not focused on general practices serving disadvantaged populations that tend to
have lower levels of engagement in national initiatives.193–195 In order to establish the best way to approach
practices across England, we consulted the PCAG, which provided us with helpful insights into the best
way to recruit practices to endorse the pre-invitation. The five NHS BCSP hub directors also provided
feedback on recruitment materials developed by the research team.
We anticipated that a modest incentive would engage GPs, especially those from more disadvantaged areas.
Effective incentives include realistic information on potential additional consultations about the NHS BCSP
made to the general practice (these were found to be marginal in the English NHS BCSP pilot191), feedback on
uptake and positivity rates, comparisons with regional and national benchmarks, and provision of promotional
material for waiting rooms. The PCAG suggested that offering GPs information about the outcome of the RCT
in their area would be an incentive that could realistically be provided by the hubs within their existing capacity.
Recruitment materials
The PCAG was consulted regarding the development of the general practice recruitment materials. The
group suggested the recruitment materials should comprise an invitation letter with an example of the GPE
pre-invitation (S1) letter on the reverse, along with an additional information sheet.
The recruitment letter was to be sent from the NHS BCSP hub directors to the general practices in the
areas that they covered. The aim of the invitation was to provide information about the potential
effectiveness of endorsement by the general practice on bowel cancer screening uptake and to outline
what would be involved. It was agreed that the recruitment letter would need to be short, concise and
have easy, multiple response options (i.e. post, e-mail or telephone). It was also agreed that it should
incorporate an incentive for GPs to take part, in the form of feedback of how the GPE affected the
screening uptake of their patients (see Appendix 28).
The NHS BCSP supplied the research team with the list of all current general practices in the BCSS with
individuals who were eligible for gFOBt screening in England. It became apparent early on that the NHS
Prescription Services (from which the BCSS derives general practice information) truncates practice names
before they are added to the BCSS. There was concern among the research team that if the truncated
name were to be used on the endorsed pre-invitation, people receiving the invitations might not recognise
it or might become confused by the shortened practice name, and that it would look unprofessional.
Therefore, the research team reviewed the Prescription Services general practice database and chose the
most appropriate name from the registered practice details to include in the general practice invitation
letter. Practices were able to indicate their preferred practice name to the research team as long as the
general practice name did not exceed 40 characters.
It was agreed that the information sheet would emphasise the importance of bowel cancer screening, the
effect of GPE on uptake and what would be expected of general practices if they did agree for their
practice name to be used (see Appendix 29).
The most important aim of the invitation materials was to ensure that GPs and practice managers
understood that endorsing the programme would involve very little or no extra work for them.
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Rather, they were simply giving their permission for their practice name to be added automatically to the
NHS BCSP pre-invitation (S1) letters sent out to their patients (see Appendix 27). Once drafted, the PCAG
and a further 10 GPs (who had not been involved in the development process) evaluated the draft
recruitment materials. These groups considered the content of the invitation materials to be satisfactory
and provided helpful guidance with respect to the recipient of the materials, suggesting that the invitation
letter should be addressed to the practice manager as well as the lead GP, together with feedback relating
to minor wording and formatting issues.
Pilot study
Following further refinement of the materials, the research team conducted a pilot study to test the materials
on a sample of 250 general practices representing all socioeconomic areas in England. Each of the 250 general
practices was sent the recruitment materials by post and then received a follow-up telephone call from the
ASCEND research team within 1 week. The aim of the follow-up call was to ascertain whether or not the
materials had been received, whether or not members of the practice had discussed the invitation, if they had
any comments about the invitation, if their practice name appeared correctly in the placeholder, how often the
practice takes part in research and the number of GPs working at the practice. Practices that did not respond
within 4 weeks were sent a reminder letter, with a second reminder at 8 weeks if no response had been
recorded. A total of 78% of pilot practices agreed to endorse the NHS BCSP (more than double the anticipated
response of 30%, based on previous experience of general practice recruitment to research studies).196
National recruitment
National recruitment involved sending invitations to the remaining general practices in England that were
not involved in the pilot study described above (n = 7934). The recruitment of practices took place over
36 weeks and was completed approximately 2 weeks before the intervention was scheduled to take place.
As with the pilot, practices were sent the invitation letter and information sheet followed by two postal
reminders (including the information sheet) after 4 and 8 weeks, as necessary. A third reminder letter was
sent at 18 weeks from the initial invitation, without an information sheet, and included an enhanced
statement on letters sent to practices located in more deprived postcode areas (quintiles 4 or 5).
The decision to send a third reminder letter was based on the response to the initial invitation and
subsequent reminder letters. By the time the second reminder letter had been sent out to practices, a
trend appeared to be emerging in the type of practices responding. As seen in Figure 9, practices in more
deprived areas were less likely to respond.
Previous research has shown that GPs serving patients in more deprived areas are less optimistic about
bringing about behavioural change in their patients, which could explain the gradient observed here.198 To
address this, two versions of the third reminder (without an information sheet) were sent out to remaining
practices in the UK. This time, practices in deprived areas (quintiles 4 and 5) received the following
additional message:
We are particularly keen to include practices that look after patients from more deprived areas
because those people are less likely to take part in screening.
Results
Response
The number of general practices that granted permission to use their practice names in this ASCEND
intervention exceeded our expectation. It was anticipated that 30% of general practices across all IMD
quintiles would give permission to use their names in screening pre-invitations. The final number of
general practices agreeing to take part in the intervention was 6480, the breakdown of which can be seen
in Table 17.
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Between the start of recruitment and the RCT, 42 practices were excluded from the general practice list.
A total of 40 practices had registered as closed, one practice was registered as a prison prescribing cost
centre and one practice was registered as a walk-in centre, neither of which should have been included in
the initial recruitment list.
Screening-eligible individuals registered with practices that were either excluded (n = 42), did not respond
to our request (n = 1644) or actively expressed their disapproval of our study (n = 18) were not randomised
to receive this intervention.
Including the enhanced statement on the third reminder letters sent to practices located in more deprived
postcodes showed little change in practice response and the response was lower than after sending the
previous reminder letters (Table 18). Furthermore, the response rate from practices in quintiles 4 and 5 was
still lower than that from practices in quintiles 1, 2 and 3.
Patient and public involvement and engagement
A PCAG comprising professionals including GPs, a practice manager and coapplicants was convened,
to assist with the development of the materials used to recruit GPs to endorse the programme and
the wording of the endorsement itself. The GPs and practice manager were recruited with help from the
Primary Care Research Network for Greater London and through contacts made during the course of
the ASCEND programme.
A summary of uptake rates of general practices agreeing to take part in the GPE trial was sent to all
general practices that had requested this information during their recruitment to the study.
TABLE 17 Uptake rates: general practices agreeing to endorse the NHS BCSP
Status
Invitation
letter
First reminder
letter
Second reminder
letter
Third reminder
letter
Invited, n 8142a 4983 3123 2082
Refused, n 8 7 3 0
Agreed, n 3295 1837 881 467
Agreement by letter (%) 40.5 36.9 28.2 22.4
Cumulative agreement (%) 40.5 63.0 73.9 79.6
a A total of 8184 practices were included in the initial invitation, of which 42 were excluded for reasons explained in
Results, Response.
TABLE 18 Third reminder letter by deprivation of the general practice population
Status
Third reminder letter
(Q1–Q3)
Third reminder letter, enhanced
(Q4–Q5) Total
Invited, n 776 1306 2082
Agreed, n 190 277 467
Agreement by letter (%) 24.5 21.2
Q, quintile.
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Summary
This intervention was powered on a very conservative estimate that only 30% of practices would agree
to endorse the NHS BCSP and, therefore, we were pleasantly surprised to find that the majority of general
practices agreed to do so (80%). The overwhelming response from general practices shows their positive
support towards the NHS BCSP.
The high uptake from general practices could be because no additional work was involved in order to take
part, as practices simply had to agree that their name could be used on the screening invitation letters.
Unlike other research in the UK involving GPE letters, practices did not have to provide an electronic
signature or letterhead in order to take part.37,199
Recruitment letters were sent on NHS BCSP hub letterhead and signed by hub directors, which could have
influenced practice response more than a letter from the ASCEND research team. Hub directors already
sign all correspondence from the NHS BCSP sent to GPs in their region regarding their patients’ screening
pathways.
One invitation and three reminder letters were sent to general practices over a 5-month period, which
could have encouraged practices that were too busy or indecisive about responding to earlier letters.
The RCT of the GPE intervention took place in June 2013. Further details are provided in Chapters 9–11.
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Chapter 8 Workstream 2, intervention 4:
development of the enhanced reminder intervention
This intervention is similar to the GPE intervention described in Chapter 7 in that it also involved a smallchange being made to a current NHS BCSP letter: the reminder (S10) letter (see Appendix 6).
Background
The value of sending reminders has been well established. A recent meta-analysis of interventions to
increase uptake in cancer screening reviewed six separate studies that compared mailing a letter with
mailing a letter plus a postal reminder.196 In all six studies, results were in favour of using mailed reminder
letters,196 consistently showing that reminder letters significantly improve uptake. Importantly, research
on breast screening attendance has suggested that reminders (telephone or letter) may be helpful
in increasing uptake in low-income women,200 particularly if the content of the reminder message
is personally relevant and addresses barriers to screening participation, which are known to be
socially graded.
Socially graded barriers to cancer screening include lack of awareness of bowel cancer and lack of
perceived benefits of bowel cancer screening. There is a strong socioeconomic gradient in cancer
awareness. People with a low level of education and a low household income are more likely to have
lower awareness of cancer and of the increasing risk of cancer with age.201–203 This may be particularly true
for bowel cancer which, among other cancers, tends to be under-reported in the media relative to the
population burden, as shown by a recent content analysis of UK media coverage.204 Recent evidence has
also demonstrated that low awareness of bowel cancer is significantly more prevalent among more
deprived groups.204
In addition to the lack of familiarity with the disease, there is also strong evidence that lower SECs are
associated with lack of perceived value of cancer screening. Evidence from the UK FS trial showed that
individuals from lower socioeconomic groups tend to perceive the barriers to screening to be higher and
the benefits of screening to be lower than do individuals from higher socioeconomic groups.205 Therefore,
for the fourth intervention of the ASCEND study, we developed an ER letter which aimed to increase the
personal relevance of the reminder letter by using an additional message to target low awareness of bowel
cancer and reinforce the value of cancer screening.
Development of the enhanced reminder letter
We developed the specific messages of the ER letter, consistent with the findings from the workstream 1
focus group concerning beliefs about lack of susceptibility to bowel cancer and an associated failure to
understand the potential benefits of screening. In addition, we added a set of reminder-related questions
as part of the focus group study in workstream 1. When participants in the focus groups were asked what
they thought of the current NHS BCSP reminder (S10) letter, the consensus was that the reminder letter
made little impact or impression on them:
Researcher: So you remember getting a letter – what did you think when you got that letter through?
FG08 P1: It didn’t, nothing, I just thought, I’ve not done it [laughs] I’m not doing it, no.
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Participants had little recall of receiving the letter:
Researcher: OK, does anyone else remember getting a reminder letter?
FG03 P3: No I never got anything.
FG03 P1: Don’t think I did.
When participants did recall receiving the reminder letter, they described putting it to one side or
discarding it:
I hadn’t done it, and I still haven’t – got into one of my piles, that’s the trouble and I don’t know
which pile it’s in.
FG03 P2
I binned it straightaway, binned it straightaway.
FG06 P7
Bowel Cancer Screening Programme reminder letter helpline monitoring
We examined data from workstream 1 focus groups relating to issues with the usual reminder letter (S10)
(see Appendix 6). These issues were itemised, along with other known common issues raised at the reminder
stage, and listed in a helpline pro forma (see Appendix 30) to collect feedback on calls made to NHS BCSP
hubs about the usual reminder (S10) letter. Owing to the high volume of calls made to the hubs each day,
the pro forma needed to be quick and easy to complete so as not to have a negative impact on the helpline
workload. Short written instructions on how to complete the pro forma were also designed. These requested
helpline assistants to simply note the date of the call and select a tick box option to record the nature of the
call (e.g. ‘did not receive the kit’). A free-text box was also provided for any further information. The calls to
the hub would remain completely confidential and anonymous (a footnote was added to the pro forma
requesting assistants to refrain from adding any identifying information about the caller).
The initial version of the pro forma was sent to the hub director and hub helpline staff in the North East
NHS BCSP Hub for evaluation. Feedback was given in a teleconference between the research team and the
hub director and hub helpline staff, during which minor formatting suggestions to improve the ease of data
collection were advised. Once these changes were accommodated, the North East Hub agreed to pilot the
pro forma for 1 week and return the completed forms to the ASCEND research team. Once the completed
forms were returned, we made some minor amendments to the form to strengthen the link with the
specific aim of the ASCEND project, which was to elicit more detail on the potential misapprehensions the
public may have about the current reminder letter. We addressed this by adding an additional column for
recording queries about the content of the letter, with a prompt for the helpline assistant to elaborate
further in the ‘additional comments’ column. We also emphasised this aim as part of the general
introduction provided with the pro forma.
The second version of the pro forma (see Appendix 32) was then used to monitor calls in the North East
Hub for 4 weeks. After the first week of monitoring, hub staff reported that the form was easy and not
too burdensome for the helpline staff to complete and no further changes were made to the pro forma.
We asked the North East Hub staff to return all forms to the ASCEND research team once data collection
was complete.
Staff at the Midlands and North West NHS BCSP Hub also agreed to use the helpline pro forma to monitor
calls made to their hub for 1 month (from 4 July 2011 to 25 July 2011) and return their completed forms to
the ASCEND team. The delay between monitoring in the North East Hub and Midlands and North West
Hub was due to the requirement to train helpline staff in using the pro forma and to ensure that the
monitoring took place at a time convenient to the hub.
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Once the forms had been returned, we then undertook a frequency analysis of issues relating to the
reminder (S1/S10) letter recorded in both hubs over a 1-month period. From 894 phone calls made to the
hubs relating to the reminder letter, the majority referred to not having received the original screening
invitation/test kit (30%) or mislaying the original screening invitation/test kit (22%). These data were used
to inform the development of the ER intervention.
Practicalities of adding text to the reminder letter
We were aware from the development of the GPE invitation letter (see Chapter 7) that we would be
restricted by the format of the usual reminder letter. In common with the invitation letter, we were advised
by the NHS BCSP that the main body of text on the usual reminder letter could not be changed. Therefore,
before developing the wording for the ER, we contacted colleagues at the HSCIC to ensure that the
enhancement we developed would fit into the usual letter without disrupting the format. We were granted
space for a one-line ‘reminder’ banner at the top of the letter and an additional five-line paragraph at the
bottom of the letter.
Following this, the first ER prototype was developed. Input was provided by the research team and after
some minor adjustments it was presented to four more focus group participants from workstream 1. The
feedback from these groups referred mainly to recommendations on how best to format the ER messages.
The consensus was that the messages needed to stand out more in order to attract people’s attention:
Yeah, I think a lot of that should be bolder, so it stands out . . .
FG15 P2
. . . put in a nice big box and so you see it and you think wow, I need to do that.
FG15 P2
Just in bold print or something.
FG16 P1
We made amendments to the final version of the ER letter following this feedback and this version (see
Appendix 32) was sent to HSCIC for programming and formatting in preparation for the implementation
of this intervention. The results of the trial are reported in Chapter 10.
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Chapter 9 Workstream 3 randomised controlled
trials: introduction and methods
Introduction
In workstream 2 we developed and tested four intervention strategies designed to target known barriers to
uptake in lower socioeconomic groups (see Chapters 5–8). These were (1) ‘gist’ information, a leaflet
summarising the key screening information in language suited to respondents with lower health literacy;
(2) ‘narrative’ information, a leaflet describing the experiences of people who had taken part in screening;
(3) a GPE added to the screening invitation letter; and (4) enhancing the reminder letter by reiterating the
screening offer: ER. In workstream 3, we conducted national RCTs for each of these interventions. This
chapter describes how the RCTs were carried out.
Methods
Interventions
We were required to ensure that the interventions added to, rather than replaced, the current invitation
system in the NHS BCSP, described in Chapter 2. Thus, the first two interventions involved the addition of
‘gist’ and ‘narrative’ information leaflets to screening invitation letters (S1). The remaining two interventions
involved modifications to current letters produced by the BCSS. These were a GPE banner added to the
invitation letter (S1) and ER intervention added to the reminder letter (S10). Figure 10 shows the stages at
which the interventions were to run within the screening programme. For examples of the usual invitation
letter (S1) and usual reminder letter (S10) (see Appendices 3 and 7, respectively).
Usual practice in the Bowel Cancer Screening Programme
Men and women aged between 60 and 74 years in England and registered with a GP are invited to be
screened for bowel cancer and are sent a gFOBt kit through the post to complete at home. Subjects are
invited every 2 years through their regional NHS BCSP hub, which also analyses the tests, sends out test
results and contacts diagnostic Screening Centres in its region to arrange for further investigation of
subjects with positive gFOBts. On their screening due date, hubs send eligible subjects an invitation letter
(S1) that explains that they are due for screening and to expect a gFOBt kit shortly. The kit letter (S9) is
posted to them 1 week later and includes a cover letter, information booklet and a gFOBt kit. If after
4 weeks they have not responded, a reminder letter (S10) is posted.
Intervention 1: ‘gist’ information leaflet
The leaflet (see Appendix 13) was pre-printed and included with all the S1 invitation letters on predetermined
randomisation dates (see Appendix 33). The trial was run in all five NHS BCSP hubs between 5 and 16 November
2012. The trial took place on 10 working days within that period with an assumption that all the hubs would
send S1 invitation letters to their population on every day during that period, resulting in 50 randomised day
clusters in each of the five hubs: 25 with usual S1 letters and 25 with the ‘gist’ information leaflet added.
Intervention 2: ‘narrative’ information leaflet
This leaflet (see Appendix 25) was pre-printed and included with all the S1 invitation letters on predetermined
randomisation dates. The trial was run in all five NHS BCSP hubs on 10 working days between 4 and
15 March 2013. As with intervention 1, the trial took place on the assumption that all hubs would send S1
invitation letters to their population each day during that period, resulting in 50 randomised day clusters in
each of the five hubs: 25 with usual S1 letters and 25 with the ‘narrative’ information leaflet added.
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Intervention 3: general practitioner endorsement of invitation (S1) letter
In the months preceding the GPE intervention, we contacted all general practices in England (n = 8184) to
ask if they would give permission to allow their practice name to be used on screening invitations during
the 4-week study period (recruitment of general practices is described in detail in Chapter 7). Eighty per
cent of general practices agreed to take part in the study (Figure 11).
The research team worked closely with HSCIC, the organisation responsible for the design and maintenance
of the BCSS. The system identifies the population eligible for screening in each of the five hubs and the
hubs are responsible for creating all the letters that are sent to the screening participants and their GPs.
For the purpose of our study, HSCIC modified the BCSS to enable selection of invitees belonging to general
practices which agreed to endorse the NHS BCSP prior to creation of each invitation letter (S1). In addition,
the BCSS took into account the dates when GPE invitations needed to be produced by any of the five hubs.
The schema of processes involved within the BCSS and the hubs are shown in Figure 12.
The GPE trial ran for 20 working days in each hub, resulting in 10 clusters of invitees receiving an endorsed
invitation letter and 10 control clusters in each hub. The intervention took place between 3 and 28 June
2013, and intervention 4 was designed to run 5 weeks after the start of intervention 3 so as to include all
non-responding participants.
Intervention 4: enhanced reminder letter
This trial ran for 20 working days in each hub, resulting in 10 clusters of invitees receiving the ER on
random days within the trial period. This intervention took place 5 weeks from the start of intervention 3
(GPE), between 8 July and 2 August 2013, in all the hubs in order to achieve the factorial design as shown
in Figure 13. This design allowed us to examine the effect of the ER alone and its effect subsequent to
GPE. The schema of processes for the ER within the BCSS and the hubs is shown in Figure 14.
Comparators
Interventions 1 and 2 compared the effectiveness of an additional leaflet (gist or narrative) added to the
materials posted with the S1 letter with usual NHS BCSP practice.
Interventions 3 and 4 compared the effectiveness of the GPE banner on the S1 letter and the enhanced
text on the S10 reminder letter with usual practice (see Figure 13).
Randomisation
Cluster randomisation was used in all four trials. Individuals who were routinely invited for screening by
the NHS BCSP in England were allocated to receive an intervention on randomly selected days within the
pre-specified time period. In consultation with all NHS BCSP hubs, we identified several periods in the
calendar which would enable us to run our trials outside major public holidays and also to allow temporal
separation of the interventions, when necessary. Two weeks before the start of each intervention, the
BCSS
Population eligible to be invited for bowel cancer screening
Group B
(non-endorsing GP practices)
Usual S1
Group A
(endorsing GP practices)
Usual S1GP-endorsed S1
ASCEND
Intervention 3
FIGURE 11 Flow chart showing the possible statuses for intervention 3.
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randomisation sequence for each NHS BCSP hub was generated by a statistician. For each set of random
numbers, days were allocated to the intervention materials (standard information leaflet + gist or narrative
in trials 1 and 2; GPE invitation in trial 3; ER letter in trial 4) or usual care (standard information leaflet for
trials 1 and 2, standard invitation/reminder letters for trials 3 and 4), based on whether the number was
ASCEND research in the NHS BCSP: intervention 3
Specify
Intervention 3
Research
Specify GP
practice
endorsement file
Specify randomised
date table for
each hub
Define
Intervention 3
in BCSS
NHS CFH
third-line support
BCSS
Import GP practice 
endorsement file
for trial
Import randomised
date table
Hub
Create invitation
run
Prepare invitation
batch
Print letters
Provide 
pre-invitation
letter with GP 
endorsement text
Is this an 
identified 
date for this 
hub?
Yes
Provide 
pre-invitation
letter without GP
endorsement text
Prepare invitation
letter batch
Has the 
GP practice
endorsed the
trial?
Yes
No
No
FIGURE 12 Intervention 3 (GPE) within the BCSS. CFH, Connecting for Health.
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BCSS
Population eligible to be invited for bowel cancer screening
Group B
(non-endorsing GP practices)
Usual
S10
Group A
(endorsing GP practices)
Usual S1Usual S1GP-endorsed S1
ASCEND
Intervention 3
Enhanced
S10
Usual
S10
Enhanced
S10
Usual
S10
Enhanced
S10
ASCEND
Intervention 4
FIGURE 13 Factorial design of interventions 3 (GPE) and 4 (ER).
ASCEND research in the NHS BCSP: intervention 4
Specify
Intervention 4
Research
Specify randomised
date table for
each hub
Define
Intervention 4
NHS CFH
third-line support
BCSS
Import 
randomisation table
Hub
Prepare reminder
letter batch
Print letters
Provide 
reminder
letter with 
additional text
Process reminder
letters for the hub
Prepare reminder
letter batch
Is this 
an identified
date for this 
hub?
Yes
No
Provide 
reminder
letter without 
additional text
FIGURE 14 Intervention 4 (ER) within the BCSS.
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above or below the median of the random numbers. The BCSS is designed to generate batches of
invitations by screening centre. Because the number of daily invitations to each screening centre
population is quite variable, we expected some imbalance in the numbers receiving intervention versus
control interventions in some hubs. Therefore, in addition to randomising by day, the hubs ensured that
letter batches were generated for each screening centre every day during each intervention.
For interventions 1 and 2, each of the NHS BCSP hubs received a table with dates on which their
population should receive the leaflet interventions. These tables with randomisation dates were also given
to HSCIC (the organisation responsible for the BCSS) and to REAL Digital International (Croydon, UK), the
company that distributes invitations for three of the NHS BCSP hubs (London, Southern and Eastern). The
other two hubs print all the materials ‘in-house’.
For interventions 3 and 4, cluster randomisation was undertaken directly by the BCSS. HSCIC was given
randomisation dates for each hub and these were programmed into the BCSS to specify which days
would generate intervention letters. As a further measure of quality assurance, randomisation schedules
were not provided to the hubs and were instead sent only to HSCIC. Hubs were effectively ‘blind’ to the
randomisation schedule and reported back to confirm whether or not the intervention was included
on the S1 letter every day, which the Trial Office then checked against the randomisation schedule.
Randomisation schedules were supplied to the HSCIC 2 weeks in advance of the trial.
Blinding
Blinding was not possible but the possibility of biasing participation was minimal owing to the lack
of direct contact with participants. Individuals were unaware of a comparator condition unless a
member of their household received an invitation during the study period that contained different
information materials.
Eligible population
All men and women aged 60–74 years who are registered with a GP are eligible to be screened for bowel
cancer in England and were therefore eligible to be included in our trials. Invited individuals could contact
their NHS BCSP hub and opt out of the current screening episode or choose to be ‘ceased’ from the
screening programme if they wish. ‘Ceased’ subjects, if ceased prior to their screening due date, would
not be invited to be screened.
Because the screening programme started in 2006, many of the eligible population had been invited
and/or had participated in previous rounds of screening.
Consent
Consent forms were not required in this study because the interventions took place as part of subjects’
usual communication from the NHS BCSP. The activities of the NHS BCSP are covered by National
Information Governance Board approval with regard to the handling of patient-identifiable data (reference
PIAG 1–08(a)/2003).
Exclusion criteria
We had two exclusion criteria:
1. In intervention 3 (GPE invitation letters) we randomised people eligible to receive this intervention only
if they were registered with practices which had agreed to endorse the NHS BCSP. However, owing to
the intensive approach we took to contact all general practices in England (see Chapter 7), permission
to link the screening invitation to the practice address was granted by 6480 out of the 8142 practices
(80%). If no permission was granted, individuals attending that practice were excluded from the
GPE trial.
2. Participants requesting translation of materials were excluded from the analysis (see Translation of
materials into other languages).
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Outcomes
Primary outcome
Screening uptake was defined as the return of a gFOBt kit within 18 weeks of the invitation that led to a
‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or ‘abnormal’ (i.e. requiring
referral for further testing, usually colonoscopy) by the date of data extraction (18 weeks after the last day
of the intervention).
Index of Multiple Deprivation
The English Indices of Deprivation 2010206 use 38 separate indicators, organised across seven distinct
domains (income, employment, health and disability, education skills and training, barriers to housing and
other services, crime, and living environment). These are combined, using appropriate weights, to calculate
the IMD. This is an overall measure of multiple deprivation experienced by people living in an area and is
calculated for every LSOA in England. Each LSOA covers approximately 1500 individuals. The IMD can be
used to rank every LSOA in England according to their relative level of deprivation. We used IMD quintile
because of its demonstrated ability to explain socioeconomic variations in bowel cancer screening uptake
at the LSOA level.12 IMD is freely available and widely accepted and used, enabling direct comparison of
our results with other studies.
Secondary outcomes
Our secondary outcomes were:
1. time taken to return gFOBt kit by IMD quintile
2. proportion of spoilt kits and their relationship to IMD quintile
3. proportion of non-delivered kits by IMD quintile
4. incremental cost per screening invitation
5. incremental cost per screening invitation, both by IMD quintile and overall
6. all of the above outcomes analysed using other socioeconomic variables.
Statistics
Sample size calculations
The sample size calculations were based on achieving a reduction in the socioeconomic gradient measured
as an increasingly larger percentage point increase in uptake in increasingly more deprived quintiles. We
anticipated that this would be accompanied by an improvement in mean overall uptake of screening,
although this was not necessary to the sample size calculation.
Randomised controlled trials of each intervention were powered assuming that there would be a similar
proportional effect in each NHS BCSP hub. Instead of positing an absolute effect (which may differ across
hubs, given their different demographic characteristics), we assumed a fixed proportional effect. Because
different hubs have different underlying uptake rates, we did not assume generalisability of absolute
uptake rates or of absolute effects of the intervention on uptake rates as is common in clinical trial
interpretation. Instead, we made the less sweeping assumption that proportional effects of interventions
on uptake rates within specific IMD quintiles would be comparable across hubs.
Calculations of effects of interventions 1 and 2
We estimated an average increase of 3%, based on increasing uptake by 5% in the lowest IMD quintile
(most socially disadvantaged group) and 1% in the highest quintile; giving an overall 1%–2%–3%–4%–5%
difference by quintile (1% change in the least deprived group, 2% in the next least deprived, etc.). This
estimate was drawn from the outcomes that are considered feasible in research aiming to increase screening
uptake.207 It would result in 35,175 more people being screened per year (11,366 in the lowest IMD quintile
and 1932 in the highest). These numbers were calculated before the NHS BCSP had been extended to
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individuals aged up to and including 74 years in every hub. However, this had been achieved by the time the
RCTs were carried out and so we expected the actual numbers of screened individuals to be higher than
originally calculated.
We based our sample size calculations on the ability to detect a difference in the parameter b, where
the logit of the overall participation rate = a + bx (participation in each IMD quintile). This can be
re-expressed as a comparison of two proportions where each proportion is a weighted average of the
within-quintile uptake rates.208 The analytical results of the sample size calculations were confirmed by
computer simulations.
Because the NHS BCSP hubs vary in the size of the population they serve, baseline uptake rates and
socioeconomic profile, we calculated the required sample size for each hub separately. Thus, for 90%
power to detect as significant a change in the gradient conferring as a 5-percentage-point increase in
lowest quintile uptake versus a 1-percentage-point increase in the highest quintile, the estimated numbers
required per group (intervention and control) overall in all hubs combined were 13,500, 12,200, 11,700,
5400 and 4500 if we assumed that all participants had the composition of Midlands and North West,
London, North East, Eastern, and Southern Hubs, respectively. We used the maximum of the calculated
sample sizes, that for the Midlands and North West, as a failsafe option. This meant that, whatever the
socioeconomic composition and underlying uptake rate of the hub or combination of hubs in any given
RCT, the study size would be adequate. Thus, each RCT needed a total of 13,500 participants per arm
across all hubs. However, as we randomised by day with an average of approximately 3000 letters sent per
hub per day, we needed to increase this by the variance inflation factor:
VIF = 1 + ½3000(1 + c2)−1r, (1)
where VIF is the variance inflation factor, c is the coefficient of variation between days with respect to
number of invitations and r is the intraclass correlation coefficient of uptake levels by day. From data
supplied by the hubs, c was estimated as 0.42 and r as 0.0002, provided the duration was of the order
of 1 month, so that there was no serious seasonal variation. Thus, we needed to multiply the study
sizes by 1.7. We therefore aimed to achieve 23,000 per arm or 46,000 in total for each RCT to detect
a 1%–2%–3%–4%–5% difference in uptake in the least to most deprived IMD quintile (90% power;
p < 0.05).
Bearing in mind that a total of 60–70,000 invitations are sent out nationally in a typical working week, this
would mean that the required sample size could be obtained within a working week (5 days). However,
the number of clusters would be small. We therefore used 2 weeks’ (10 days’) invitations for each of the
narrative and gist interventions. This resulted in the study being overpowered, but achieved 40–50 day/hub
clusters, which conferred confidence of avoiding inadvertent bias, for example owing to one large but
aberrant day/hub cluster.
Calculations for interventions 3 and 4
The same fundamental assumptions were made as above. In addition, for the GPE intervention, with all
the hubs participating and all general practices participating, we would require the same period and study
size as for the narrative and the gist interventions. However, assuming 30% general practice participation,
in order to recruit 46,000, we would need to run the trial for close to 3 weeks (15 days). As a failsafe
measure, we allowed 4 full working weeks (20 days) to achieve approximately 40,000 subjects per arm
and a total of 100 day/hub clusters. In addition, for the ER and in order to be conservative, we doubled
the time required, assuming that around 50% of individuals need reminders and that the ER has only the
same effect on those receiving it as any other intervention applied to the entire invited population. This
could theoretically have been achieved in 2 weeks but, as a failsafe, we ran the trial for 4 weeks, which
would amount to approximately 60,000 reminders and a total of 50 day/hub clusters per arm.
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Data analyses
We undertook a descriptive analysis of sociodemographic characteristics in the two arms across each
intervention and analysed uptake differences by LR. Although randomisation should ensure comparability,
the analysis was performed with and without adjustment for age, sex, screening round and hub.209 The
question of whether or not the intervention had a greater impact on uptake in the lower SEC groups was
assessed by a test of interaction between trial arm and IMD quintile in the LR analysis. Analyses were also
performed with conservative variance estimation in order to take account of the cluster randomisation. We
also used hierarchical LR to account for heterogeneities (i.e. owing to varying policies and procedures in
PCTs). We adjusted for screening episode status and checked for heterogeneity of effects between incident
and prevalent screens. The use of the maximum sample size from the calculation above also enabled
subgroup analyses by sex, age, hub and incident versus prevalent screening episode. A secondary analysis
of time taken to return the gFOBt kit by IMD quintile was examined using the log-rank method.210
Analyses were performed on an intention-to-treat basis using SAS v9.3 (SAS Institute Inc., Cary, NC, USA)
and Stata v12.1 (StataCorp LP, College Station, TX, USA).
Definitions of variables
Interventions
For each intervention, the term SI refers to the standard NHS BCSP invitation information posted (the
control group for each intervention).
Index of Multiple Deprivation quintiles
Individuals were categorised by IMD quintile based on the ranking of LSOAs using overall IMD score:206
l least deprived (0–8.49)
l second quintile (8.50–13.79)
l third quintile (13.80–21.35)
l fourth quintile (21.36–34.17)
l most deprived (34.18–87.80).
Bowel Cancer Screening Programme hub codes
The hubs are referred to below using the NHS BCSP-specific hub codes:
l BCS01: Midlands and North West
l BCS02: Southern
l BCS03: London
l BCS04: North East
l BCS05: Eastern.
Screening episode
Individuals were categorised by screening according to the following three subgroups:
1. ‘Prevalent first-time invitees’ (i.e. subjects invited to be screened for the first time)
2. ‘Prevalent previous non-responders’ (i.e. subjects invited to be screened at least once previously, who
have never responded)
3. ‘Incident’ (i.e. subjects screened previously).
Adequately screened
An individual was defined as ‘adequately screened’ if they returned a gFOBt kit within 18 weeks of the
invitation that led to a ‘definitive’ test result of either ‘normal’ (i.e. no further investigation required) or
‘abnormal’ (i.e. requiring referral for further testing, usually colonoscopy) by the date of data extraction
(18 weeks after the last day of the intervention).
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Local and concurrent initiatives
It was unfeasible to use hierarchical LR to account for heterogeneities. Instead we attempted to identify all
research initiatives and health promotion activities between October 2012 and October 2013. This covered
the period directly before, during and directly after the ASCEND trials. In order to identify these initiatives
we contacted specific key informants from a wide range of national and regional organisations, as well as
a number of opportunistic contacts. More detailed methods and our results are reported in Appendix 34.
Translation of materials into other languages
Text on the back of the usual invitation letter appears in 13 languages, inviting individuals to ask an
English-speaking person to call the telephone helpline on their behalf to request the written materials in
the language required. ‘The Facts’ leaflet is available in 21 languages.7 Data on the number of calls made
to the telephone helpline with requests for written information in another language were collected
routinely by only one hub.
We intended to translate each of the ASCEND interventions into all of the languages currently offered by
the NHS BCSP. This would require including a code within the invitation letter which callers would give to
the telephone helpline assistant at the hub so the hub would know whether to send translations of the
intervention materials or the usual materials. However, during the development of the interventions, the
NHS BCSP hub directors informed us that they believed that very few requests for translated materials
would be made during the intervention periods (10 days for narrative and ‘gist’ leaflets; 20 days each
for GPE and ER). To confirm this, each hub monitored telephone requests for translated materials over
10 days. Four hubs undertook this exercise during March 2012 to reflect the period in which one of the
interventions (the narrative leaflet) was scheduled to take place in 2013. The fifth hub (Midlands and North
West) provided us with the data it collected over 23 days in March 2011.
Very few requests for translated materials were made during the monitoring periods (Table 19). It was
therefore agreed between the research team and the funders that paying for translations was not an
efficient use of resources.
Measuring costs
We calculated the extra costs incurred by each intervention in terms of the incremental cost per screening
invitation. Originally as part of workstream 3 we planned to calculate the incremental cost per screening
invitation of each intervention taking a lifetime time horizon and including the costs of each intervention,
screening costs and costs of diagnosing and managing bowel cancer from the perspective of the NHS and
Personal Social Services. The costs were to be considered alongside the primary outcomes of the RCT in a
cost–consequences analysis framework to identify which interventions should be combined in the RCT of
the complex intervention to be tested in a fourth workstream. Owing to the RCT results (see Chapter 10),
workstream 4 was not funded and the resourcing for the health economic analysis was limited. Hence,
the economic analysis was reduced to a simple calculation of intervention costs. As the intervention costs
were expected to be extremely small, the reviewers argued that we did not need to undertake a more
comprehensive economic analysis in workstream 3. Note that since the plans for the economic analysis
were curtailed, we used the limited resources available to instead undertake a new study evaluating
individual-level factors affecting inequality in bowel cancer screening uptake.
All costs were based on actual costs incurred during the study and valued using market prices. For the
gist and narrative interventions, extra costs were incurred when printing and transporting the additional
leaflets. Average marginal costs per person screened were calculated by dividing the total additional costs
by the number of people receiving each intervention in the two trials. For the GPE and the ER, costs were
incurred when modifying the NHS BCSP information technology (IT) system to incorporate the GPE as part
of the standard invitation and the ER as part of the reminder letter. No additional intervention costs
were incurred.
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Ethics
Ethics approval
Ethics approval was obtained from the UK National Research Ethics Service, London, Harrow Ethics
Committee, Reference number 12/LO/1396, prior to commencement of the study. Local Ethics Committee
approval was not required as this was a national trial incorporated within the NHS BCSP. Site approval was
obtained at each of the NHS BCSP hubs.
Risks for trial participants
Risks to individuals associated with the ASCEND programme were not any higher than the risks associated
with a usual screening invitation from the NHS BCSP. During workstreams 1 and 2, the ASCEND project
gained input from patient representatives and charities who provided advice on the design and approach
taken by the study and the development of interventions. No concerns were raised.
Clinical trial documentation
In accordance with UCL Records Management Policy, the UCL Joint Research Office and the European
Union Good Clinical Practice Directive 2005/28/EC, all primary research data will be retained for a
minimum of 20 years following completion of the study.
TABLE 19 Calls to the NHS BCSP requesting translation of materials in five hubs (London, Southern, Eastern, North
East and Midlands and North West)
Language requested
NHS BCSP hub
Total requests in
each languageLondona Southerna Easterna North Easta
Midlands and
North Westb
Arabic 1 0 0 0 0 1
Bengali 2 1 0 0 1 4
Czechc 0 0 1 0 0 1
Farsi 1 0 0 0 0 1
French 0 0 0 0 1 1
Gujarati 1 1 3 0 0 5
Hindi 0 0 1 0 0 1
Italian 1 0 0 0 0 1
Nepalesed 0 2 0 0 0 2
Polish 0 0 0 0 1 1
Punjabi 0 0 0 1 12 13
Traditional Form Chinese 3 0 1 0 2 6
Turkish 0 0 1 0 0 1
Urdu 0 0 2 2 2 6
Welshc 0 0 0 0 1 1
Total 9 4 9 3 20 45
a Calls received by hubs during a 10-day period, between 12 and 23 March 2012.
b Calls received by hub during a 23-day period, between 1 and 31 March 2011.
c Languages not routinely offered in the NHS BCSP.
d Language offered by Southern Hub only.
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Data management
A data analyst at the NHS BCSP Southern Hub working on behalf of all NHS BCSP hubs designed and
piloted the data extraction algorithms. The raw data were extracted by HSCIC from BCSS and given to the
data analyst at the Southern Hub to clean and anonymise by replacing BCSS pseudoanonymised identifiers
with project-specific identifiers that cannot be cross-referenced to any other BCSS data sets. The IMD score
was supplied in lieu of postcode.
The Southern Hub specified the data to be extracted by HSCIC on behalf of the ASCEND research team.
Data were extracted using direct Search and Query Language queries on the BCSS with the additional use
of Oracle Business Intelligence Enterprise Edition bespoke reports. Patient-identifiable information included
practice, IMD score (derived from postcode) and year of birth.
Data transfer between HSCIC and the Southern Hub was carried out via an encrypted network connection
(NHS.NET) or NHS secure file transfer (SFT).
The raw data were then loaded into an encrypted Oracle database at the Southern Hub and algorithms
were written to process and anonymise the data into the format required by the ASCEND academic
statisticians. Any permutations of geodemographic variables that could lead to potentially identifiable
patient information were subject to further levels of anonymisation at this stage.
Although anonymised, data transfer between Southern Hub and the ASCEND research team used
password-protected files and SFT protocol. The ASCEND research team kept the data secure and did not
attempt to reverse engineer, link the data to other data sets or use the data for any purpose other than
the ASCEND project. The project adhered to the NHS Cancer Screening Programmes Confidentiality and
Disclosure Policy.
The data were extracted from the BCSS 18 weeks following the last intervention date for interventions
1 and 2 in March and July, respectively, and in November 2013 for interventions 3 and 4.
Quality control and quality assurance
Process evaluation
Prior to the start of any of the interventions the trial managers visited all NHS BCSP hubs and conducted
semistructured interviews with hub directors and managers. The principle objective of these interviews was
to identify organisational and resource-related barriers to successful roll-out of each intervention.
Particular note was taken of any adverse effects (e.g. excessive extra workload) that could make
implementation of any of the interventions unfeasible. With an increase in gFOBt uptake we expected an
increase in the workload in the hubs and in associated screening centres. In addition, we expected that
general practices may experience an increase in their workload following intervention 3 (e.g. an increase in
patients asking questions about the screening invitation).
It was expected that subjects, screening centres and general practices would communicate their experience
to the NHS BCSP helpline and so we asked the hubs to record all queries associated with the interventions
while the trials were taking place (and for up to 18 weeks afterwards to ensure all queries were included).
The hubs reported no substantial organisational or resource-related barriers and no increase in helpline
queries. A summary of the queries received is described in the process evaluation report in Appendix 35.
Evaluation of intervention fidelity
In order to ensure fidelity of the interventions, the trial managers established and piloted quality check
methods at each hub to ascertain whether or not the appropriate materials were sent to eligible people on
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particular days. In agreement with all the hubs, a standard operating procedure (SOP) was also put in place
prior to the start of each trial.
In addition, hubs were to approach a random subsample of 100 recipients of each intervention 2 weeks
after receipt of the information materials. However, at the time of the inventions, this exercise was not
feasible owing to additional workload incurred by hubs in setting up the new FS screening programme,
which started after the completion of the ASCEND programme. Instead, a more extensive quality
assurance process was implemented as an objective and less intrusive assessment of fidelity, described in
Interventions 1 and 2 and Interventions 3 and 4.
Interventions 1 and 2
These two interventions required inclusion of an additional information leaflet with each S1 invitation letter
on pre-specified random dates. Randomisation tables were provided to each hub and also to REAL Digital
International, the company that prints and distributes NHS BCSP letters for the Eastern, Southern and
London Hubs.
The quality checks for interventions 1 and 2 included adding one ‘monitor’ letter with each batch of letters
the hubs produced during the trial. Monitor letters were addressed to the imperial trial office in order to
check that the contents of letters corresponded to the randomisation schedule for the hub. In addition,
hubs also undertook an internal quality assurance measure to include photographic evidence of the
content of the letters each day at the start of the packing processing, as well as signing off a logbook
spreadsheet to note when the intervention was included.
Interventions 3 and 4
These two interventions required insertion of the name of the individual’s general practice into the S1
letter or additional text into the S10 letter. This involved implementing changes on the BCSS. We
conducted extensive consultations with HSCIC, whose programmers applied the necessary changes to the
BCSS to ensure that GPE letters and ER letters were generated on pre-specified random dates. Changes to
the BCSS included addition of a variable that indicated whether a subject had received an intervention or
was a part of the control cluster.
The research team provided HSCIC with details of all the general practices that had agreed to endorse the
NHS BCSP and randomisation dates for each hub.
The process diagrams for the GPE and ER letters are detailed in Figures 12–14.
In order to ensure fidelity, and similarly to the first two interventions, a SOP was produced for each hub to
follow and was monitored closely by the trial managers during the intervention periods. The quality checks
included a logbook designed to enable the hub staff to report back on whether or not intervention
banners were present on their daily S1 and S10 letter batches. Hub staff sent copies of the completed
logbooks on a daily basis to the trial office as evidence of the appropriate randomisation for each hub.
The trial managers produced a post-trial report after each intervention on the effectiveness in adherence to
the SOPs and feedback from the hubs.
Monitoring and auditing
An Independent Data Monitoring and Ethics Committee was established to monitor the progress of the
trial. Data were supplied to the Committee and meetings took place on the following dates: 28 January
2013, 12 July 2013 and 11 April 2014.
An advisory group was also established and included all ASCEND coapplicants and a number of external
experts. The advisory group met formally in September 2012 and also provided expert input on an
individual basis as required throughout the study period.
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The chief investigator was responsible for the day-to-day monitoring and management of the study. The
UCL Hospital/UCL/Royal Free Joint Research Office, on behalf of UCL as sponsor, monitors and conducts
random audits on a selection of studies in its clinical research portfolio each year. Monitoring and auditing
was conducted in accordance with the Department of Health Research Governance Framework for Health
and Social Care (and the second edition of this document was published in April 2005)211 and in accordance
with the sponsor’s monitoring and audit policies and procedures.
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Chapter 10 Workstream 3: the ASCEND national
randomised controlled trial results
Introduction
Chapter 9 described how the four RCTs were carried out, and in this chapter we present the results from
the four trials. The gist and narrative trials were run over 10 consecutive days in November 2012 and
March 2013, respectively. The GPE and ER RCTs were run over 20 consecutive days in June 2013 and
July–August 2013, respectively.
Findings
Trial sample sizes were as follows: gist (n = 163,525), narrative (n = 150,417), GPE (n = 265,434) and ER
(n = 168,480); Table 20.
Interventions 1 and 2 each comprised 50 clusters, as planned. Interventions 3 and 4 were supposed to
each comprise 100 clusters; however, owing to protocol violations whereby the incorrect randomisation
was employed on three occasions, intervention 3 ended up comprising 98 clusters and intervention 4
comprised 99 clusters.
Overview of results for all trials
Tabular data will be presented in the following order below:
l baseline data for each trial and each arm (see Tables 21–24 for gist, narrative, GPE and ER, respectively)
l numbers and percentages adequately screened for each trial and trial arm by sex, hub, screening
episode type and age (see Tables 25–28, respectively)
l numbers and percentages adequately screened for each trial, trial arm by SEC quintile (see Tables 29–32,
respectively)
l LR results for each trial by sex, hub, screening episode type and age (see Tables 33–36, respectively)
l LR results for each trial by SEC quintile (see Tables 37–40, respectively)
l test results for heterogeneity of intervention effect by screening episode type for each intervention for
each trial (see Table 41)
l times taken to return kits for each trial by SEC quintile (see Tables 42–45, respectively)
l diagnostic outcomes by arm for each trial (see Tables 46–49, respectively).
TABLE 20 Summary of the ASCEND RCTs: dates and numbers in each trial
Cluster randomisation nationally by hub
and day: Eastern, London, North East,
Midlands and North West and Southern
Length of trial
(weekdays)
Trial sample size
(number of clusters) Dates of trials
Intervention 1: gist leaflet 10 weekdays 163,525 (50 clusters) 5–16 November 2012
Intervention 2: narrative leaflet 10 weekdays 150,417 (50 clusters) 4–15 March 2013
Intervention 3: GPE 20 weekdays 265,434 (98 clusters) 3–28 June 2013
Intervention 4: ER 20 weekdays 168,480 (99 clusters) 8 July–2 August 2013
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We report an overview of the results in this subsection and brief summaries of main results trial by trial in
the following four subsections.
Tables 21–24 show the baseline characteristics age sex, SECs, hub and screening episode type (incident,
prevalent first invitation or prevalent previous non-responder), of subjects in each trial, by trial arm. These
demonstrate that the baseline characteristics were well balanced in each trial. In BCS05, the intervention
group was slightly larger than the control group in two trials (gist and GPE) and slightly smaller than the
control group in the other two trials. In BCS02, the control group was slightly larger in the GPE RCT. In all
cases, these imbalances were expected because of the process of randomising by day and hub, since
numbers of invitations sent varied by hub and day. In all four trials the proportion of individuals screened
decreased as deprivation increased in both arms. Individuals were categorised by IMD quintiles based on
the national distribution of scores, rather than by the distribution of scores in our sample (i.e. not 20% in
each quintile).
TABLE 21 Gist intervention: baseline characteristics
Variablesa SI+ gist (N= 84,421) SI (N= 79,104)
Age at invite (years), median (range) 66 (59–74) 66 (59–74)
IMD deprivation score, median (range) 14.9 (0.5–87.8) 14.8 (0.5–87.8)
Sex, % (n)
Female 51.2 (43,195) 51.4 (40,671)
Male 48.8 (41,226) 48.6 (38,433)
SEC quintile, % (n)
Least deprived (0–8.49) 22.6 (19,055) 23.5 (18,554)
Second quintile (8.50–13.79) 23.5 (19,787) 23.2 (18,295)
Third quintile (13.80–21.35) 21.7 (18,320) 20.3 (15,993)
Fourth quintile (21.36–34.17) 17.5 (14,747) 17.1 (13,469)
Most deprived (34.18–87.80) 14.7 (12,374) 16.0 (12,660)
Missing 138 133
Hub, % (n)
BCS01 26.6 (22,469) 30.8 (24,369)
BCS02 24.5 (20,651) 26.6 (21,004)
BCS03 8.8 (7416) 8.4 (6636)
BCS04 16.1 (13,614) 16.3 (12,858)
BCS05 24.0 (20,271) 18.0 (14,237)
Screening episode, % (n)
Incident 53.3 (45,019) 53.3 (42,143)
Prevalent first-time invitees 15.4 (13,034) 15.7 (12,410)
Prevalent previous non-responders 31.2 (26,368) 31.0 (24,551)
a Definitions of all variables are provided in Chapter 9.
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TABLE 22 Narrative intervention: baseline characteristics
Variablesa SI+ narrative (N= 73,722) SI (N= 76,695)
Age at invite (years), median (range) 65 (59–74) 65 (59–74)
IMD deprivation score, median (range) 15.1 (0.5–87.8) 15.1 (0.5–87.8)
Sex, % (n)
Female 51.5 (37,937) 51.0 (39,086)
Male 48.5 (35,785) 49.0 (37,609)
SEC quintile, % (n)
Least deprived (0–8.49) 23.2 (17,027) 22.3 (17,073)
Second quintile (8.50–13.79) 22.5 (16,517) 23.1 (17,675)
Third quintile (13.80–21.35) 20.8 (15,287) 21.1 (16,161)
Fourth quintile (21.36–34.17) 17.6 (12,897) 17.5 (13,385)
Most deprived (34.18–87.80) 16.0 (11,722) 15.9 (12,127)
Missing 272 274
Hub, % (n)
BCS01 29.1 (21,421) 27.5 (21,118)
BCS02 28.0 (20,667) 21.8 (16,723)
BCS03 11.5 (8509) 11.5 (8795)
BCS04 17.7 (13,053) 16.8 (12,900)
BCS05 13.7 (10,072) 22.4 (17,159)
Screening episode, % (n)
Incident 49.1 (36,232) 53.8 (41,293)
Prevalent first-time invitees 20.7 (15,281) 16.3 (12,510)
Prevalent previous non-responders 30.1 (22,209) 29.8 (22,892)
a Definitions of all variables are provided in Chapter 9.
TABLE 23 General practice endorsement intervention: baseline characteristics
Variablesa SI+GPE (N= 131,423) SI (N= 134,011)
Age at invite (years), median (range) 65 (59–74) 65 (59–74)
IMD deprivation score, median (range) 14.7 (0.5–87.8) 14.6 (0.5–87.8)
Sex, % (n)
Female 51.0 (66,986) 51.2 (68,591)
Male 49.0 (64,437) 48.8 (65,420)
SEC quintile, % (n)
Least deprived (0–8.49) 23.1 (30,350) 23.4 (31,381)
Second quintile (8.50–13.79) 23.6 (30,952) 23.4 (31,340)
Third quintile (13.80–21.35) 21.3 (27,950) 21.0 (28,181)
Fourth quintile (21.36–34.17) 17.1 (22,450) 17.2 (23,007)
Most deprived (34.18–87.80) 14.6 (19,174) 14.6 (19,540)
Missing 547 562
continued
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TABLE 23 General practice endorsement intervention: baseline characteristics (continued )
Variablesa SI+GPE (N= 131,423) SI (N= 134,011)
Hub, % (n)
BCS01 27.4 (35,993) 25.8 (34,598)
BCS02 24.2 (31,760) 30.3 (40,550)
BCS03 9.0 (11,818) 9.9 (13,255)
BCS04 16.2 (21,272) 16.0 (21,439)
BCS05 23.3 (30,580) 18.0 (24,169)
Screening episode, % (n)
Incident 52.3 (68,695) 52.3 (70,134)
Prevalent first time invitees 17.0 (22,287) 17.6 (23,582)
Prevalent previous non-responders 30.8 (40,441) 30.1 (40,295)
a Definitions of all variables are provided in Chapter 9.
TABLE 24 Enhanced reminder intervention: baseline characteristics
Variablesa SI+ ER (N= 78,067) SI (N= 90,413)
Age at invite (years), median (range) 65 (59–74) 64 (59–74)
IMD deprivation score, median (range) 16.4 (0.5–87.8) 16.2 (0.5–87.8)
Sex, % (n)
Female 48.4 (37,747) 48.2 (43,574)
Male 51.6 (40,320) 51.8 (46,839)
SEC quintile, % (n)
Least deprived (0–8.49) 20.4 (15,933) 20.9 (18,928)
Second quintile (8.50–13.79) 21.3 (16,594) 21.5 (19,446)
Third quintile (13.80–21.35) 20.6 (16,092) 20.2 (18,286)
Fourth quintile (21.36–34.17) 18.8 (14,679) 18.6 (16,853)
Most deprived (34.18–87.80) 18.5 (14,441) 18.2 (16,489)
Missing 328 411
Hub, % (n)
BCS01 28.2 (22,051) 28.2 (25,490)
BCS02 24.5 (19,131) 25.6 (23,107)
BCS03 13.8 (10,809) 11.5 (10,385)
BCS04 15.7 (12,291) 14.2 (12,796)
BCS05 17.7 (13,785) 20.6 (18,635)
Screening episode, % (n)
Incident 30.4 (23,722) 28.6 (25,813)
Prevalent first time invitees 18.6 (14,483) 23.5 (21,271)
Prevalent previous non-responders 51.1 (39,862) 47.9 (43,329)
a Definitions of all variables are provided in Chapter 9.
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Tables 25–28 summarise the number of individuals in each trial arm who returned a gFOBt kit (or kits) that
led to a ‘definitive’ screening test result within 18 weeks of being sent the routine screening invitation (i.e.
who were adequately screened). Thus, overall uptake was 57.4% for gist, 57.7% for narrative, 57.9% for
GPE and 25.4% for the ER. Once again, the distribution of adequately screened individuals was broadly
similar in both arms of each trial. However, the proportion of adequately screened individuals decreased as
the deprivation score increased in both arms (Tables 29–32). For example, in the gist trial, the proportion
decreased from 65.8% for the least deprived to 43.0% for the most deprived in the intervention arm and
from 65.6% for the least deprived to 42.0% for the most deprived in the control arm (see Table 29).
Univariate analyses (Tables 33–36) demonstrate the lack of significant association between screening uptake
and intervention in any of the four trials in subgroups of screening episode, age, sex and hub. Analyses were
performed with conservative variance estimation to take account of the cluster randomisation result in wider
CIs. The GPE intervention increased the odds of uptake by 6% among incident responders (p = 0.045; see
Table 35). In addition, an interaction with deprivation score was seen for incident responders to the ER
(p = 0.054; see Table 36).
Fully adjusting for screening episode, age, sex and hub (Tables 37–40) confirmed that the gist and
narrative interventions did not have a significant effect on uptake overall. The GPE invitation and ER both
increased the odds of uptake by 7% (p < 0.0001 and p = 0.001 in a fully adjusted model; see Tables 39
and 40). GPE also had a stronger effect in the more deprived IMD quintiles but the interaction was not
significant (p = 0.5). However, the ER trial showed a significant interaction with deprivation (p = 0.005),
with a stronger effect in the most deprived quintile (OR = 1.11, 95% CI 1.04 to 1.20; p = 0.003) than in
the least deprived quintile (OR = 1.00, 95% CI 0.94 to 1.06; p = 0.98).
TABLE 25 Gist intervention: proportion of individuals who were adequately screened, according to intervention arm
Variables SI+ gist (N= 48,653) SI (N= 45,290)
Sex, % (n)
Female 59.2 (25,585) 59.1 (24,017)
Male 56.0 (23,068) 55.4 (21,273)
Hub, % (n)
BCS01 54.9 (12,336) 54.6 (13,297)
BCS02 59.0 (12,177) 61.9 (12,991)
BCS03 55.0 (4078) 55.2 (3665)
BCS04 58.2 (7918) 57.4 (7382)
BCS05 59.9 (12,144) 55.9 (7955)
Screening episode, % (n)
Incident 85.2 (38,351) 85.0 (35,830)
Prevalent first-time invitees 49.6 (6466) 48.2 (5981)
Prevalent previous non-responders 14.5 (3836) 14.2 (3479)
Age (years)
60–64 54.9 (19,727) 54.2 (18,200)
65–69 60.8 (18,657) 61.1 (17,346)
70+ 57.7 (10,269) 56.9 (9744)
Total 57.6 (48,653) 57.3 (45,290)
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TABLE 26 Narrative intervention: proportion of individuals who were adequately screened, according to intervention arm
Variables SI+ narrative (N= 41,822) SI (N= 44,904)
Sex, % (n)
Female 59.3 (22,499) 60.9 (23,811)
Male 54.0 (19,323) 56.1 (21,093)
Hub, % (n)
BCS01 53.4 (11,439) 57.6 (12,163)
BCS02 61.5 (12,712) 60.2 (10,069)
BCS03 45.4 (3864) 49.2 (4327)
BCS04 59.1 (7716) 60.8 (7837)
BCS05 60.5 (6091) 61.2 (10,508)
Screening episode, % (n)
Incident 85.6 (31,031) 85.7 (35,389)
Prevalent first-time invitees 50.2 (7678) 49.8 (6231)
Prevalent previous non-responders 14.0 (3113) 14.3 (3284)
Age (years)
60–64 53.3 (18,264) 55.2 (19,014)
65–69 60.9 (14,673) 62.4 (16,673)
70+ 57.9 (8885) 59.2 (9217)
Total 56.7 (41,822) 58.5 (44,904)
TABLE 27 General practice endorsement intervention: proportion of individuals who were adequately screened,
according to intervention arm
Variables SI+GPE (N= 76,520) SI (N= 77,122)
Sex, % (n)
Female 60.8 (40,707) 60.2 (41,290)
Male 55.6 (35,813) 54.8 (35,832)
Hub, % (n)
BCS01 55.2 (19,869) 55.4 (19,150)
BCS02 62.7 (19,915) 60.3 (24,437)
BCS03 49.5 (5850) 48.2 (6385)
BCS04 59.8 (12,710) 58.9 (12,631)
BCS05 59.4 (18,176) 60.1 (14,519)
Screening episode, % (n)
Incident 86.4 (59,380) 85.7 (60,119)
Prevalent first-time invitees 51.4 (11,465) 49.4 (11,646)
Prevalent previous non-responders 14.0 (5675) 13.3 (5357)
Age (years)
60–64 55.9 (33,331) 54.8 (33,480)
65–69 61.0 (27,382) 60.5 (27,466)
70+ 58.7 (15,807) 58.8 (16,176)
Total 58.2 (76,520) 57.5 (77,122)
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TABLE 28 Enhanced reminder intervention: proportion of individuals who were adequately screened, according to
intervention arm
Variables SI+ ER (N= 20,166) SI (N= 22,712)
Sex, % (n)
Female 27.2 (10,267) 26.4 (11,511)
Male 24.5 (9899) 23.9 (11,201)
Hub, % (n)
BCS01 23.7 (5231) 23.1 (5899)
BCS02 30.5 (5827) 29.4 (6795)
BCS03 22.6 (2444) 21.1 (2196)
BCS04 23.7 (2911) 22.2 (2836)
BCS05 27.2 (3753) 26.8 (4986)
Screening episode, % (n)
Incident 59.2 (14,033) 58.1 (14,985)
Prevalent first-time invitees 25.8 (3739) 25.4 (5398)
Prevalent previous non-responders 6.0 (2394) 5.4 (2329)
Age (years)
60–64 26.7 (10,251) 26.1 (12,229)
65–69 26.8 (6674) 24.8 (6898)
70+ 21.9 (3241) 22.6 (3585)
Total 25.8 (20,166) 25.1 (22,712)
TABLE 29 Gist intervention: proportion of individuals who were adequately screened, according to SEC quintilea
Variable SI+ gist (N= 84,421), % (n) SI (N= 79,104), % (n)
Adequately screened 57.6 (48,653) 57.3 (45,290)
First quintile (least deprived) 65.8 (12,547) 65.6 (12,178)
Second quintile 62.2 (12,305) 62.4 (11,412)
Third quintile 58.6 (10,732) 58.4 (9335)
Fourth quintile 52.0 (7663) 51.9 (6987)
Fifth quintile (most deprived) 43.0 (5322) 42.0 (5316)
a A total of 271 (138 SI+ gist and 133 SI) individuals missing SECs, 146 of whom were adequately screened (84 SI+ gist and 62 SI).
TABLE 30 Narrative intervention: proportion of individuals who were adequately screened, according to SEC quintilea
Variable SI+ narrative (N= 73,722), % (n) SI (N= 76,695), % (n)
Adequately screened 56.7 (41,822) 58.5 (44,904)
First quintile (least deprived) 64.6 (11,005) 66.8 (11,411)
Second quintile 62.1 (10,253) 62.7 (11,080)
Third quintile 58.3 (8911) 59.4 (9601)
Fourth quintile 50.7 (6535) 52.9 (7083)
Fifth quintile (most deprived) 42.4 (4966) 46.0 (5580)
a A total of 546 (272 SI+ narrative and 274 SI) individuals missing SECs, 301 of whom were adequately screened
(152 SI + narrative and 149 SI).
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TABLE 31 General practice endorsement intervention: proportion of individuals who were adequately screened,
according to SEC quintilea
Variable SI+GPE (N= 131,423), % (n) SI (N= 134,011), % (n)
Adequately screened 58.2 (76,520) 57.5 (77,122)
First quintile (least deprived) 65.2 (19,792) 66.0 (20,716)
Second quintile 63.1 (19,530) 62.6 (19,604)
Third quintile 59.3 (16,571) 58.0 (16,336)
Fourth quintile 53.0 (11,902) 51.5 (11,839)
Fifth quintile (most deprived) 44.0 (8433) 42.6 (8324)
a A total of 1109 (547 SI+GPE and 562 SI) individuals missing SECs, 595 of whom were adequately screened
(292 SI+GPE and 303 SI).
TABLE 32 Enhanced reminder intervention: proportion of individuals who were adequately screened, according to
SEC quintilea
Variable SI+ ER (N= 78,067), % (n) SI (N= 90,413), % (n)
Adequately screened 25.8 (20,166) 25.1 (22,712)
First quintile (least deprived) 34.7 (5522) 34.9 (6601)
Second quintile 30.8 (5107) 29.7 (5782)
Third quintile 26.8 (4316) 25.0 (4578)
Fourth quintile 21.1 (3104) 20.4 (3436)
Fifth quintile (most deprived) 14.1 (2040) 13.3 (2198)
a A total of 739 (328 SI + ER and 411 SI) individuals missing SECs, 194 of whom were adequately screened (77 SI + ER
and 117 SI).
TABLE 33 Gist intervention: summary of LR results by subgroup
Gist intervention
Univariate OR Univariate OR with conservative variance
OR (95% CI) p-value OR (95% CI) p-value
p-value for
interaction with
IMD score
Hub
BCS01 1.01 (0.98 to 1.05) 0.46 1.01 (0.83 to 1.24) 0.90 0.10
BCS02 0.89 (0.85 to 0.92) < 0.001 0.89 (0.84 to 0.94) < 0.001 0.93
BCS03 0.99 (0.93 to 1.06) 0.78 0.99 (0.64 to 1.52) 0.97 < 0.01
BCS04 1.03 (0.98 to 1.08) 0.22 1.03 (0.89 to 1.19) 0.68 0.09
BCS05 1.18 (1.13 to 1.23) < 0.001 1.18 (0.97 to 1.43) 0.09 0.58
Sex
Female 1.01 (0.98 to 1.04) 0.60 1.01 (0.91 to 1.12) 0.89 0.78
Male 1.02 (1.00 to 1.05) 0.09 1.02 (0.92 to 1.14) 0.65 0.33
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TABLE 33 Gist intervention: summary of LR results by subgroup (continued )
Gist intervention
Univariate OR Univariate OR with conservative variance
OR (95% CI) p-value OR (95% CI) p-value
p-value for
interaction with
IMD score
Screening episode
Incident 1.01 (0.98 to 1.05) 0.49 1.01 (0.95 to 1.08) 0.67 0.38
Prevalent first-time invitees 1.06 (1.01 to 1.11) 0.02 1.06 (0.96 to 1.16) 0.23 0.13
Prevalent previous
non-responders
1.03 (0.98 to 1.08) 0.23 1.03 (0.94 to 1.13) 0.50 0.09
Age (years)
< 65 1.03 (1.00 to 1.06) 0.05 1.03 (0.94 to 1.13) 0.52 0.86
65–69 0.98 (0.95 to 1.02) 0.36 0.98 (0.85 to 1.13) 0.83 0.47
70+ 1.04 (0.99 to 1.08) 0.11 1.04 (0.90 to 1.19) 0.64 0.46
Total 1.02 (1.00 to 1.04) 0.12 1.02 (0.92 to 1.13) 0.77 0.48
TABLE 34 Narrative intervention: summary of LR results by subgroup
Narrative intervention
Univariate OR Univariate OR with conservative variance
OR (95% CI) p-value OR (95% CI) p-value
p-value for
interaction with
IMD score
Hub
BCS01 0.84 (0.81 to 0.88) < 0.001 0.84 (0.67 to 1.06) 0.14 0.68
BCS02 1.06 (1.01 to 1.10) 0.01 1.06 (0.89 to 1.25) 0.52 0.78
BCS03 0.86 (0.81 to 0.91) < 0.001 0.86 (0.68 to 1.08) 0.20 0.67
BCS04 0.93 (0.89 to 0.98) < 0.01 0.93 (0.81 to 1.07) 0.34 0.25
BCS05 0.97 (0.92 to 1.02) 0.21 0.97 (0.80 to 1.18) 0.75 0.74
Sex
Female 0.93 (0.91 to 0.96) < 0.001 0.93 (0.81 to 1.07) 0.34 0.47
Male 0.92 (0.89 to 0.95) < 0.001 0.92 (0.81 to 1.05) 0.20 0.20
Screening episode
Incident 1.00 (0.96 to 1.04) 0.82 1.00 (0.92 to 1.08) 0.91 0.46
Prevalent first-time invitees 1.02 (0.97 to 1.07) 0.47 1.02 (0.91 to 1.14) 0.77 0.26
Prevalent previous
non-responders
0.97 (0.92 to 1.03) 0.32 0.97 (0.88 to 1.07) 0.58 0.18
Age (years)
< 65 0.92 (0.90 to 0.95) < 0.001 0.92 (0.82 to 1.05) 0.21 0.11
65–69 0.94 (0.90 to 0.97) < 0.001 0.94 (0.79 to 1.11) 0.45 0.88
70+ 0.95 (0.90 to 0.99) 0.02 0.95 (0.82 to 1.09) 0.43 0.17
Total 0.93 (0.91 to 0.95) < 0.001 0.93 (0.81 to 1.06) 0.27 0.27
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
107
TABLE 35 General practice endorsement intervention: summary of LR results by subgroup
GPE intervention
Univariate OR Univariate OR with conservative variance
OR (95% CI) p-value OR (95% CI) p-value
p-value for
interaction with
IMD score
Hub
BCS01 0.99 (0.96 to 1.02) 0.69 0.99 (0.90 to 1.10) 0.91 0.42
BCS02 1.11 (1.08 to 1.14) < 0.001 1.11 (0.99 to 1.24) 0.07 0.01
BCS03 1.05 (1.00 to 1.11) 0.035 1.05 (0.88 to 1.26) 0.56 0.95
BCS04 1.04 (1.00 to 1.08) 0.08 1.04 (0.94 to 1.14) 0.47 0.31
BCS05 0.97 (0.94 to 1.01) 0.132 0.97 (0.84 to 1.13) 0.73 0.25
Sex
Female 1.02 (1.00 to 1.05) 0.031 1.02 (0.94 to 1.12) 0.58 0.22
Male 1.03 (1.01 to 1.06) 0.003 1.03 (0.96 to 1.12) 0.40 0.13
Screening episode
Incident 1.06 (1.03 to 1.09) < 0.001 1.06 (1.00 to 1.13) 0.045 0.68
Prevalent first-time invitees 1.09 (1.05 to 1.13) < 0.001 1.09 (1.01 to 1.16) 0.02 0.44
Prevalent previous
non-responders
1.06 (1.02 to 1.11) 0.002 1.06 (1.00 to 1.13) 0.055 0.22
Age (years)
< 65 1.05 (1.02 to 1.07) < 0.001 1.05 (0.98 to 1.12) 0.20 0.06
65–69 1.02 (1.00 to 1.05) 0.09 1.02 (0.92 to 1.13) 0.66 0.55
70+ 0.99 (0.96 to 1.03) 0.71 0.99 (0.89 to 1.10) 0.90 0.32
Total 1.03 (1.01 to 1.04) 0.001 1.03 (0.95 to 1.11) 0.49 0.11
TABLE 36 Enhanced reminder intervention: summary of LR results by subgroup
Univariate OR Univariate OR with conservative variance
OR (95% CI) p-value OR (95% CI) p-value
p-value for
interaction with
IMD score
Hub
BCS01 1.03 (0.99 to 1.08) 0.14 1.03 (0.96 to 1.11) 0.38 0.99
BCS02 1.05 (1.01 to 1.10) 0.02 1.05 (0.92 to 1.20) 0.44 0.001
BCS03 1.09 (1.02 to 1.16) 0.01 1.09 (0.93 to 1.28) 0.29 0.90
BCS04 1.09 (1.03 to 1.16) 0.004 1.09 (0.97 to 1.22) 0.14 0.73
BCS05 1.02 (0.97 to 1.08) 0.35 1.02 (0.84 to 1.25) 0.81 0.98
Sex
Female 1.04 (1.01 to 1.07) 0.012 1.04 (0.95 to 1.14) 0.41 0.37
Male 1.04 (1.00 to 1.07) 0.03 1.04 (0.95 to 1.13) 0.45 0.24
Screening episode
Incident 1.05 (1.01 to 1.08) 0.013 1.05 (0.97 to 1.12) 0.21 0.05
Prevalent first-time invitees 1.02 (0.98 to 1.07) 0.35 1.02 (0.95 to 1.10) 0.51 0.12
Prevalent previous
non-responders
1.12 (1.06 to 1.19) < 0.001 1.12 (1.03 to 1.23) 0.008 0.43
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TABLE 37 Gist intervention: summary of LR results by IMD quintile
Variable
Univariate (gist)
Univariate (gist) with
conservative variance
Multivariatea with
conservative variance
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
IMD quintile
First quintile
(least deprived)
1.01 (0.97 to 1.05) 0.67 1.01 (0.92 to 1.11) 0.85 1.06 (1.01 to 1.11) 0.02
Second quintile 0.99 (0.95 to 1.03) 0.70 0.99 (0.91 to 1.09) 0.86 1.02 (0.97 to 1.07) 0.50
Third quintile 1.01 (0.97 to 1.05) 0.69 1.01 (0.90 to 1.13) 0.88 1.00 (0.94 to 1.08) 0.92
Fourth quintile 1.00 (0.96 to 1.05) 0.88 1.00 (0.91 to 1.11) 0.94 1.01 (0.94 to 1.08) 0.86
Fifth quintile
(most deprived)
1.04 (0.99 to 1.10) 0.10 1.04 (0.92 to 1.18) 0.50 1.04 (0.96 to 1.12) 0.37
Total 1.02 (1.00 to 1.04) 0.12 1.02 (0.92 to 1.13) 0.77 1.03 (0.99 to 1.06) 0.15
a Adjusted for screening episode, age, sex and hub.
TABLE 36 Enhanced reminder intervention: summary of LR results by subgroup (continued )
Univariate OR Univariate OR with conservative variance
OR (95% CI) p-value OR (95% CI) p-value
p-value for
interaction with
IMD score
Age (years)
< 65 1.03 (1.00 to 1.06) 0.07 1.03 (0.96 to 1.11) 0.44 0.06
65–69 1.11 (1.07 to 1.15) < 0.001 1.11 (0.99 to 1.25) 0.08 0.62
70+ 0.96 (0.91 to 1.01) 0.13 0.96 (0.83 to 1.10) 0.56 0.79
Total 1.04 (1.02 to 1.06) 0.001 1.04 (0.95 to 1.14) 0.42 0.21
TABLE 38 Narrative intervention: summary of LR results by IMD quintile
Variable
Univariate (narrative)
Univariate (narrative) with
conservative variance
Multivariatea with
conservative variance
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
IMD quintile
First quintile
(least deprived)
0.91 (0.87 to 0.95) < 0.001 0.91 (0.81 to 1.01) 0.08 0.98 (0.93 to 1.04) 0.57
Second quintile 0.97 (0.93 to 1.02) 0.24 0.97 (0.88 to 1.08) 0.62 1.00 (0.94 to 1.06) 0.91
Third quintile 0.95 (0.91 to 1.00) 0.04 0.95 (0.85 to 1.08) 0.46 1.05 (0.97 to 1.13) 0.24
Fourth quintile 0.91 (0.87 to 0.96) < 0.001 0.91 (0.78 to 1.06) 0.25 1.00 (0.94 to 1.06) 0.95
Fifth quintile
(most deprived)
0.86 (0.82 to 0.91) < 0.001 0.86 (0.74 to 1.00) 0.05 0.92 (0.86 to 0.98) 0.02
Total 0.93 (0.91 to 0.95) < 0.001 0.93 (0.81 to 1.06) 0.27 1.00 (0.96 to 1.03) 0.80
a Adjusted for screening episode, age, sex and hub.
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Multivariate analyses including an interaction term between intervention arm and screening episode
showed no significant interaction for any of the four interventions (Table 41).
Median times (ranges) to return the kits following the date the S1 letter was sent are shown in Tables 42–44
and median times (ranges) to return the kits following the date of the S9 reminder letter being sent are
shown in Table 45. These times are broadly similar for the gist, narrative and GPE interventions, and
approximately double the time to return a kit after a reminder letter. They are also similar in intervention and
control arms and across IMD quintiles.
Follow-up appointments at screening centres were arranged and diagnostic outcomes are known for
individuals who had a definitive abnormal screening result. Tables 46–49 demonstrate that the proportions
of individuals with known outcomes, and the distribution of diagnoses, are similar across trials and
trial arms.
TABLE 39 General practice endorsement intervention: summary of LR results by IMD quintile
Variable
Univariate (GPE)
Univariate (GPE) with
conservative variance
Multivariatea with
conservative variance
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
IMD quintile
First quintile
(least deprived)
0.97 (0.93 to 1.00) 0.04 0.97 (0.88 to 1.05) 0.43 1.04 (0.99 to 1.08) 0.08
Second quintile 1.02 (0.99 to 1.06) 0.16 1.02 (0.95 to 1.10) 0.54 1.06 (1.02 to 1.10) 0.004
Third quintile 1.06 (1.02 to 1.09) 0.002 1.06 (0.98 to 1.14) 0.16 1.08 (1.03 to 1.13) 0.001
Fourth quintile 1.06 (1.03 to 1.10) 0.001 1.06 (0.98 to 1.16) 0.15 1.09 (1.04 to 1.15) 0.001
Fifth quintile
(most deprived)
1.06 (1.02 to 1.10) 0.01 1.06 (0.97 to 1.15) 0.19 1.07 (1.01 to 1.13) 0.02
Total 1.03 (1.01 to 1.04) < 0.001 1.03 (0.95 to 1.11) 0.49 1.07 (1.04 to 1.10) < 0.0001
a Adjusted for screening episode, age, sex and hub.
TABLE 40 Enhanced reminder intervention: summary of LR results by IMD quintile
Variable
Univariate (ER)
Univariate (ER) with
conservative variance
Multivariatea with
conservative variance
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
IMD quintile
First quintile
(least deprived)
0.99 (0.95 to 1.04) 0.67 0.99 (0.90 to 1.09) 0.85 1.00 (0.94 to 1.06) 0.98
Second quintile 1.05 (1.00 to 1.10) 0.03 1.05 (0.97 to 1.14) 0.21 1.04 (0.98 to 1.11) 0.20
Third quintile 1.10 (1.05 to 1.15) < 0.001 1.10 (1.02 to 1.18) 0.02 1.13 (1.06 to 1.20) < 0.001
Fourth quintile 1.05 (0.99 to 1.11) 0.10 1.05 (0.96 to 1.14) 0.29 1.09 (1.02 to 1.17) 0.009
Fifth quintile
(most deprived)
1.07 (1.00 to 1.14) 0.04 1.07 (0.97 to 1.18) 0.19 1.11 (1.04 to 1.20) 0.003
Total 1.04 (1.02 to 1.06) 0.001 1.04 (0.95 to 1.14) 0.42 1.07 (1.03 to 1.11) 0.001
a Adjusted for screening episode, age, sex and hub.
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TABLE 41 Tests for heterogeneity of effects between incident and prevalent (first-time invitees) and prevalent
(previous non-responders) screens in all four interventions
Intervention Test for heterogeneity
1 (gist) p= 0.75
2 (narrative) p= 0.84
3 (GPE) p= 0.96
4 (ER) p= 0.10
TABLE 42 Gist intervention: time taken to return the gFOBt kit by IMD quintile
Variable SI+ gist, median (range) SI, median (range)
Time taken to return the gFOBt kit in days 23 (12–126) 22 (11–126)
First quintile (least deprived) 24 (12–126) 22 (12–126)
Second quintile 23 (12–126) 22 (12–126)
Third quintile 23 (12–126) 22 (12–126)
Fourth quintile 23 (13–126) 21 (11–126)
Fifth quintile (most deprived) 21 (12–126) 21 (12–126)
TABLE 43 Narrative intervention: time taken to return the gFOBt kit by IMD quintile
Variable SI+ narrative, median (range) SI, median (range)
Time taken to return the gFOBt kit in days 26 (11–126) 26 (10–126)
First quintile (least deprived) 26 (13–126) 27 (13–126)
Second quintile 26 (11–126) 27 (13–125)
Third quintile 25 (11–126) 26 (12–125)
Fourth quintile 25 (13–125) 26 (10–126)
Fifth quintile (most deprived) 24 (13–126) 26 (12–126)
TABLE 44 General practice endorsement intervention: time taken to return the gFOBt kit by IMD quintile
Variable SI+GPE, median (range) SI, median (range)
Time taken to return the gFOBt kit in days 22 (8–126) 23 (11–126)
First quintile (least deprived) 23 (12–126) 24 (11–126)
Second quintile 23 (12–126) 24 (13–126)
Third quintile 22 (11–126) 23 (11–126)
Fourth quintile 22 (8–126) 22 (13–126)
Fifth quintile (most deprived) 21 (12–126) 22 (12–125)
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TABLE 45 Enhanced reminder intervention: time taken to return the gFOBt kit by IMD quintile
Variable SI+ ER, median (range) SI, median (range)
Time taken to return the gFOBt kit in days 11 (–4 to 89) 11 (0–89)
First quintile (least deprived) 11 (–4 to 89) 11 (0–89)
Second quintile 11 (–4 to 89) 11 (0–89)
Third quintile 11 (–4 to 89) 11(0–89)
Fourth quintile 11 (–4 to 89) 11 (0–89)
Fifth quintile (most deprived) 11 (–2 to 89) 11 (0–89)
TABLE 46 Gist intervention: diagnostic outcome for adequately screened individuals with a definitive abnormal result
Variable SI+ gist (N= 911), % (n) SI (N= 792), % (n)
Diagnostic outcome known 81.7 (744) 79.9 (633)
Abnormal (including abnormal no histology) 25.9 (236) 24.2 (192)
Cancer detected 5.2 (47) 6.6 (52)
High-risk adenoma 8.2 (75) 7.1 (56)
Intermediate-risk adenoma 12.8 (117) 11.1 (88)
Low-risk adenoma 15.5 (141) 15.8 (125)
Normal (no abnormalities found) 14.1 (128) 15.2 (120)
Diagnostic outcome unknown 18.3 (167) 20.1 (159)
TABLE 47 Narrative intervention: diagnostic outcome for adequately screened individuals with a definitive
abnormal result
Variable SI+ narrative (N= 675), % (n) SI (N= 688), % (n)
Diagnostic outcome known 81.2 (548) 79.5 (547)
Abnormal (including abnormal no histology) 23.0 (155) 22.2 (153)
Cancer detected 6.5 (44) 7.1 (49)
High-risk adenoma 9.3 (63) 7.7 (53)
Intermediate-risk adenoma 12.6 (85) 10.9 (75)
Low-risk adenoma 17.8 (120) 17.2 (118)
Normal (no abnormalities found) 12.0 (81) 14.4 (99)
Diagnostic outcome unknown 18.8 (127) 20.5 (141)
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Summary of results of the gist trial
Overall rates of being adequately screened were 57.6% in the intervention arm and 57.3% in the control
arm. This difference was not significant, either in the standard analysis (OR = 1.02, 95% CI 1.00 to 1.04;
p = 0.12) or in the multivariate adjusted conservative variance analysis (OR = 1.03, 95% CI 0.99 to 1.06;
p = 0.15). There was no significant heterogeneity of the intervention effect by SECs, with ORs in the
multivariate adjusted conservative variance analysis of 1.06 (95% CI 1.01 to 1.11) in the least deprived
quintile and 1.04 (95% CI 0.96 to 1.12) in the most deprived quintile. The only significant intervention
effect was observed in the least deprived quintile and only in the multivariate adjusted conservative
variance analysis (p = 0.02).
Summary of results of the narrative trial
Overall rates of being adequately screened were 56.7% in the intervention arm and 58.5% in the control
arm. This difference was significant in the standard analysis (OR = 0.93, 95% CI 0.91 to 0.95; p < 0.001)
but not in the multivariate adjusted conservative variance analysis (OR = 1.00, 95% CI 0.96 to 1.03;
p = 0.80). There was no significant heterogeneity of the intervention effect by SECs, with ORs in the
multivariate adjusted conservative variance analysis of 0.98 (95% CI 0.93 to 1.04) in the least deprived
quintile and 0.92 (95% CI 0.86 to 0.98) in the most deprived quintile, the latter being the only significant
result (p = 0.02) in subgroups of SECs.
TABLE 48 General practice endorsement intervention: diagnostic outcome for adequately screened individuals with
a definitive abnormal result
Variable SI+GPE (N= 1458), % (n) SI (N= 1396), % (n)
Diagnostic outcome known 82.2 (1198) 82.7 (1154)
Abnormal (including abnormal no histology) 25.3 (369) 25.8 (360)
Cancer detected 7.3 (106) 6.3 (88)
High-risk adenoma 7.4 (108) 8.1 (113)
Intermediate-risk adenoma 11.4 (167) 12.4 (173)
Low-risk adenoma 16.2 (237) 15.7 (219)
Normal (no abnormalities found) 14.4 (211) 14.4 (201)
Diagnostic outcome unknown 17.8 (260) 17.3 (242)
TABLE 49 Enhanced reminder intervention: diagnostic outcome for adequately screened individuals with a
definitive abnormal result
Variable SI+ ER (N= 399), % (n) SI (N= 435), % (n)
Diagnostic outcome known 79.4 (317) 76.6 (333)
Abnormal (including abnormal no histology) 24.8 (99) 20.7 (90)
Cancer detected 7.3 (29) 8.0 (35)
High-risk adenoma 5.5 (22) 6.9 (30)
Intermediate-risk adenoma 11.0 (44) 12.9 (56)
Low-risk adenoma 14.8 (59) 16.5 (72)
Normal (no abnormalities found) 16.0 (64) 11.5 (50)
Diagnostic outcome unknown 20.6 (82) 23.4 (102)
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
113
Summary of results of the general practice endorsement trial
Overall rates of being adequately screened were 58.2% in the intervention arm and 57.5% in the control
arm. This was significant in both the standard univariate analysis (OR = 1.03, 95% CI 1.01 to 1.04;
p < 0.001) and the multivariate adjusted conservative variance analysis (OR = 1.06, 95% CI 1.04 to 1.10;
p < 0.001). There was a suggestion of a greater effect in more deprived quintiles with an OR of 1.04
(95% CI 0.99 to 1.08) in the least deprived quintile and an OR of 1.07 (95% CI 1.01 to 1.13) in the most
deprived, both in the multivariate adjusted conservative variance analysis, but this heterogeneity was not
significant (p = 0.5). As noted above (see Chapter 9, Comparators), there was overlap between the study
populations of the GPE and ER trials. Table 50 shows the status of subjects by the two trials, cross-
tabulated. This shows that, in the GPE trial, a larger proportion of the intervention group than of the
control group were randomised. However, the unadjusted OR for participation within 4 weeks associated
with GPE (before the reminder could have been received) was 1.06, which was higher than the 1.03
observed for participation overall.
Summary of results of the enhanced reminder trial
Overall rates of being adequately screened were 25.8% in the intervention arm and 25.1% in the control
arm. This difference was statistically significant in both the univariate standard analysis (OR = 1.04, 95% CI
1.02 to 1.06; p = 0.001) and the multivariate adjusted conservative variance analysis (OR = 1.07, 95% CI
1.03 to 1.11; p = 0.001). There was a significantly stronger effect of the intervention in more deprived
quintiles (p = 0.005). In the multivariate adjusted conservative variance analysis, the OR associated with the
intervention in the least deprived quintile was 1.00 (95% CI 0.94 to 1.06) and in the most deprived
quintile, was 1.11 (95% CI 1.04 to 1.20). The effect of the intervention in the multivariate adjusted
conservative variance analysis was significant in all deprivation quintiles except for the least deprived.
Concurrent initiatives
We identified 65 research initiatives and 101 health promotion activities, of which 14% and 59%,
respectively, were localised and specific to bowel cancer screening uptake. Of these, three research
initiatives and 27 health promotion activities occurred within a 3-month time frame of each of the
ASCEND interventions.
Measuring costs
For the gist and narrative interventions costs of £3106 and £3887, respectively, were incurred for printing
and transporting the additional leaflets. These costs were incurred for screening 88,421 and 73,722
participants, and the average incremental cost per screening invitation of providing the interventions was
£0.04 and £0.05, respectively.
TABLE 50 The GPE trial status cross-tabulated by ER trial status
ER trial status
GPE trial population
TotalUsual letter, n GPE letter, n Not in GPE trial, n
Not in ER trial 74,200 66,502 140,702
Control in ER trial 37,880 30,259 22,274 90,413
ER intervention in ER trial 21,931 34,662 21,474 78,067
Total 134,011 131,423 43,748 309,182
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Using the results from the individual RCTs, it is possible to estimate the potential number of additional
cancers and polyps that might be detected if GPE and the ER were implemented nationally across England.
We calculated average marginal effects of GPE and the ER from the RCTs and used these to predict their
impact on the detection of colorectal adenomas and cancer in the NHS BCSP.
With regard to GPE, a 7% increase in the odds of screening all participants, as found in the multivariable
analysis of the trial data, was associated with predictive margins (adjusted average probabilities of uptake)
of 0.584 (95% CI 0.581 to 0.586) in the intervention group and 0.574 (95% CI 0.571 to 0.577) in the
control group. This translates into a 1.7% relative increase in the probability of screening among all
participants (0.584/0.574) and a 1-percentage-point absolute increase (0.584–0.574; the average marginal
effect). Although this appears to be a relatively small effect, in absolute terms the impact would be large if
it was rolled out nationally given the population size. In the 2013/14 fiscal year, the number invited for
screening in the NHS BCSP in England was 3,976,616 (Bowel Cancer Screening System National. National
Fiscal Summary 12 June 2015. Claire Nickerson, Public Health England, 2015, personal communication).
An average marginal effect of 1% (i.e. 0.010) suggests that if GPE were implemented nationally, then
39,766 extra people each year would be screened. In 2013/14, the positivity rate among the screened
population was 1.84% (Bowel Cancer Screening System National. National Fiscal Summary 12 June 2015.
Claire Nickerson, Public Health England, 2015, personal communication). Evidence suggests that 83%
of people with a positive test result attend a SSP clinic and undergo further investigation212 and, among
those who go on to have further investigations, 10.1% will have a CRC and 27.2% will have colorectal
adenomatous polyps classed as medium or high risk that require further investigation.212 Hence, if GPE was
implemented nationally this could detect up to an additional 165 people (39,766 × 0.0184 × 0.83 × 0.272)
with polyps classed as high or intermediate risk and 61 people (39,766 × 0.0184 × 0.83 × 0.101) with a
CRC each year.
For the ER there was also a 7% increase in the odds of screening, this time achieved among those
randomised in the ER trial, that is, receiving a reminder letter. This was associated with predictive margins
(adjusted average probabilities of uptake) of 0.259 (95% CI 0.255 to 0.265) in the intervention group
and 0.250 (95% CI 0.248 to 0.253) in the control group. This implies a 3.6% relative increase in the
probability of screening (0.259/0.250) and a 0.9-percentage-point absolute increase (0.259 minus 0.250;
the average marginal effect). In the 2013/14 fiscal year, the number of reminder (S10) letters sent in the
NHS BCSP in England was 2,144,277 (Bowel Cancer Screening System National. National Fiscal Summary
12 June 2015. Claire Nickerson, Public Health England, 2015, personal communication). An average
marginal effect of 0.9% (i.e. 0.009) suggests that if the ER were implemented nationally, then 19,298
extra people each year might be screened. We assume as above that the positivity rate among the
screened population was 1.84% in 2013/14, that 83% of people with a positive test result attend a SSP
clinic and undergo further investigations and that among those who go on to have further investigations,
10.1% will have a CRC and 27.2% will have colorectal adenomatous polyps classed as medium or high
risk requiring further investigation. On this basis, if the ER was implemented nationally it might detect up
to an additional 80 people (19,298 × 0.0184 × 0.83 × 0.272) with polyps classed as high or intermediate
risk and 30 people (19,298 × 0.0184 × 0.83 × 0.101) with a CRC in England each year.
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Chapter 11 Workstream 3 randomised controlled
trials: discussion
Introduction
The results presented in Chapter 10 demonstrate that the gist and narrative trials showed no effect on the
gradient in uptake (interactions with deprivation quintile: p > 0.05) or overall uptake (gist: OR= 1.03, 95% CI
0.99 to 1.06; p = 0.15; narrative: OR= 1.00, 95% CI 0.96 to 1.03; p = 0.80). In the GPE trial, there was no
effect on the gradient but an increase in overall uptake (OR = 1.07, 95% CI 1.04 to 1.10; p < 0.0001). The ER
trial showed a significant interaction with deprivation (p < 0.05) with a stronger effect in the most deprived
(OR = 1.11, 95% CI 1.04 to 1.20; p = 0.003) than the least deprived quintile (OR = 1.00, 95% CI 0.94 to
1.06; p = 0.98) and higher overall uptake (OR = 1.07, 95% CI 1.03 to 1.11; p < 0.001).
Interpretation
Reducing socioeconomic inequalities in cancer mortality is a priority worldwide. Cancer screening is a
major part of a combined effort to bring diagnoses forward to an earlier, more treatable, stage. However,
even in the UK, where screening does not incur any cost to the individual, uptake is consistently lower in
more socioeconomically deprived groups.213,214 Together, our four trials constitute the largest evaluation
of interventions designed specifically to reduce inequalities in uptake within an organised screening
programme. An important strength of the ASCEND trial was that the trials were powered to measure the
impact of interventions on SEC gradient in the total eligible population rather than just focusing on
disadvantaged groups. Our interventions therefore had the potential to reach a much larger number of
non-participants. Use of routinely collected data enabled us to include the whole study population with
the exception of a very small group of individuals without IMD scores for their postcodes (see Appendix 36)
in our analysis. The lack of attrition accelerates the potential for implementation of these interventions. Each
intervention also had a well-established rationale and empirical background, and followed a structured,
comprehensive development process. However, only the ER demonstrated a reduction in the SEC gradient
in uptake. The gist and narrative interventions showed no effect at all on uptake, while GPE increased
uptake overall but did not modify the SEC gradient. None of our interventions promoted an earlier response.
The gist and narrative leaflets were designed to make the screening offer more visible to people with
lower literacy skills on the basis of extensive evidence that lower SECs are associated with lower literacy.
Both leaflets demonstrated this potential when their effect was evaluated on the basis of knowledge and
attitudes, with additional evidence that the narrative leaflet increased intention to attend screening.171,215
However, in the trials, neither of the leaflets increased bowel cancer screening uptake, either in lower SEC
groups or overall. One possible explanation for the discrepancy from the pilot data is the emerging body of
evidence indicating that the determinants of intention may differ from the determinants of action and
perhaps we influenced intentions rather than actions.35 Another possible explanation relates to the fact
that both leaflets had to be added to the existing invitation/information, rather than being provided as an
alternative (because the existing materials are approved nationally to ensure appropriate provision of
essential information). Consequently, although the new leaflets were designed to be simple, they
nonetheless increased the total mass of written material that participants received and this may have
undermined the goal of making the screening offer more visible. We also did not have the resources to
translate the leaflets into different languages, which may have limited their impact in more ethnically
diverse urban regions, although we saw no hub-specific effects.
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
117
A specific issue with the narrative leaflet was that we tried to address negative beliefs about being
diagnosed with bowel cancer by presenting two case studies of patients who had been diagnosed early
and reported their support of the programme and the relief associated with having their lives saved.
However, we acknowledge that these examples may inadvertently work against this effect by reinforcing
the link between screening and cancer. This may have overridden the positive messages in the leaflet.
Although the pilot study did indicate that the leaflet was associated with increased screening intentions,
we were able to observe this effect only among responders to the questionnaire. Our national trial of GPE
significantly increased uptake overall. The effect size was smaller than in many previous studies,36,196,216,217
but this was probably because most of those had used letters directly from the GP or had an individual
GP’s signature on the letter. In the NHS BCSP, all invitation letters come from the hubs; therefore, the only
practical option was to include a banner noting that the individual’s general practice supported the
programme, but without individual GPs’ names or signatures. It would not be surprising if this diluted the
impact. However, given the exceptionally high level of agreement by general practices to endorse the NHS
BCSP, the small one-off cost to modify the standard invitation letter within the NHS BCSP IT system
(to adjust for any recent changes in practice name) and the zero marginal cost per person screened, we
recommend that the NHS BCSP consider adding GPE to the screening invitation letter.
Because previous studies had shown effects of GPE in low-income groups (e.g. Ahmed et al.218), we had
hypothesised that it might have a stronger effect in lower than in higher SEC groups. No previous study
had been powered to examine effects on the SEC gradient and the size of the present trial provides a
definitive negative result, at least with the format of GPE that was used.
The one intervention that reduced the SEC gradient was the ER. Our aim was to offer anyone who may not
have engaged with the original materials an additional opportunity to see the screening offer. Unlike the
gist and narrative interventions, which tried to achieve this with an additional leaflet, the ‘enhancement’
was incorporated into the one-page reminder letter. The information pack which contained this letter did
not include any of the other usual information materials (e.g. ‘The Facts’ booklet) and was therefore much
thinner than the invitation letter used in the other trials. It is likely that this increased its visibility and impact.
Although the change in the gradient was small (as was the effect on overall uptake), this intervention was
also virtually ‘cost free’ and, therefore, offers a practical way for the screening programme to achieve a
reduction in the SEC gradient.
The ASCEND programme inevitably had limitations in terms of the range and types of interventions that
were tested. People from socioeconomically deprived backgrounds are likely to be struggling with multiple
social and economic challenges and this could make it difficult for them to prioritise cancer screening, but
these ‘upstream’ issues are never going to be addressed by minor variations in the format of the screening
offer. Similar observations have also been made in other NHS BCSPs where addressing psychosocial
variables through written materials has also failed.196 Nonetheless, we believe that ensuring that the
screening offer is not only mailed to all eligible adults, but is equally accessible to respondents at all levels of
literacy, is an obligation of the NHS screening programmes. We also did not address broader attitudes to
cancer outcomes that could be important. For example, cancer fatalism is known to be higher in lower SEC
groups and has been shown to be associated with later stage of diagnosis;219 however, fatalism is not easily
modified with simple written materials. There were also other downstream barriers that we did not address,
of which the most well established is ‘faecal aversion’. The gFOBt is widely regarded as unpleasant and
some individuals are likely to be more averse to contact with faecal material than others,220 although there is
no existing evidence that this barrier is socially graded. In contrast, the need to store the gFOBt kit between
samples could be a socioeconomically graded barrier because it requires privacy and privacy may be limited
for people living in less advantaged circumstances. In the context of the ASCEND study, we were unable
to identify ways of addressing this barrier, but it is possible that if the NHS BCSP implements the faecal
immunochemical test (FIT), which typically requires only one sample, inequalities in participation would be
reduced. Use of FIT has recently been shown to reduce the SEC gradient in uptake (compared with gFOBt)
as part of an evaluation of FIT in the Scottish NHS BCSP.221
WORKSTREAM 3 RANDOMISED CONTROLLED TRIALS: DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
One issue that should be considered is whether or not individuals who did not take up the offer are
making a ‘rational’ decision (e.g. judging that screening would not offer benefit given their personal
circumstances). The lower perceived life expectancy in lower SEC groups222 has been put forward as one
explanation for differential engagement in activities that produce benefit only in the distant future.31
Contrary to this view is evidence that ‘non-attenders’ often express interest in screening once they have
discussed it in a one-to-one setting,223 suggesting that, when the information is presented verbally with
opportunities to clarify, screening is widely perceived to be advantageous. In addition, inequalities in breast
screening uptake (involving women of a similar age) are much lower than for bowel cancer screening in
women, with an absolute difference from the least to most deprived IMD quintile of only 10% in one
study,213 suggesting that screening per se is not the problem.
Although the over-riding message of this study is the challenge of shifting the gradient in screening participation
within the context of a national screening programme, the research design in which strategies to be tested are
embedded in routine programme delivery provides a model for future research. There may also be scope to
improve the impact of the interventions. The gist and narrative leaflets may have been ‘swamped’ among other
elements of the mailing. One alternative could be to supply the necessary screening information in smaller
‘bites’ by integrating additional communication points into the screening pathway. There may also be scope for
additional reminder letters. Given that successive reminders would, through a process of elimination, target an
increasingly deprived population, this should also reduce the uptake gradient. More controversially, it may be
timely to consider adding direct contact with health professionals or trained lay experts to present the case for
screening and support informed decision-making for some population groups. ‘Patient navigation’ has been
shown to increase uptake across a number of cancer screening programmes and has been designed specifically
with low literacy and socially disadvantaged groups in mind.223
In conclusion, three out of four trials of interventions aimed at tackling inequalities in screening uptake
failed to reduce the SEC gradient. An ER letter was the only strategy to significantly reduce the gradient,
while GPE increased overall uptake. Given their minimal cost, these interventions could be implemented
immediately to support the enhanced and equitable delivery of cancer screening within the NHS BCSP.
The results of these trials are testament to the difficulty of modifying inequalities in screening within an
organised programme, but they highlight the importance of continuing to research effective strategies to
achieve equity in early diagnosis of cancer.
Comparison with other studies
The effectiveness of the ER letter in reducing the socioeconomic gradient in uptake of a public health
intervention is significant because such an effect has rarely (if ever) been demonstrated. Cesar Victora’s
‘inverse equity hypothesis’, which predicts that new public health interventions initially reach those of higher
socioeconomic status and only later affect the poor when the affluent have achieved new minimum achievable
levels for morbidity, has been confirmed internationally.224 Our results are therefore highly noteworthy.
The results of the ER could be explained in relation to insights gained from our own qualitative work
(workstream 1), previous evidence and health behaviour theory. For example, there was strong evidence
that reminders significantly increase uptake of cancer screening.203,225 However, workstream 1 focus group
participants consistently reported not recognising the letter. The text at the top of the letter was therefore
designed to clearly state the purpose and may have increased its personal relevance (‘A reminder to you’).
The additional text at the bottom of the letter aimed to further increase the urgency of the letter by
addressing well-established predictors of CRC screening uptake. The first sentence clearly stated the
importance of CRC screening as a way to reduce risk of CRC. Perceived risk has been extensively studied as
a predictor of cancer screening.226–228 Importantly, the message was designed to be simple and direct about
the increased risk of CRC without using complex statistical information following the sample principles
underlying the development of the gist leaflet and thereby increasing its effectiveness among low-literate
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individuals.143 The second sentence addressed response efficacy (i.e. the belief that screening is effective),
which is a key construct in the Health Belief Model, which has been found useful in trying to predict CRC
screening uptake.229 Third, we reduced perceived barriers to screening by affirming that ‘it is never too late
to screen’ and increased self-efficacy by offering guidance about how to seek further guidance.
Future research should focus on which of these aspects had the strongest impact, particularly among
socioeconomically deprived individuals.
The gist RCT was the first trial of information materials guided by FTT. Several studies have shown that
people, particularly older adults, have a preference for extracting gist-like representations from health
information.93,94 However, there have been no trials of whether or not materials developed with these
preferences in mind have an impact on screening knowledge or behaviour. Our null results add to the
mixed evidence for behaviour change interventions using educational materials.230 Three trials of mailed
materials focusing on barriers to screening uptake reported an increase in uptake: one in FS screening231
and two in gFOBt screening.178,232 Two other trials observed no effect37,233 and one saw reduced uptake
with mailed materials.234 A recent US-based study also failed to demonstrate a statistically significant
increase in uptake associated with adding an educational pamphlet, video and simplified gFOBt kit
instruction sheet to usual care materials.235
The narrative RCT was the first trial to incorporate personal quotations and stories regarding the NHS BCSP
experience into information material. Presenting information in a narrative format is becoming a popular
form of health communication and has shown encouraging results in the science literature.156,158 Dillard
et al.162 found that by integrating a short narrative to non-narrative factual information, the anticipated
impact of barriers to screening (via colonoscopy) was reduced, while perceived personal risk and intention
to have a colonoscopy were enhanced.162 The inclusion of a bowel cancer screening narrative has also
been found to increase colonoscopy attendance fourfold when compared with providing non-narrative
information only.165 Until now, no research has focused on narratives in relation to screening via gFOBt.
The evaluation/pilot trial of the current narrative leaflet indicated an increase in intention and positive
outcomes on factors predictive of screening intention, including enhanced personal risk and reduced
impact of disgust as a barrier.171 However, within the RCT, this intention did not translate to an increase
in screening attendance, again adding to the mixed evidence available on the effectiveness of health
education interventions. Another reason why both gist and narrative leaflets did not show the promised
effect is that the development of such interventions is limited to a highly selected sample of people willing
to participate in research. This was true of both studies pre-testing the effectiveness of our leaflets despite
a concerted effort to develop links with community organisations and by purposefully selecting primary
care practices serving deprived areas.
The GPE intervention was successful in gaining approval from four out of five general practices, which
is an unprecedented general practice participation rate compared with other studies, allowing us to
randomise over 260,000 individuals from 6480 general practices. By comparison, the largest study of GPE
to date randomised 2400 individuals.36 Importantly, this large sample size allowed us to be the first study
to address the question of whether or not GPE that has been shown to positively influence uptake also has
the ability to reduce the socioeconomic gradient. The ability to conduct a study of GPE on such a large
scale meant that we had to curtail the requirements on general practices. Furthermore, integrating the GPE
in an existing letter severely reduced the number of characters used in the message. Both of these issues
could have adversely affected the strength and visibility of the message.
Taken together, these results indicate that despite a strong theoretical background and extensive
pre-testing, the design of effective behavioural interventions is challenging.
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Methodological strengths
Among the strengths of our trial were its national coverage, substantial power to detect small differences
in uptake, and an intervention, which, if effective, could easily and cost-effectively be incorporated into
the existing NHS BCSP. We used novel, innovative methods to develop a gist leaflet that enhanced
comprehension and carried out extensive user testing and piloting to demonstrate its accessibility to adults
with basic literacy skills. Similarly, the narrative leaflet was designed by drawing on the expertise of
colleagues in social marketing, health psychology and public health promotion. The final layout and
content were established through focus groups and one-to-one interviews with members of the public,
with subsequent piloting in the community confirming its acceptability.
Research limitations
Unlike the narrative and the gist pilot, it was not possible to pre-test the impact of the GPE and the ER
interventions. In the case of the GPE, the main issue to be addressed during workstream 2 was that of
recruiting general practices. In addition, our ability to manipulate the length and content of the message
was severely limited by requirements stipulated by the NHS BCSP. In the case of the ER letter it was
impossible to pre-test its impact on a population outside the screening programme. It is therefore difficult
to ascertain the degree to which people perceived these interventions (e.g. whether or not they noticed
them and accepted or rejected their respective messages). Given that all of these interventions were run in
a routine screening programme, we were also prevented from conducting any further evaluation of the
interventions among people who had been part of the interventions. Doing so would have required
seeking consent from individuals and would have been dominated by individuals who had participated
in screening.
These trials had limitations. The NHS BCSP hub directors were clear that parallel RCTs and individual
randomisation of subjects for all interventions could not be performed for feasibility reasons. Therefore,
cluster randomised trials were adopted as the strongest alternative. Cluster randomised trials can have
compromised statistical efficiency owing to clustering, which increases the sample size required to achieve
appropriate power.236 This was addressed in our sample size calculation and our target was surpassed in
all trials.
A further limitation is the possibility that the study groups became contaminated, such that individuals in
the control groups were exposed to the interventions. Although this limitation is noted, it would also have
applied to a parallel randomised trial.
Although it is possible that localised initiatives may have affected uptake rates in specific regions, it is
considered unlikely that they would have confounded the ASCEND intervention results overall, primarily
because it is improbable that concurrent interventions would occur on the same alternate days as
each intervention.
In addition, our findings may have been influenced by other factors operating within a cluster affecting
the outcome. We surveyed the number and location of health promotion activities occurring during the
period of the trials, but we cannot rule out the possibility that these reduced the effectiveness of
the interventions.
Finally, our study did not include evaluation of the sociopsychological determinants of the behaviour of
individuals during the decision-making period. This explains the limitations outlined above, such as our focus
on behavioural intentions rather than actions and our inability to obtain an in-depth and comprehensive
understanding of the determinants of social variations in decision-making processes in real time. It is
possible that ethnographic case studies of everyday practices through sustained observation within different
sociocultural contexts in addition to semistructured interviews conducted over the decision-making time
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period could yield important insights. However, it should also be recognised that the completion of the
screening test (and, therefore, the final decision-making step) takes place in the privacy of one’s home
(making observation and interview data more difficult and resource intensive to obtain) and that frank
interview responses might be influenced by sociocultural norms on the appropriateness of discussing an
intimate topic. Furthermore, observation and explicit exploration of decision-making (which might otherwise
be exclusively implicit) could influence the decision made.
Patient and public involvement
Our Patient Representative, Mr Roger Band, reviewed and commented on the results of the all the trials.
Conclusion
The four largest trials of interventions aimed at reducing socioeconomic inequalities in screening uptake
within an organised NHS BCSP failed to substantially affect the gradient. However, the ability of the simple
reminder message to achieve the hypothesised reduction in inequalities is a highly notable achievement
that has been rarely (if ever) documented in the published literature. Furthermore, the effectiveness of gist
and narrative information leaflets when used alone are unknown and should be explored as part of
alternative communication opportunities.
These results highlight the difficulty of modifying inequalities in screening uptake through easily
implementable, cost-effective, interventions that respect informed decision-making.
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Chapter 12 Conclusions and recommendations for
future research
Socioeconomic inequalities in health and health care are widespread internationally. Research is usuallydesigned to improve access to, and uptake of, health care and health outcomes among socially
disadvantaged groups. To our knowledge, this is the first national research programme to focus on the
entire population in order to improve uptake across the whole socioeconomic gradient. By developing
four theoretically based interventions that aimed to increase the uptake of bowel cancer screening across
the socioeconomic gradient, we hope to ultimately reduce inequalities in cancer outcomes. Here we
summarise our key findings and their implications for future research and practice. These results are
equally applicable to the FIT, which the NHS BCSP have begun to introduce as a pilot in 2014.
1. The national RCT of the ER (see Chapter 10) demonstrated a significant effect on both the social
gradient in uptake and uptake overall. Given the extremely low marginal cost of this intervention,
the findings suggest that implementation by the NHS BCSP would be beneficial.
2. Our national trial of GPE significantly increased uptake overall (although it did not reduce the social
gradient in uptake) (see Chapter 10). Given the exceptionally high level of agreement by general
practices to endorse the NHS BCSP, the small one-off cost to modify the standard invitation letter
within the NHS BCSP IT system (to adjust for any recent changes in practice name) and the zero
marginal cost per person screened, the evidence suggests that the NHS BCSP could usefully consider
adding GPE to the screening invitation letter.
3. Enhanced and explicit involvement of familiar health-care settings and professionals should be further
investigated, with an emphasis on tailoring NHS involvement to the specific needs of defined
sociocultural groups. The impact of such initiatives on the social gradient and ethnic differences in
uptake should be examined.
4. The evidence suggests that policies aimed at reducing the gradient in bowel cancer screening
participation could include strategies aimed at increasing acceptability and comprehension of the
screening test among those with lower levels of literacy. This is supported by the strong relationship
between health literacy and SECs. The pilot of the gist leaflet in workstream 2 demonstrated that
improving the accessibility of screening information to individuals with low health literacy may improve
their comprehension of the decision, but additional intervention may be required to have an impact on
screening behaviour. This observation was supported by the null effect of the gist leaflet on screening
behaviour in workstream 3. One alternative approach suggested from data in workstream 1 is patient
navigation, a method involving a trained health professional offering one-to-one support to help
address individual barriers to screening. A patient navigation trial has been carried out by members of
our team to promote uptake of FS in the UK screening programme.237 Effective interventions should
also emphasise the social implications of screening and its benefit not just to the individual but to their
family and friends.
5. Our exploration of why non-participants subsequently undergo screening (see Chapter 3) found that
talking increased awareness of screening uptake among peers and significant others and was key to
overcoming objections and to subsequent screening participation. Our results suggest that initiatives
such as the advertising campaign in Greater Manchester to normalise open discussions about bowel
cancer screening should be designed and evaluated (Audrey Howarth Greater Manchester Bowel
Cancer Screening Health Improvement Team, 2012, personal communication).
6. Reasons for low CRC screening uptake shared across South Asian faith groups were limitations posed
by the written word, low awareness of CRC and screening, and difficulties with handling faeces and
gFOBt completion. In addition, we identified that written materials are particularly inappropriate for
the Sylheti-speaking Bangladeshi Muslim community, because they are unlikely to be able to read
either Bengali or English. Sikh participants described a social stigma surrounding cancer which may
hinder engagement with screening. A preference for information to be delivered verbally within a
familiar community setting was described across faith groups. To increase accessibility to CRC
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screening in South Asian communities, screening information should be delivered via local ethnic
media and face to face within community groups and faith settings.
7. The gist and narrative leaflets were designed to make the screening offer more visible to people with
lower literacy skills on the basis of extensive evidence that social disadvantage is associated with lower
literacy. The gist leaflet improved comprehension compared with standard information alone (see
Chapter 5) and the narrative leaflet led to stronger screening intentions than the standard information
(see Chapter 6). However, there was no significant increase in uptake when examined in combination
with the nationally approved standard materials. This may be because the determinants of action
differ from the determinants of intention, and we influenced intentions rather than actions. In
addition, although the new leaflets were designed to provide simple information, they nonetheless
increased the total mass of written material that participants received and this may have undermined
the goal of making the screening offer more visible. The leaflets supplemented rather than replaced the
existing NHS BCSP information booklet because this was a requirement of the NHS National Cancer
Screening Programme. One way forward could be to allow RCT testing of the leaflets in comparison to
existing materials. An alternative approach could be to supply the necessary screening information in
smaller ‘bites’ by integrating additional ‘communication points’ into the screening pathway.
8. We demonstrated that it is possible to successfully engage GPs in applied health research. Nationally,
80% of general practices agreed to participate in the RCT of GPE in the NHS BCSP (see Chapter 7).
This exceptionally high response rate was achieved by adopting the following practices, all of which
have implications for future research requiring GP collaboration: recruitment letters were sent by NHS
BCSP hub directors rather than from the ASCEND research team, GPs had to do no more than agree
that their practice name could be used on the screening invitation letters, and we sent up to three
reminder letters at approximately monthly intervals.
9. Our research programme ASCEND was a highly successful example of experts from academia and
from the health service working effectively across traditional boundaries to create new knowledge
to improve the delivery of health services. We also demonstrated that, although studies of health
care delivery typically rely on observational and quasi-experimental methods, it is possible to use a
randomised design without adding substantially to the cost or difficulty of the study. We have also
provided an example of applying a randomised design without loss of external validity, thereby
offering an unparalleled ability to provide credible evidence of the impact of ER and GPE and
potentially accelerating the pace for their widespread implementation.
10. In the future, further development of the randomised design should be considered, involving ‘realist’
RCTs.238 These could first explore decision-making processes leading to change and then test how
intervention effects vary with context and among different sociocultural groups. Such RCTs could be
orientated towards building and validating theories about how interventions interact with context to
produce outcomes. They would comprise an important extension of existing pragmatic methods and
enhance our understanding of sociocultural variations in screening uptake.
Research recommendations are summarised in Box 2. They are equally applicable to gFOBt and to FIT.
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BOX 2 Recommendations for future research to reduce the social gradient and increase overall uptake of bowel
cancer screening
1. The co-design and experimental ‘realist’ evaluation of socioculturally appropriate bowel cancer screening
information interventions tailored to defined ethnic and social groups.
2. Research is required which evaluates the appropriateness and cost-effectiveness of:
i. verbal (rather than written) information
ii. enhanced involvement of familiar NHS settings and professionals
iii. targeted translation and literacy assistance methods
iv. additional reminders (including the use of text messaging technology).
3. The use of an action research methodology, in which researchers work alongside and ‘within’ a defined
community to codevelop a solution to a problem (i.e. low screening uptake within South Asian
communities) may be a valuable route to the development of culturally appropriate interventions for
non-English-language speakers.
4. Exploration of the reasons for lower screening uptake among the sick and disabled, followed by the
co-design and testing of interventions to enhance informed decision-making in these groups.
5. National ‘realist’ experimental evaluations of the gist and narrative leaflets in comparison with existing NHS
BCSP information materials.
6. Design and experimental evaluation (in ‘realist’ RCTs) of initiatives to normalise open discussions about
bowel cancer screening.
7. Further exploration of the ER to better understand the individual contribution of its different components.
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Appendix 1 The Bowel Cancer Screening
Programme screening pathway
The screening pathway
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Appendix 2 The Bowel Cancer Screening
Programme S1 Letter
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Appendix 3 The Bowel Cancer Screening
Programme ‘The Facts’ Booklet
This appendix contains public sector information licensed under the Open Government Licence v3.0.
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Appendix 5 The Bowel Cancer Screening
Programme ‘How to do the kit’ leaflet
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Programme S10 letter
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Appendix 8 Focus group participant
information sheet
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Appendix 9 Focus group consent form
 
 
 
                      
 
 
 
 Study Title: Attitudes to the Bowel Cancer Screening Programme 
CONSENT FORM 
 
Please complete this form after you have read the Information Sheet and/or 
listened to an explanation about the research.  
 
Name of Researchers: Cecily Palmer and Mary Thomas  
Contact number: 020 7679 5632 
 
                                              Please tick each box 
 
 
1. I have read and understand the patient information sheet dated 31/03/2011 (version 2). I 
have had time to think about the study and to ask questions.  
 
2.  I know that I can leave the group discussion at any time, if I want to, without giving any 
reason and without my medical care being affected.    
 
3.  I understand that all the information I provide for the purposes of this study will be kept 
strictly confidential. 
 
 
4.  I understand that the researchers will need to know my name, address and contact details. 
These will be used only to contact me about the study. 
I give permission for the researchers to have this information. 
 
5.  I agree to the group discussion being audio recorded and understand that these audio 
recordings will be stored securely and destroyed after the study is complete. 
 
6. I agree that the researchers can quote sections of the group discussion in their reports – but 
they must make sure my name is never given out.
 
 
7.  I agree to take part in this study. 
 
 
 
I would like you to send me a summary of the findings when they are ready. Please tick: 
 Yes  /    No 
Version: 1 Date: 01-04-2011 
UCL Project ID number: X/XX1 
Patient ID:  
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Once you have ticked the boxes above, please sign below:  
 
 
________________________ _____________________ ____________ 
Name of participant Signature Date 
 
 
Please give us the following information so that we are able to contact you: 
 
Your surname (or family name) …………………………….
 ……………………….. 
   Please turn over → 
 
Your forenames ………………
 ……………………………………………………….. 
 
Your postcode  
 
 
The best telephone number to contact you 
on:.................................................................. 
 
We would be grateful if you could answer the following questions about you to 
help us decide the best discussion group for you. 
 
1. Please tick the correct box: 
  I am a man 
  I am a woman 
 
2. What is your ethnic group (tick one)? 
 
  White  African/Caribbean  Chinese 
 
  Indian  Pakistani  Bangladeshi 
 
  Other (please state)   
 
 
3. What language would you prefer to speak in during the group discussion? 
 English 
 Other (please state)........................................................................................... 
 
 
4. Employment: Please tick the correct box: 
 I am employed – my occupation is ............................................................................. 
 I am retired – my previous occupation was ................................................................ 
  I am unemployed – longest held previous occupation................................................ 
 I do not and did not work but my partner works or did work until retirement – My 
partner’s current or previous occupation..........................................................................  
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THANK YOU FOR COMPLETING THIS CONSENT FORM 
PLEASE RETURN IT TO US IN THE FREEPOST ENVELOPE PROVIDED 
(no stamp is required) 
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Appendix 10 Focus group topic guide
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• 
• 
• 
• 
• 
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
182
Appendix 11 Think-aloud sociodemographic
questionnaire
What is your name? ____________________________________ 
  
What is your age?                                What area of the country are you from?________________________________ 
  
What is your marital status? 
 
Single 
 
Married 
Cohabiting/living 
with a partner 
 
Divorced/Separated 
 
Widowed 
     
  
Is English your first language? 
 
  Yes 
 
  No 
 
 
 
  
Please tick the box which best describes your living arrangement 
 
Rent from local authority 
 
Rent from private 
landlord 
Own home/buying with 
mortgage 
 
Other 
 
 
   
  
Does your house have a car or a van? 
No Yes Yes more than 1 
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Are you currently: 
 Employed full-time  Full-time homemaker 
 Employed part-time  Retired 
 Unemployed  Student 
 Self-employed  Disabled or too ill to work 
What is the highest level of educational or professional qualification you have obtained? 
 GCSE/O-Level/CSE  Degree level education 
 Vocational Qualifications (NVQ1+2)  Other _______________________ 
 A-Level or highers  No formal qualifications 
 Higher educational qualifications (below degree level)  Still studying 
Which of these best describes your ethnic background? 
 Asian or Asian British  Chinese 
 Black or Black British (African)  White British 
 Black or Black British (Caribbean)  Do not wish to answer 
 Mixed  Any other ethnic groups 
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   __________________________
__ 
In general, how easy or hard do you find it to understand medical statistics? 
Very easy Easy Hard Very Hard 
    
In general, would you say your health is... 
Poor Fair Good Very Good Excellent 
     
Have you ever attended any of the following? 
Breast cancer screening  Cervical cancer screening Prostate Cancer testing (PSA – Men only) 
   
Have you ever been diagnosed as having cancer? 
Yes No (If yes, name)    
 _________________________________________________ 
Have any of your friends or family members been diagnosed as having cancer? 
Yes No (If yes, name of cancer) Relationship with you  
 ___________________________                      
__________________________________ 
Have you been diagnosed with any chronic condition? 
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Yes No (If yes, name)    
 ___________________________ 
Have you been diganosed with any bowel conditions? 
Yes No (If yes, name)    
 ___________________________ 
During the past 12 months, not counting times you went to accident and emergency, how many times did 
you go to a doctor, nurse of other health professional to get care for yourself? 
None 1 time 2 times 3 times 4 times 5-9 times 
      
Have you ever looked for information about cancer from any source? 
Yes No (If yes, where)    
  ___________________________   
How much attendtion do you pay to information about health or medical topics on tv, radio, magazines or 
newspapers? 
A lot Some A little Not at all 
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Appendix 12 Early version of the ‘gist’ leaflet
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Appendix 13 Intervention 1: the ‘gist’ leaflet
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Appendix 14 Gist pilot study questionnaire:
control group
 
 
 
 
 
 
  
Questionnaire  
 
Evaluation of NHS Bowel Cancer Screening 
patient information materials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We would like to hear your views on bowel cancer and bowel cancer 
screening so that we can improve the information we give to others in 
the future. We are inviting all men and women aged 45-59 years from 
your GP practice to take part in a survey.    
To take part, we ask that you: 
 1) Read through all the contents of the NHS labelled envelope 
 2) Complete this short questionnaire  
 3) Return the completed questionnaire in the freepost envelope 
     provided (no stamp is required) 
It is up to you to decide whether to take part or not.  Your decision will 
not affect the quality of medical care you receive now or in the future. 
 
The contents of the NHS labelled envelope are for you to read 
through only. 
You will not be sent a screening test kit as part of this study.  
When you reach your 60th birthday, the NHS will send you an 
FOB screening test kit. 
 
 
If you have any questions please contact: 
 
Samuel Smith 
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Please answer all of the questions on 
each page 
 
 
Imagine you have just turned 60 and have received the bowel screening test kit (FOB test kit) in 
the post, would you do the test? 
Definitely not Probably not Yes, probably Yes, definitely 
    
 
Remember, doing the test involves taking small amounts of your stools (poo) on three different 
days and putting them on the FOB test kit.  Realistically speaking, how likely are you to do this? 
Definitely not Probably not Yes, probably Yes, definitely 
    
 
No I have read part of it  
I have read 
it all 
I have read it all 
more than once 
Have you read the orange booklet, 
‘Bowel Cancer Screening: The Facts’, 
found inside the NHS envelope? 
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Imagine you have just turned 60 and are making a decision 
about doing an FOB test kit  
 
Yes Unsure No 
Do you know the benefits of doing an FOB test kit?    
Do you know the disadvantages of doing an FOB test kit?    
Are you clear about which benefits matter most to you?    
Are you clear about which disadvantages matter most to 
you?    
Do you have enough information about the FOB test?     
 
Compared to others of the same sex and age, my chances of getting bowel cancer are  
Much below 
average Below average Average Above average 
Much above 
average 
     
If I never do the FOB screening test, I would feel very vulnerable to bowel cancer 
Strongly 
disagree  Disagree   Not sure Agree Strongly agree  
     
If I never do the FOB screening test, I think my chances of dying from bowel cancer would 
be  
Almost 
zero  Very small  Small  Moderate Large  Very large 
 Almost 
certain 
       
 Strongly disagree Disagree Agree 
Strongly 
agree 
Doing the FOB test would be an important thing for me 
to do     
Doing the FOB test would be disgusting     
Doing the FOB test would be tempting fate     
Doing the FOB test would make me anxious      
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Doing the FOB test would make me feel I was doing 
something positive for my health      
Doing the FOB test would give me peace of mind     
Doing the FOB test would make me worry more about 
bowel cancer     
Doing the FOB test and receiving a normal result 
would reassure me that I do not have bowel cancer     
I would be confident that I could do the FOB test 
correctly     
I would be unlikely to have the time to do the FOB 
test     
I would not have the privacy to do the FOB test      
I would not want to keep small amounts of my stools 
on a card in the house     
I would regret it if I did not do the FOB test      
I would be embarrassed if others knew I had done the 
FOB test      
I would do the FOB test because I would want to stay 
healthy for my family     
The thought of bowel cancer scares me     
I would only do the FOB test if I had symptoms of 
bowel cancer      
I would be afraid of getting an abnormal result from 
my FOB test      
Bowel cancer is a life-threatening illness      
Bowel cancer cannot be cured no matter when it is 
found or how it is treated       
I avoid information about cancer from the TV, 
newspapers and radio     
If I feel healthy I do not go to the doctor for a routine 
check-up     
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I like to ignore the fact that I could get cancer     
The FOB test can’t be that important because my GP 
has never told me I had to do it     
The FOB test wouldn’t affect my chances of dying from 
bowel cancer     
I do not need to be screened for bowel cancer because I 
have regular bowel movements      
I do not need to be screened for bowel cancer because I 
include enough fruit and vegetables in my diet     
I do not need to be screened for bowel cancer because I 
don’t eat too much red meat     
I do not need to be screened for bowel cancer because I 
exercise regularly     
What percentage of people in England, aged 60 to 74, do you think do the FOB test? 
None 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
           
 Strongly disagree Disagree Agree 
Strongly 
agree 
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 True False Don’t know 
Doing the FOB test lowers the risk of dying from 
bowel cancer    
The FOB test is done at home    
Most people who do the FOB test will receive an 
abnormal result    
Only women are sent a FOB test     
Bowel cancer is a common cancer in people 
over 60    
People only need to do the FOB test once in 
their life    
The FOB test can miss bowel cancer    
People with an abnormal result always have 
cancer    
People aged 60-74 years are sent the FOB test    
 
Which of the following numbers represents the biggest risk of getting a disease? 
  1 in 100   1 in 1000   1 in 10 
 
HERE ARE SOME QUESTIONS ABOUT YOU AND YOUR BACKGROUND 
 
 
What is your age?     
              
                    years 
What is your gender?  
 Male    Female    
What is your marital status? 
Single Married Cohabiting / living with partner Divorced / separated Widowed 
 
Which of these best describes your ethnic group? 
White British  Caribbean  Indian  White and Asian  Chinese 
White Irish   African  Pakistani  White and Black Caribbean  Any other 
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Other White 
background  
Other Black 
background  Bangladeshi  
White and Black 
African 
  
     Other Asian   Other Mixed    
Please tick the box which best describes your living arrangement:  
 Rent: local authority / housing association / council  Own your home / have a mortgage 
 Rent: private landlord  Other 
Does your household have a car or van? 
  No   Yes, one   Yes, more than one 
Are you currently ? (please tick all that apply) 
 employed full-time  full-time homemaker  disabled or too ill to work  
 employed part-time  retired  self-employed 
 unemployed  student   
What is the highest level of educational or professional qualification you have obtained?  
 GCSE / O-level / CSE   Masters / PhD or equivalent 
 Vocational qualifications (e.g. NVQ1+2)   Other (Specify ) 
 A-level or equivalent (e.g. NVQ3)   No formal qualifications  
 Bachelor Degree or equivalent (e.g. NVQ4)    
 
Would you say that for someone of your age, your own health, in general, is ? 
Poor Fair Good Excellent 
    
 
Have you ever done any kind of test that involves taking a small amount of your stool (poo) before? 
  Yes   No   Not sure 
 
Have you ever had cancer?    
Yes  No  Not sure  
   
If ‘Yes’, what type of cancer was it? (please print here) 
___________________________________________ 
Have any of the following people ever been diagnosed with bowel cancer? (Please tick all that apply) 
 Wife / Husband / Partner   Close friend 
 Family member (blood relative)  Other friend 
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 Family member (non blood relative)  Not sure 
How worried are you about getting bowel cancer? 
Not worried at all A bit worried Quite worried Very worried 
    
 
HERE ARE SOME QUESTIONS ABOUT THE INFORMATION BOOKLET 
 
 
If you have any other good or bad comments to make about the booklet, 
‘Bowel Cancer Screening: The Facts’, please write them in the box below. 
 
 ‘Bowel Cancer Screening: The Facts’ (Orange booklet) 
 
 
 
 
 
 
 
 
Thank you very much for taking the time to complete the 
questionnaire.  Your answers are very important to our research. 
For me, the orange booklet, ‘Bowel Cancer Screening: The Facts’, was  
1 2 3 4 5 6 7 
Easy to 
read 
     Hard to read 
1 2 3 4 5 6 7 
Useful      Not at all useful 
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Please return this questionnaire in the enclosed freepost envelope. 
No stamp is required. 
 
If you lose the freepost envelope please post to:  
 
                        FREEPOST UNIVERSITY COLLEGE LONDON 
                        (BOWEL SCREENING STUDY) 
 
              
 
If you would like to receive a copy of the results from this study please tick here  
 
If you would like to be contacted about taking part in future studies please tick here  
 
 
If you ticked either of the boxes above please write down your contact details below. In order to 
keep our costs down, we would prefer to contact you by e-mail if this is possible. 
 
Name: _____________________________________________________________________________
Email address:_______________________________________________________________________
Address: ____________________________________________________________________________
___________________________________________________________________________________
___________________________________________________________________________________
Telephone: __________________________________________________________________________
 
 
This page will be removed from the questionnaire as soon as the researchers 
receive it to make sure your questionnaire answers are treated confidentially. 
 
 
 
 
 
 
 
 
 
 
 
 
The return of a completed questionnaire is confirmation of your 
consent to take part in the study and allows the researchers to use 
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Appendix 15 Gist pilot study questionnaire:
intervention group
Questionnaire  
 
Evaluation of NHS Bowel Cancer Screening 
patient information materials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We would like to hear your views on bowel cancer and bowel cancer 
screening so that we can improve the information we give to others in 
the future. We are inviting all men and women aged 45-59 years from 
your GP practice to take part in a survey.    
To take part, we ask that you: 
 1) Read through all the contents of the NHS labelled envelope 
 2) Complete this short questionnaire  
 3) Return the completed questionnaire in the freepost envelope
     provided (no stamp is required) 
 
It is up to you to decide whether to take part or not.  Your decision will 
not affect the quality of medical care you receive now or in the future. 
 
The contents of the NHS labelled envelope are for you to read 
through only. 
You will not be sent a screening test kit as part of this study.  
When you reach your 60th birthday, the NHS will send you an 
FOB screening test kit.
 
 
If you have any questions please contact: 
 
Samuel Smith 
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Please answer all of the questions on each page  
 
 
magine you have just turned 60 and have received the bowel screening test kit (FOB test kit) in the post, 
would you do the test? 
Definitely not Probably not Yes, probably Yes, definitely 
    
 
Remember, doing the test involves taking small amounts of your stools (poo) on three different days and 
putting them on the FOB test kit.  Realistically speaking, how likely are you to do this? 
Definitely not Probably not Yes, probably Yes, definitely 
    
 
Imagine you have just turned 60 and are making a decision about 
doing an FOB test kit  
 
Yes Unsure No 
Do you know the benefits of doing an FOB test kit?    
Do you know the disadvantages of doing an FOB test kit?    
Are you clear about which benefits matter most to you?    
Are you clear about which disadvantages matter most to you?    
Do you have enough information about the FOB test?     
 
Compared to others of the same sex and age, my chances of getting bowel cancer are  
Much below 
average Below average Average Above average 
Much above 
average 
     
If I never do the FOB screening test, I would feel very vulnerable to bowel cancer  
Strongly disagree  Disagree   Not sure Agree Strongly agree  
 
No I have read part of it  
I have read 
it all 
I have read 
it all more 
than once 
Have you read the blue leaflet ‘The NHS 
Bowel Cancer Screening Programme: The 
Essentials’, found inside the NHS 
envelope? 
    
Have you read the orange booklet, ‘Bowel 
Cancer Screening: The Facts’, found inside 
the NHS envelope? 
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If I never do the FOB screening test, I think my chances of dying from bowel cancer would be  
Almost zero  Very small  Small  Moderate Large  Very large  Almost certain 
       
 
 Strongly disagree Disagree Agree 
Strongly 
agree 
Doing the FOB test would be an important thing for me to 
do     
Doing the FOB test would be disgusting     
Doing the FOB test would be tempting fate     
Doing the FOB test would make me anxious      
Doing the FOB test would make me feel I was doing 
something positive for my health      
Doing the FOB test would give me peace of mind     
Doing the FOB test would make me worry more about 
bowel cancer     
Doing the FOB test and receiving a normal result would 
reassure me that I do not have bowel cancer     
 
I would be confident that I could do the FOB test correctly     
I would be unlikely to have the time to do the FOB test     
I would not have the privacy to do the FOB test      
I would not want to keep small amounts of my stools on a 
card in the house      
I would regret it if I did not do the FOB test      
I would be embarrassed if others knew I had done the 
FOB test      
I would do the FOB test because I would want to stay 
healthy for my family     
 
The thought of bowel cancer scares me     
I would only do the FOB test if I had symptoms of bowel     
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cancer  
I would be afraid of getting an abnormal result from my 
FOB test      
Bowel cancer is a life-threatening illness      
Bowel cancer cannot be cured no matter when it is found 
or how it is treated       
I avoid information about cancer from the TV, newspapers 
and radio     
If I feel healthy I do not go to the doctor for a routine 
check-up     
     
 Strongly disagree Disagree Agree 
Strongly 
agree 
I like to ignore the fact that I could get cancer     
The FOB test can’t be that important because my GP has 
never told me I had to do it     
The FOB test wouldn’t affect my chances of dying from 
bowel cancer     
 
I do not need to be screened for bowel cancer because I 
have regular bowel movements      
I do not need to be screened for bowel cancer because I 
include enough fruit and vegetables in my diet     
I do not need to be screened for bowel cancer because I 
don’t eat too much red meat     
I do not need to be screened for bowel cancer because I 
exercise regularly     
 
What percentage of people in England, aged 60 to 74, do you think do the FOB test? 
None 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
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 True False Don’t know 
Doing the FOB test lowers the risk of dying from 
bowel cancer    
The FOB test is done at home    
Most people who do the FOB test will receive an 
abnormal result    
Only women are sent a FOB test     
Bowel cancer is a common cancer in people over 
60    
People only need to do the FOB test once in 
their life    
The FOB test can miss bowel cancer    
People with an abnormal result always have 
cancer    
People aged 60-74 years are sent the FOB test    
 
Which of the following numbers represents the biggest risk of getting a disease? 
  1 in 100   1 in 1000   1 in 10 
 
HERE ARE SOME QUESTIONS ABOUT YOU AND YOUR BACKGROUND 
 
 
What is your age?     
              
                    years 
What is your gender?  
 Male    Female    
What is your marital status? 
Single Married Cohabiting / living with partner Divorced / separated Widowed 
 
Which of these best describes your ethnic group? 
White British  Caribbean  Indian  White and Asian  Chinese 
White Irish   African  Pakistani  White and Black Caribbean  Any other 
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Other White 
background  
Other Black 
background  Bangladeshi  
White and Black 
African 
  
     Other Asian   Other Mixed    
Please tick the box which best describes your living arrangement:  
 Rent: local authority / housing association / council  Own your home / have a mortgage 
 Rent: private landlord  Other 
Does your household have a car or van? 
  No   Yes, one   Yes, more than one 
Are you currently ? (please tick all that apply) 
 employed full-time  full-time homemaker  disabled or too ill to work  
 employed part-time  retired  self-employed 
 unemployed  student   
What is the highest level of educational or professional qualification you have obtained?  
 GCSE / O-level / CSE   Masters / PhD or equivalent 
 Vocational qualifications (e.g. NVQ1+2)   Other (Specify ) 
 A-level or equivalent (e.g. NVQ3)   No formal qualifications  
 Bachelor Degree or equivalent (e.g. NVQ4)    
 
Would you say that for someone of your age, your own health, in general, is ? 
Poor Fair Good Excellent 
    
 
Have you ever done any kind of test that involves taking a small amount of your stool (poo) before? 
  Yes   No   Not sure 
 
Have you ever had cancer?    
Yes  No  Not sure  
   
If ‘Yes’, what type of cancer was it? (please print here) 
___________________________________________ 
Have any of the following people ever been diagnosed with bowel cancer? (Please tick all that apply) 
 Wife / Husband / Partner   Close friend 
 Family member (blood relative)  Other friend 
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 Family member (non blood relative)  Not sure 
How worried are you about getting bowel cancer? 
Not worried at all A bit worried Quite worried Very worried 
    
 
HERE ARE SOME QUESTIONS ABOUT THE INFORMATION GUIDES 
 
For me, the blue leaflet, ‘NHS Bowel Cancer Screening Programme: The Essentials’, was   
1 2 3 4 5 6 7 
Easy to read      Hard to read 
1 2 3 4 5 6 7 
Useful      Not at all useful 
For me, the orange booklet, ‘Bowel Cancer Screening: The Facts’, was  
1 2 3 4 5 6 7 
Easy to read      Hard to read 
1 2 3 4 5 6 7 
Useful      Not at all useful 
 
If you have any other good or bad comments to make about the two information guides, please 
write them in the boxes below: 
 
‘NHS Bowel Cancer Screening Programme: The Essentials’ (Blue leaflet) 
 
 
 
 
 
 
 
 ‘Bowel Cancer Screening: The Facts’ (Orange booklet) 
 
 
 
 
 
 
 
 
Thank you very much for taking the time to complete the questionnaire.  Your 
answers are very important to our research. 
 
Please return this questionnaire in the enclosed freepost envelope. 
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No stamp is required. 
 
If you lose the freepost envelope please post to:  
 
               FREEPOST UNIVERSITY COLLEGE LONDON 
               (BOWEL SCREENING STUDY) 
 
 
If you would like to receive a copy of the results from this study please tick here  
 
If you would like to be contacted about taking part in future studies please tick here  
 
If you ticked either of the boxes above please write down your contact details below. In order to 
keep our costs down, we would prefer to contact you by e-mail if this is possible. 
 
Name: ______________________________________________________________________________ 
Email address:_______________________________________________________________________ 
Address: ____________________________________________________________________________ 
____________________________________________________________________________________
____________________________________________________________________________________
Telephone: __________________________________________________________________________ 
 
 
This page will be removed from the questionnaire as soon as the researchers 
receive it to make sure your questionnaire answers are treated confidentially. 
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The return of a completed questionnaire is confirmation of your 
consent to take part in the study and allows the researchers to use 
the personal information you provide in their research. This 
information will not be given to anyone outside University College 
London (UCL). 
 
All data you provide to the researchers will be treated in the 
strictest confidence and will be stored securely in accordance with 
the Data Protection Act 1998. 
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Appendix 16 Narrative interview study
participant information sheet
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
215
APPENDIX 16
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
217

Appendix 17 Narrative interview study
consent form
CONSENT FORM 1 
 
Telling Your Story: The Bowel Cancer Screening Experience 
Principle Researcher: Dr Christian Von Wagner 
Researcher: Dr Lesley McGregor 
 
Please complete this form after you have read the Patient Information Sheet and/or 
listened to an explanation about the research.  
 
This study has been approved by the UCL Research Ethics Committee (Project ID 
number:  XXX). 
 
Thank you for your interest in taking part in this study. Before you agree to take part, 
the researcher must explain the study to you. If you have any questions, please ask the 
researcher before you decide whether or not to take part. If you do decide to take part 
please read and sign the statement below. 
 
  
 I, (please print name) 
____________________________________________________________ 
1. …have read and understand the Patient Information Sheet. I have had time to think about the 
study and the researcher has answered my questions. I know what the interview will involve.   
2. …understand that if I decide at any time that I no longer wish to take part in this study, I can 
notify the researchers involved and withdraw immediately. 
3. …understand that my participation will be audio recorded and I consent to use of this material 
as part of the study. 
4.  …understand that my photograph may be taken to be shown alongside quotes from my 
interview. These quotes may be used in a leaflet or for teaching purposes. 
5.  …understand that the information I provide will be handled in accordance with the Data 
Protection Act 1998. 
6.  …consent to the processing of my personal information for the purposes of this research study. 
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____________________________________________   _____________________ 
Signature                                Date 
 
7. …agree to take part in this research study. 
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Appendix 18 Narrative interview study
demographic question sheet
 
 
Telling Your Story: The Bowel Cancer Screening Experience 
SOCIO-DEMOGRAPHIC FORM 
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At the end of this research project the results will be written up and published in academic journals. If you 
would like to be informed of any journal articles published, please tick here.  
 
 
 
 
Thank you again for participating. 
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Appendix 19 Narrative interview study additional
consent form for photographs
 
 
 
 
CONSENT FORM 2 
Telling Your Story: The Bowel Cancer Screening Experience 
Principle Researcher: Dr Christian Von Wagner,   
Researcher: Dr Lesley McGregor 
Thank you for taking part in this study. To ensure you are happy with how we now use the 
information you have provided us we ask that you read and complete this form. 
_________________________ 
For the development and production of the leaflet, I agree to the researchers presenting the 
following information with my story:  (Please circle as appropriate) 
  
UCL’s photograph of me YES  /  NO 
My own photograph YES  /  NO 
A model photograph YES  /  NO 
My first name YES  /  NO 
A false name YES  /  NO 
My age YES  /  NO 
A false age (within 2 years of  my own age) YES  /  NO 
My town YES  /  NO 
Another town/area YES  /  NO 
 
 (Please tick) 
I understand and accept that the University College London (UCL) will store and use my 
data and personal details in accordance with the Data Protection Act 1998.   
   
    
I understand that the developed leaflet will be added to the current NHS Bowel Cancer 
Screening Programme invitation pack for a trial period and, if successful, may continue to be 
part of the NHS invitation pack to be distributed across England. The NHS will only use the 
developed leaflet.  
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I understand and accept that my full name and address will not be attached to my story to 
assist anonymity. However, I understand and accept that if my story is published, complete 
anonymity cannot be guaranteed. 
   
   
I understand and accept that each time my data is required for a research project by UCL, I 
will be contacted for my permission and that I am under no obligation to say yes. The data 
WILL NEVER be used without my consent. 
  
 
 
 
    
A full explanation of the possible uses for my data at UCL had been given to me.    
 
 
*The charity Beating Bowel Cancer (BBC) would also like access to the story and 
photograph you provided UCL for possible use in media or charity materials: 
 
I agree to the researchers at UCL passing on a copy of the following information about me to 
BBC. (Please circle your response) 
       
My contact details YES  /  
NO 
 
  (If NO, the remaining list does not 
apply) 
My story, as approved by 
me 
YES  /  
NO 
 
 
My photograph(s) YES  /  
NO 
 
 
 
 
 
_____________________________________ 
Name  (please print) 
 
 
_____________________________________ 
Signature 
 
 
________________________________ 
Date 
 
I understand that BBC will not use my data without contacting me first to 
obtain my permission. The data WILL NOT be used without my consent. 
   
   (Please 
tick) 
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Appendix 20 Narrative interview study
debrief form
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Appendix 21 ‘Narrative’ leaflet: iteration 1
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Appendix 22 ‘Narrative’ leaflet: iteration 2
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Appendix 23 ‘Narrative’ leaflet: iteration 3
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Appendix 24 Feedback from focus groups and
interviews about the narrative leaflet
ID Comment Proposed action for next iteration Supported
TI1 Hyacinth’s quote is irrelevant (‘a waste of
space’) from a man’s perspective
Will keep the reference to breast cancer as it will
mean something to females, and perhaps those
with female relatives
Didn’t like use of word ‘test’ in statement
related to Monica. By this stage it is an
‘investigation’, not a test
Will change the wording
Monica’s quote: ‘It wasn’t a bad procedure’ is
not liked. Would prefer to be told exactly what
procedure would involve
Possibly take this part out. TI2 felt her quotations
were too long anyway
Roger’s quote: would have also put that it helps
to be organised
Decided against adding this as not mentioned
within Roger’s narrative
Should add detail such as people should not
wipe their bottom and use that for test
Decided this level of detail was not suitable for
the leaflet. Need to minimise barrier of disgust
Judith’s story: liked the use of the word
‘control’ here. Thought it was ‘very good’.
Wondered if ‘taking control’ could be added to
the front page
Control will be incorporated into new title
suggestions, to be discussed
Front page: OK but didn’t jump out. Doesn’t
say anything about bowel cancer
The title will be changed to make ‘bowel cancer
screening’ more obvious
TI2, TI3
Front page: a lot of wasted space due to little
photos
Will consider when redesigning front page
Leaflet looks ‘a little bit amateurish’ but enjoyed
looking at the inside of it
Medical illustrators can help us make it look
more professional and leaflet will be printed on
better quality paper for the study
Doesn’t like the colour green. Suggests a ‘nice,
sunny, yellowy, orange colour’
The suggested colour may make it too much like
the facts booklet. Yellow on white paper may
not be suitable for reading
Back page: difficult to read. Has to stop and
focus on reading it. Green colour could be why
Will make the green slightly lighter and try
making font bold or larger
TI2
TI2 Font could be a bit bigger on back page Will make the green slightly lighter and try
making font bold or larger
Title leaves you ‘wondering what it’s all about’.
Needs to mention bowel cancer so it is ‘more
explanatory’
The title will be changed to make ‘bowel cancer
screening’ more obvious
TI1, TI3
Monica’s quote is too long Will shorten it by taking the comment on
‘procedure’ out
Black font on green boxes might be better than
navy
Will try this but feel it is introducing another
colour and best to keep to 2. Will try enlarging
or bold first
Font could be bigger in green boxes Will try lightening the green colour first in the
hope the font stands out more
NHS logo reassures people it’s free but could be
put in the middle to make it more obvious
Definitely keep the logo
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ID Comment Proposed action for next iteration Supported
TI3 The title of ‘shared experiences’ seems ‘slightly
misleading’: possible suggests people know
each other
Title will be changed
Needs a more relevant headline Title will be changed TI1, TI2
Could put NIHR/NHS logo on the back as well,
in space above development sentence
Worry this would make it look like the NHS
developed the leaflet
FG1 Colour is too hard on the eye The colour will be lightened
One participant colour blind so can’t see green Had not really considered this. Google suggests
blue and yellow are good colours but not yellow
on white
Needs more information about bowel cancer As the leaflet will accompany the facts booklet we
can ignore the need for facts for the moment
Bullet points of facts in leaflet to replace some
stories
This information will be available in ‘The Facts’
booklet
Have a phrase on the front such as ‘Don’t put
me down, read me first’ of ‘I could save your
life’
Do not want to make the leaflet appear more
important than ‘The Facts’ booklet
FG2
Have an image of the kit on the leaflet As the standard information provided by the
screening programme does not include a picture
of the test, we will not add one in the leaflet
Better to have a minimum of words rather than
a maximum (sentence on front)
Will revise front cover
‘Shared experiences’ could be about anything.
Make more specific
Will add bowel cancer screening to the title TI1, TI2, TI3
More cultures need to be represented: mostly
white people and no Chinese person
Will continue to look for pictures but difficult to
find people of ethnic minorities who will agree
to have photo in leaflet. Stock photos enquire a
fee
Map is confusing: do Scotland and Wales have
their own programme or do they not have
screening?
Will take map out completely FG2
Wants% of people who make a full recovery This will be in ‘The Facts’ booklet
Bigger font and smaller pictures Do not want to make font bigger as does not
work given the size of the page
Front could be bolder – front needs to stick out
more
Will work on this
Flimsy, should be on better paper Will be painted on better paper once final
version confirmed
TI1
Facts booklet on back doesn’t do anything Will keep it. Need to refer to facts booklet in
some way
The picture of the bowel in the facts booklet
could go in leaflet. Basically want diagrams.
Body diagram on front supported
Already in the facts. Do not need to duplicate
Red suggested as colour but most agreed a
pastel green better
Will ask Medical Illustrators to advise on a lighter
shade of green
Too many boxes – not easy on the eye Lighter green might help
Font bigger for helpline Decided to take the helpline number out as this
is already in ‘The Facts’ booklet. Do not want to
discourage review of the booklet
Black font on green would be better than navy Looks too harsh. If paler green used this should
have desired effect
TI2
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ID Comment Proposed action for next iteration Supported
FG2 Point out young people can get it too Not appropriate for this leaflet
Add web address and ‘24 hour’ hotline This does not need to be included as this
information is available in ‘The Facts’ booklet. Do
not want to discourage review of the booklet
FG1
Can the test kit fit in letter box? Having a photo of kit could help dispel such
fears but as ‘The Facts’ booklet does not include
a picture of the test kit, we should not add it
Can a website address be added that leads
people to read more stories
Not possible to set up and maintain such a
website
Put NHS on envelope – not a circular. Urgency
in reading it (envelope with narrative)
We have no say over this BCSP envelope but for
the GP pilot study supports the use of the NIHR
logo
Put examples of other reasons why abnormal
results
Already text heavy so we will leave it out
Add a message to indicate urgency Not sure how to deal with this. Should not
appear more important than ‘The Facts’ booklet
FG1
Question why Scotland and Wales are not on
the map?
Map will be taken out FG1
FG, focus group; ID, identifier; TI, telephone interview.
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Appendix 25 Intervention 2: the ‘narrative’
leaflet
DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
243
 
 
APPENDIX 25
NIHR Journals Library www.journalslibrary.nihr.ac.uk
244
 DOI: 10.3310/pgfar05080 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 8
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Raine et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
245

Appendix 26 Narrative pilot study: correlation
matrix of measured beliefs
Beliefs PV SE RE AD SA PM I
Perceived vulnerability 1
Self-efficacy 0.115* 1
Response efficacy 0.231* 0.338* 1
Anticipated disgust –0.089* –0.299* –0.133* 1
Symptom absence –0.106* –0.358* –0.222* 0.276* 1
Peace of mind 0.331* 0.421* 0.457* –0.193* –0.261* 1
Intention 0.233* 0.395* 0.289* –0.251* –0.339* 0.379* 1
*p < 0.01 (two tailed).
AD, anticipated disgust; I, intention; PM, peace of mind; PV, perceived vulnerability; RE, response efficacy; SA, symptom absence;
SE, self-efficacy.
Note
n= 1157 (list wise).
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Appendix 27 Intervention 3: general practice
endorsement S1 pre-invitation letter
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Appendix 28 General practitioner recruitment
materials: letter
        
September 2012                                                                                                                   
 
«ICL_Organisation_Name» 
«Address_Line_1» 
«Address_Line_2» 
«Address_Line_3» 
«Address_Line_4» 
«Address_Line_5» 
«Postcode»
 
Dear Practice Manager/Lead GP 
 
Just a ‘YES’ from your practice could help save more lives 
 
My colleagues and I are inviting every general practice in England to allow their practice name to appear on 
the NHS Bowel Cancer Screening Programme (BCSP) invitation letters. Evidence suggests that doing so will 
increase the uptake of screening across the country and reduce the number of lives lost due to bowel cancer.  
 
Endorsing the screening programme simply involves allowing the BCSP to add your general practice name, 
«ICL_Organisation_Name», to the invitation letters received by your patients. 
 
This process of endorsement will not involve any work for your practice. 
 
Once we receive your agreement, your practice name will automatically be added to the NHS BCSP invitation 
letter (please see an example overleaf). 
 
The ‘ASCEND’ Project is a national initiative in collaboration with three major universities. This project will 
measure the effect of GP endorsement on uptake of invitations for bowel cancer screening. Please indicate on 
the reply slip below if you would like to know how your endorsement improves uptake in your area. 
 
When you have had the opportunity to discuss this letter with your colleagues, we would be grateful if you 
would reply as soon as possible to us by doing one of the following: 
 
 Complete and return the reply slip below 
 Fax this letter once you have completed the reply slip below to the ASCEND team on 020 7594 3051  
 Email the ASCEND team at rosemary.howe@imperial.ac.uk with your full practice name and code 
 Call the ASCEND team on 020 7594 3272 if you have any questions 
 
Yours faithfully 
    
Professor Stephen Halloran MBE FRCPath 
Director, Bowel Cancer Screening Programme Hub for the south of England 
 
Please complete this reply slip and either return it in the Freepost envelope provided or post the slip to: 
ASCEND Study Office, c/o Rosemary Howe, Room 505, St Marys Hospital Medical School, Norfolk Place, London, W2 1PG 
-------------------------------------------------------------------------------------------------------------------------------------------
------------------  
We agree to our general practice name, «ICL_Organisation_Name», being automatically added to the 
current NHS Bowel Cancer Screening Programme invitation letters sent to our patients. 
 
           «PRACTICE_CODE» 
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--------------------------      -------------------------------------------------------       ------------------------      -------------
------------------------- 
Practice Code                    Name of Practice Manager/Lead GP                         Date (dd/mm/yyyy)      Signature 
 
I would like to know how our practice endorsement affected screening uptake (please tick box if ‘yes’) 
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25 December 2005        
 
 
Q5 278/7/26 NHS No: 999 000
 
 
 
 
Dear Mrs Anne Belinda Example-Subject 
 
Your GP practice, «ICL_Organisation_Name», supports the Bowel Cancer 
Screening Programme 
 
This is an invitation to take part in the NHS Bowel Cancer Screening 
Programme. The programme aims to detect bowel cancer early, when 
successful treatment and cure is more likely. Screening is offered every two 
years to people aged 60-69 who are registered with a GP in England. We are 
starting to extend the screening age range, so if you are aged 70-74, you are 
being invited as part of this process. 
 
You will be sent a test kit with full instructions in about two weeks. The kit is 
simple to use in the privacy of your own home. If you want to be screened, 
wait until the kit arrives, follow the instructions, and return the kit in the 
Freepost envelope provided. You will get your results by letter within 2 
weeks. 
 
We do not have your medical history, and screening is not appropriate for 
everyone. If you have already been referred to hospital for bowel 
investigations by your GP, or if you have had previous bowel surgery, 
then screening may not be appropriate for you. Please call us for advice. 
If you don't wish to be screened, then please call and let us know. The 
Freephone number for all calls is at the top of this letter (calls are free from 
UK landlines). 
 
If you need help from family or a carer in order to use the kit, please call us (or 
ask them to call us) for further important information. You can also use the 
Freephone number if you have any questions about taking part in the 
programme. Finally, please take the time to read the enclosed leaflet 'Bowel 
Cancer Screening - The Facts', which may help to answer any questions you 
may have. 
 
Mrs Anne B Example-Subject 
Hembury House 
Cheriton 
Shobrooke 
Crediton 
Devon 
YY1 5TT 
Yours sincerely 
 
Prof S P Halloran MBE FRCPath 
Hub Director 
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Appendix 29 General practitioner recruitment
materials: information sheet
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Appendix 30 Pro forma used to record calls to
the Bowel Cancer Screening Programme about the
reminder letter (version 1)
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Appendix 31 Intervention 4: the enhanced
reminder S10 letter
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Appendix 32 Pro forma used to record calls to
the Bowel Cancer Screening Programme about the
reminder letter (version 2)
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Appendix 33 Randomisation tables for all
randomised controlled trials
TABLE 51 Intervention 1: gist – randomisation table
Trial date
NHS BCSP hub
Midlands and
North West North East Southern London Eastern
Monday 5 November Usual Gist Leaflet Usual Usual Gist Leaflet
Tuesday 6 November Gist Leaflet Gist Leaflet Usual Usual Usual
Wednesday 7 November Usual Usual Usual Usual Usual
Thursday 8 November Gist Leaflet Usual Gist Leaflet Gist Leaflet Usual
Friday 9 November Gist Leaflet Gist Leaflet Gist Leaflet Gist Leaflet Gist Leaflet
Saturday 10 November N/A N/A N/A N/A N/A
Sunday 11 November N/A N/A N/A N/A N/A
Monday 12 November Usual Usual Gist Leaflet Gist Leaflet Usual
Tuesday 13 November Gist Leaflet Gist Leaflet Usual Usual Usual
Wednesday 14 November Usual Usual Gist Leaflet Gist Leaflet Gist Leaflet
Thursday 15 November Usual Gist Leaflet Usual Usual Gist Leaflet
Friday 16 November Gist Leaflet Usual Gist Leaflet Gist Leaflet Gist Leaflet
N/A, not applicable.
Shading indicates which hub was randomised to send which intervention on which day during the intervention period.
TABLE 52 Intervention 2: narrative – randomisation table
Trial date
NHS BCSP hub
Midlands and
North West North East Southern London Eastern
Monday 4 March Narrative Leaflet Narrative Leaflet Usual Narrative Leaflet Narrative Leaflet
Tuesday 5 March Narrative Leaflet Narrative Leaflet Usual Narrative Leaflet Narrative Leaflet
Wednesday 6 March Usual Narrative Leaflet Narrative Leaflet Usual Usual
Thursday 7 March Usual Usual Usual Usual Usual
Friday 8 March Usual Usual Usual Narrative Leaflet Narrative Leaflet
Saturday 9 March N/A N/A N/A N/A N/A
Sunday 10 March N/A N/A N/A N/A N/A
Monday 11 March Narrative Leaflet Narrative Leaflet Usual Narrative Leaflet Usual
Tuesday 12 March Narrative Leaflet Usual Narrative Leaflet Usual Narrative Leaflet
Wednesday 13 March Narrative Leaflet Usual Narrative Leaflet Usual Usual
Thursday 14 March Usual Usual Narrative Leaflet Usual Usual
Friday 15 March Usual Narrative Leaflet Narrative Leaflet Narrative Leaflet Narrative Leaflet
N/A, not applicable.
Shading indicates which hub was randomised to send which intervention on which day during the intervention period.
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TABLE 53 Intervention 3: GPE – randomisation table
Trial date
NHS BCSP hub
Midlands and North West North East Southern London Eastern
Monday 3 June Usual Usual Usual Usual Usual
Tuesday 4 June GPE Usual GPE GPE GPE
Wednesday 5 June Usual GPE GPE Usual GPE
Thursday 6 June Usual GPE Usual Usual Usual
Friday 7 June GPE Usual Usual GPE GPE
Saturday/Sunday N/A N/A N/A N/A N/A
Monday 10 June GPE Usual Usual Usual GPE
Tuesday 11 June GPE GPE GPE GPE GPE
Wednesday 12 June Usual Usual Usual Usual Usual
Thursday 13 June GPE GPE GPE GPE GPE
Friday 14 June GPE GPE Usual GPE Usual
Saturday/Sunday N/A N/A N/A N/A N/A
Monday 17 June GPE GPE Usual GPE GPE
Tuesday 18 June GPE Usual GPE GPE Usual
Wednesday 19 June GPE Usual GPE GPE Usual
Thursday 20 June GPE GPE GPE Usual Usual
Friday 21 June Usual GPE Usual Usual GPE
Saturday/Sunday N/A N/A N/A N/A N/A
Monday 24 June Usual Usual GPE Usual GPE
Tuesday 25 June Usual Usual Usual Usual GPE
Wednesday 26 June Usual GPE GPE GPE Usual
Thursday 27 June Usual Usual GPE Usual Usual
Friday 28 June Usual GPE Usual GPE Usual
N/A, not applicable.
Shading indicates which hub was randomised to send which intervention on which day during the intervention period.
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TABLE 54 Intervention 4: ER – randomisation table
Trial date
NHS BCSP hub
Midlands and North West North East Southern London Eastern
Monday 8 July ER ER ER Usual ER
Tuesday 9 July ER ER Usual Usual Usual
Wednesday 10 July Usual Usual ER Usual Usual
Thursday 11 July ER Usual Usual Usual Usual
Friday 12 July Usual ER ER Usual ER
Saturday/Sunday N/A N/A N/A N/A N/A
Monday 15 July ER Usual Usual ER ER
Tuesday 16 July Usual ER ER ER ER
Wednesday 17 July Usual Usual Usual ER ER
Thursday 18 July Usual Usual Usual Usual Usual
Friday 19 July ER Usual Usual ER Usual
Saturday/Sunday N/A N/A N/A N/A N/A
Monday 22 July ER ER ER ER ER
Tuesday 23 July Usual Usual Usual ER ER
Wednesday 24 July Usual ER Usual Usual Usual
Thursday 25 July ER ER ER ER ER
Friday 26 July Usual Usual ER ER Usual
Saturday/Sunday N/A N/A N/A N/A N/A
Monday 29 July ER Usual ER ER ER
Tuesday 30 July ER ER Usual Usual Usual
Wednesday 31 July ER ER ER Usual ER
Thursday 1 August Usual Usual Usual Usual Usual
Friday 2 August Usual ER ER ER Usual
N/A, not applicable.
Shading indicates which hub was randomised to send which intervention on which day during the intervention period.
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Appendix 35 Process evaluation report
A im: the primary objective of the process evaluation was to monitor any adverse effects (i.e. excessiveextra workload for the NHS BCSP helpline that could make the future implementation of any of the
interventions unfeasible).
Pre-interventions: prior to the start of any of the interventions, two teleconferences were held between
the ASCEND team, hub directors and managers. The primary aim of the meetings was to establish how
the ASCEND team could better support the hubs during the running of the interventions. These included
discussions about hub staff requirements and monitoring any adverse impact on the NHS BCSP helpline
during the interventions.
One of the main points that arose from these meetings was the requirement for hub staff to have a
comprehensive understanding of the ASCEND interventions to enable them to respond to helpline enquiries
adequately. It was agreed that it would be beneficial for representatives from the ASCEND team to visit
each of the hubs and deliver information about each of the interventions and a question-and-answer
session for hub staff.
A helpline pro forma for staff to record any calls made to the NHS BCSP specifically relating to each
intervention during the course of each trial was designed. In addition, a list of potential frequently asked
questions (FAQs) was also created. The pro forma and FAQs belonging to the first intervention to be
trialled (the essentials leaflet) was distributed prior to the teleconferences. It was expressed during these
meetings that instructions on how to complete the pro forma should be made part of the staff training.
Once the staff training had been delivered, amendments incorporating feedback from the hubs were made
to both the helpline pro forma and the FAQs. Finalised materials relating to each specific intervention were
then distributed to the hubs before they were due to be trialled, together with a list of contact numbers
should they require any assistance once the trials commenced.
Post interventions: 1 month after each of the interventions had been trialled, an e-mail was sent to hubs
requesting that any completed helpline pro formas be returned to the ASCEND team so that any adverse
impact on the helpline could be monitored. Five calls (two Southern Hubs/three Eastern Hubs) were
reported that related specifically to the GPE letter:
Referenced that GP thought she should have screening and that she would like to if she was due.
Subject very concerned, wants to know which GP passed her details on, just recovered from
breast cancer.
Subject read out the GP endorsement at the top of the letter, I asked her if she wished to take part,
she said yes.
Asked if invitation was from GP. Advised that it was from us but endorsed by GP.
Thought that GP was inviting into a separate screening programme as previously been invited by the
programme. Didn’t want to be included into two separate screening programmes.
No calls were reported in relation to the gist, narrative or ER interventions.
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Appendix 36 Flow charts of participants for all
four ASCEND trials
Screening-eligible population across five hubs in England
5–16 November 2012
(n = 163,525)
Randomised
(n = 163,525)
Excluded
(n = 0)
Intervention
Allocated to receive standard 
information with an added 
Gist leaflet
(n = 84,421)
Analysable sample
(n = 84,283)
Excluded
missing IMD data
(n = 138)
Control
Allocated to receive 
standard information
(n = 79,104)
Analysable sample
(n = 78,971)
Excluded
missing IMD data
(n = 133)
FIGURE 15 Flow of participants through the gist trial.
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Screening-eligible population across five hubs in England
4–15 March 2013
(n = 150,417)
Randomised
(n = 150,417)
Excluded
(n = 0)
Intervention
Allocated to receive standard 
information with an added 
narrative leaflet
(n = 73,722)
Analysable sample
(n = 73,450)
Excluded
missing IMD data
(n = 272)
Control
Allocated to receive 
standard information
(n = 76,695)
Analysable sample
(n = 76,421)
Excluded
missing IMD data
(n = 274)
FIGURE 16 Flow of participants through the narrative trial.
Screening-eligible population from participating 
general practices across five hubs in England
3–28 June 2013
(n = 265,434)
Randomised
(n = 265,434)
Excluded
(n = 0)
Intervention
Allocated to receive standard 
information with name of 
endorsing general practice
incorporated into invitation letter
(n = 131,423)
Analysable sample
(n = 130,876)
Excluded
missing IMD data
(n = 547)
Control
Allocated to receive 
standard information
(n = 134,011)
Analysable sample
(n = 133,449)
Excluded
missing IMD data
(n = 562)
FIGURE 17 Flow of participants through the GPE trial.
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Reminder-eligible population across five hubs in England
8 July–2 August 2013
(n = 168,480)
Randomised
(n = 168,480)
Excluded
(n = 0)
Intervention
Allocated to receive standard 
information with an 
enhancement incorporated into 
the reminder letter
(n = 78,067)
Analysable sample
(n = 77,739)
Excluded
missing IMD data
(n = 328)
Control
Allocated to receive 
standard information in the 
reminder letter
(n = 90,413)
Analysable sample
(n = 90,002)
Excluded
missing IMD data
(n = 411)
FIGURE 18 Flow of participants through the ER trial.
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